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This thesis describes an approach aimed at enriching and cytogenetically analysing fetal
cells from maternal blood. It describes in detail the sequence from blood sampling and
enrichment through to chromosome analysis of the enriched cells and the problems
encountered at each stage. It also addresses the problems of cell deposition and the
necessity of cell identification and demonstrates the inter-dependence of the individual
techniques and how alteration of one of the stages had considerable effect on others.
Throughout, therefore, an attempt has been made to develop an integrated enrichment and
analysis procedure which, importantly, could be automated.
99.95 ± 0.07% of erythrocytes were removed by centrifugation through a Histopaque
1119 density gradient cushion with a recovery of 53.1 ± 26.9% of all the starting nucleated
cells. 99.1 ± 0.4% of leukocytes of every type were removed using a cocktail of monoclonal
antibodies conjugated to magnetic beads. Overall, it was estimated that 35% of fetal
erythroblasts could be recovered. The cells were then lysed in suspension and deposited on
to microscope slides for cytogenetic analysis.
In a prospective study involving fifteen women in early pregnancy, 15-20ml of blood was
drawn from an antecubital fossa vein and subjected to the enrichment techniques described.
Using either a Y-chromosome probe on its own or later X- and Y-probes simultaneously, the
cells were then subjected to fluorescence in situ hybridisation. Gender prediction was 86.7%
accurate (sensitivity 100%, specificity, 75.0%, p < 0.004). Furthermore, using this approach
it was also possible to confirm a diagnosis of Down's syndrome which had been made by a
conventional invasive technique one week previously.
This study showed that fetal cells, albeit in small numbers, can be isolated reliably from
maternal blood in early pregnancy. Moreover, the simple procedures could be automated, a
principle which is fundamental if maternal blood is to be used for prenatal diagnostic
purposes.
Each step in the whole sequence continues to develop. An attempt has therefore been
made to outline necessary future investigations and potential areas where enrichment and
analysis might be improved. Furthermore, the implications and applications of such a
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Chapter 1. General introduction to prenatal screening and diagnosis
Around 8% of all pregnancies warrant some form of prenatal investigation (Brock, 1982).
At present there are over 2500 indications for prenatal testing and an overall appreciation of
the incidence and prevalence of congenital abnormalities and, in particular, chromosome
abnormalities is necessary.
5.6/1000 live births are complicated by a chromosomal abnormality, accounting for 34%
of all early mortalities. Sixty-four percent of these cases develop chronic problems requiring
continuing medical and social support (Hook, 1992).
Fifteen percent of first trimester pregnancies abort of which 40% are karyotypically
abnormal, a further 7% show developmental inconsistency (certain embryonic organ systems
being more advanced than others) and another 7% demonstrate specific organ defects. Of
the first trimester karyotypic abnormalities, 52% are autosomal trisomies, 19% are 45, XO,
16% are triploid and 6% are tetraploid. Twenty-six percent of spontaneous abortions in the
second trimester are associated with at least one system defect though the absolute
proportion of spontaneous abortions compared to ongoing pregnancies is less than 3%
(Young, 1992).
Chromosomal abnormalities account for 6-7% of all major abnormalities at birth and
single gene abnormalities account for a further 6-7%. Twenty-five to thirty percent of all
perinatal loss (greater than 24 weeks' gestation to the end of the first week after birth), 27%
of all infant mortality and 19% of all deaths of children aged 1-9 years is associated with
congenital malformation (Young, 1992). Abnormalities involving chromosomes 21, 18, 13, X
and Y constitute 95-98% of all chromosomal abnormalities at birth (Whiteman and Klinger,
1991; Hook, 1992). Trisomies involving chromosomes 21, 18 and 13, account for 26%
(Hook, 1992). These proportions are rising as neonatal intensive care improves so that
mortality previously associated with prematurity continues to fall.
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Throughout this thesis particular reference is made to Down's syndrome (trisomy 21), the
collection of symptoms and clinical signs associated with three copies of a specific region of
chromosome 21. It is the most common cause of mental retardation in the UK with a birth
prevalence of 1 in 800 live births. The characteristic clinical features were described by John
Langdon Haydon Down in 1866. In 1959 Lejeune et al described the additional small
acrocentric chromosome, now known to be an extra copy of chromosome 21. Ninety-two
percent of Down's syndrome cases have 47 chromosomes with an extra chromosome 21
(usually of maternal origin), due to non-disjunction at first meiosis and 4-6% have 46
chromosomes but an extra copy of 21 q is translocated on to another chromosome (often
chromosome 13 or 14). Three percent are mosaics and tend to be clinically less severely
affected (Mikkelson and Bnandum-Nielsen, 1992).
The incidence of Down's syndrome, Edward's syndrome (trisomy 18), and Patau's
syndrome (trisomy 13) rise with advancing maternal age. All three conditions are over-
represented at term, especially trisomy 21, because of the lower attrition rate when
compared to other autosomal aneuploidies. At around 10 weeks' gestation 26.1% of all
autosomal abnormalities are trisomy 21; at 17 weeks' gestation it is 40.6% and at term it is
78% (Hook, 1992). Only 30% of Down's syndrome cases abort after the mid-second
trimester and it represents only 2.3% of all spontaneous abortions. Hence, Down's syndrome
contributes enormously to the overall prevalence rates of the clinically serious chromosomal
abnormalities.
If a woman was older than thirty years old when she had a Down's syndrome child, the
recurrence rate is 0.76%, similar to the expected overall risk of 0.72%. If she was younger
than thirty it is 0.68% whilst the expected risk would be only 0.27% for age-matched controls
(Wald and Cuckle, 1992). This probably reflects an inherent predisposition to non-disjunction
or gonadal mosaicism particularly as half of the abnormalities in recurrent trisomy cases are
different from the index case (Mikkelson and Brandum-Nielsen, 1992).
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Goldstein (1989) estimated that the cost of looking after a Down's syndrome adolescent
at home was US$24,213/ year compared to US$3,718 for an able-bodied adolescent. The
cost of institutionalisation was US$42,728/ year. Hence, it is of major economic importance
whilst the social costs are incalculable.
With this background, it is easy to appreciate the importance of antenatal diagnosis, the
impact it might have on abortion rates, especially late and distressing pregnancy losses, and
the effect on perinatal and childhood morbidity and mortality.
A screening programme detects a (predisposition to a) particular condition in people who
are generally considered to be free of the condition. Importantly, screening embodies the
principles of giving informed choice and autonomy to the widest possible range of the
population. These principles are no different for prenatal diagnosis.
Hence, prenatal testing should include as many women as possible, providing
reassurance and reducing the anxiety levels associated with reproduction. It allows
counselling so that parents realise they are not alone and gives them the opportunity to
decide whether or not they want to continue with the pregnancy (Luck, 1992). Furthermore, if
the couple wish the pregnancy to continue, the optimal mode, place and timing of delivery
and subsequent management of affected infants may be ensured (Gaudoin, 1993a).
Unfortunately, for those involved in prenatal diagnosis programmes there is the danger of
being misinterpreted as trying to create a eugenic society. This might in turn be used as a
way to divert money away from disability schemes and/or deride the value of specific groups
in human society. Every effort must be made to emphasise that this is not the case.
Accepted, affected children born to informed parents is counted as a benefit in a prenatal
screening programme and not as a cost (Modell, 1992).
The ideal screening test is simple, safe and effective, highly sensitive and highly specific,
with a high positive predictive value. Furthermore it must be repeatable and relatively
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inexpensive. Current definitive antenatal diagnostic techniques for fetal aneuploidy fulfil
many of these criteria but involve some risk to the pregnancy. As such they are only offered
to certain women.
The chance of fetal aneuploidy, especially trisomy 21, but also trisomy 13 and trisomy 18,
rises with increasing maternal age, particularly after 35 years old (Ferguson-Smith and
Yates, 1984, figure 1.1). Because of this, and because the risk of iatrogenic miscarriage is
similar to the chance of carrying an abnormal fetus, 35 years and above has been the
traditional threshold to offer definitive testing. However, since most pregnant women are less
than 35 years old, the area under the curve and to the right of the bold vertical line in figure
1.2 shows that only 30% of Down's syndrome cases are actually born to women over this
traditional age threshold (Staples et al, 1991, figure 1.2). Therefore, only 30% might be
detected if age is the sole screening criterion. Maternal serum biochemical screening has
improved detection rates but the diagnosis is still dependent on invasive testing thereafter
and, in the absence of definitive testing, many of the other common aneuploidies are
missed.
The possibility of isolating and analysing fetal cells from maternal blood as a means of
prenatal aneuploidy detection is, therefore, a very attractive concept. It could be used as a
screening procedure, available to all pregnant women and not just selected groups. Using
modern molecular biological techniques potentially any case of Down's syndrome and many
of the other common fetal aneuploidies could be detected. Initially putative diagnoses would
need to be confirmed by established diagnostic techniques but ultimately the need for
confirmatory invasive methods may be obviated and counselling of the couple performed on
the basis of the blood result alone.
This thesis reviews the currently available diagnostic tests and their limitations and much
of the published literature on isolating fetal cells from maternal blood. It describes the work
carried out by myself and others at the MRC-Human Genetics Unit, enriching for fetal cells
17
and subsequently performing limited cytogenetic analyses on these cells. The rationale for
each stage, the results and the problems incurred are explained.
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Maternal age (in years)
From Ferguson-Smith and Yates, 1984. Note the steep rise in the rates of Down's syndrome with increasing maternal age.
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Figure 1.2. Number of Down's Syndrome births in S. Australia 1960-1989 related to Maternal Age
Maternal Age (in years)
From Staples et al, 1991. Note that the majO-ity of births actually occur to women less than 35 years old.
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Chapter 2. Current antenatal diagnostic procedures
2.1 Introduction
The aims and benefits of prenatal screening have been described in Chapter 1 and at
present there are over two thousand specific indications to offer prenatal diagnosis.
Principally these are to search for chromosome abnormalities, inborn errors of metabolism
(to demonstrate enzyme activity or protein deficiency), measurement of metabolites in
amniotic fluid or to culture infective agents.
As antenatal screening and diagnosis has developed, the tendency has been to earlier
and/ or less invasive methods. The isolation of fetal cells from maternal blood is the natural
progression in this field and to understand it's need it is necessary to appreciate the
development and limitations of currently available techniques. There are clearly vast
numbers of published studies in this field which, out of necessity, compels selection and
inclusion of some whilst omitting others. The techniques can be divided into non-invasive
(effectively only ultrasound scanning) and invasive, which involve some risk to the
pregnancy. Although not diagnostic, an overview of maternal serum biochemical screening
for Down's syndrome is given and, for completeness, a number of novel tests are also
reviewed.
2.2 Amniocentesis
The cells found in amniotic fluid are shed from a variety of tissues, notably the fetal skin,
gastrointestinal, genito-urinary and respiratory tract, the amniotic membranes and the
umbilical cord. However, only 20% of the cells are viable and can be cultured.
Amniocentesis involves needle aspiration of amniotic fluid from the uterine cavity.
Ultrasound visualises a pool of amniotic fluid and the placenta to avoid placental perforation.
Maternal blood contamination does not affect cell cultures but it does increase the chance of
confusing results as maternal leukocytes are cultured as well.
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The failure to determine the true fetal karyotype using amniocentesis is rare because all
the different cultured cell types arise from the inner cell mass which reflects the fetal
karyotype more accurately than trophoblast cells. Overall only 0.6% of all amniocenteses
require a further invasive procedure for cytogenetic clarification (MacLachlan, 1992). The
fetal loss rate up to 28 weeks' gestation, and corrected for spontaneous background losses,
is about 1% (Smidt-Jensen et al, 1992). Major and minor fetal trauma has been documented
though never if ultrasound has been used and chorio-amnionitis is rare. Chronic amniotic
fluid leakage increases the risk of premature labour, respiratory distress syndrome and
pneumonia at birth but other abnormalities, such as neurodevelopmental delay, are no
different from age-matched controls. Despite placental location there may be transplacental
haemorrhage following amniocentesis, necessitating prophylactic anti-D immunoglobulin for
Rhesus- negative women (Bowman and Pollock, 1985).
The major drawback of amniocentesis is the late stage of pregnancy, usually 16-19
weeks' gestation, at which the procedure is performed so it is well into the second trimester
before karyotypic abnormalities are detected. The fetus is well formed, the woman is
experiencing fetal movements and she is obviously pregnant to those around her. Data
suggest that such women, years after termination of pregnancy, experience greater pangs of
guilt than those who undergo termination of pregnancy for fetal abnormality at earlier
gestations (MacKenzie, 1992).
Early amniocentesis is performed at 10-11 weeks' gestation but to confer advantage over
chorionic villus sampling (CVS) it must be as safe or safer and give as fast and reliable
results so that the time for the less traumatic procedure of suction termination of pregnancy
has not passed. Unfortunately the estimated amniotic fluid volume at 10 weeks' gestation is
only 30ml, at 13 weeks' only 70ml, rising to 200ml at 16 weeks' gestation.
Kennerknecht et al (1992) performed amniocentesis on 100 women immediately prior to
first trimester termination of pregnancy. Tenting of the amniotic membranes, so blocking the
lumen of the needle limited the amount of fluid which could be drawn off and at lesser
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gestations, longer culture times were required, presumably because there were fewer cells
and culture conditions were suboptimal. The success rate in terms of definitive cytogenetic
results was only 40-50% when the procedure was performed at less than 9 weeks' gestation,
80-90% at 9-11 weeks' and 100% at twelve weeks' or more. They concluded that early
amniocentesis is feasible but, because of the prolonged culture times and high cytogenetic
failure rates, it offered no great advantage over second trimester amniocentesis.
In a much larger study of 1375 patients, Lockwood and Neu (1993) estimated that
although the mean turnaround time (the time from procedure to cytogenetic results being
available to the clinician) was greater for early amniocentesis, results were available 3.5
weeks before results from the standard procedure. However, 94% of their samples were
greater than 12 weeks' gestation and they had an overall culture failure rate of 1.4%
compared with their failure rate of less than 0.5% for the standard procedure.
In a controlled study comparing early amniocentesis with CVS and controls (no prenatal
investigations), infants in the early amniocentesis group had significantly more respiratory
problems than the other two groups (Greenough et al, 1997). In the Canadian Early and Mid-
trimester Amniocentesis Trial (1998) 1916 women underwent amniocentesis before 13
weeks' gestation compared to 1775 women who underwent amniocentesis after 15 weeks'
gestation. There were more cases of postprocedural amniotic-fluid leakage (p < 0.001),
greater fetal loss (p < 0.02) and more cases of talipes equinovarus (p = 0.0001) in the early
amniocentesis group.
Termination of pregnancy is psychologically and physically less traumatic in the first
trimester. However, given that many of the cases in the initial reports were performed in the
early second trimester, with results available at a variable period after the procedure, it
suggests that there is no great advantage conferred by these relatively late "early"
amniocenteses. Furthermore, the questions raised about the immediate and long term safety
of early amniocentesis requires urgent investigation in a properly controlled manner.
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2.3 Chorionic villus sampling
The chorion frondosum contains the mitotically active villus cells and becomes the
definitive placenta. Chorionic villus sampling (CVS) involves biopsy and subsequent
cytogenetic analysis of this tissue.
In 1968 Hahnemann and Mohr successfully cultured these cells and although many
groups persevered over the next few years with sampling techniques and cytogenetic
analysis it received scant attention as the problems associated with amniocentesis were
being overcome. However, interest in first trimester prenatal diagnosis was rekindled in the
early 1980's largely as a result of improved culturing from tiny amounts of tissue and the
development of quality ultrasound imaging which allowed reliable and accurate biopsy.
The Canadian collaborative group (1989) reported that CVS had a higher frequency of
abnormal cytogenetic results compared to amniocentesis (3.8% compared to 1.9%). The
difference in abnormality rates in this multicentre study to some extent reflected the earlier
gestational age of sampling at CVS as many of these pregnancies might have gone on to
abort spontaneously but there was also a significantly higher false positive rate. Overall
9.9% of women undergoing CVS required further invasive testing. Cultures failed in 1.5% of
CVS samples compared with only 0.1% of amniocentesis samples whilst maternal cell
contamination was also more common in CVS samples because maternal cells (the decidua)
are intimately associated with the villi. Furthermore, 1.6% of CVS samples demonstrated
confined placental mosaicism (CPM, or pseudomosaicism). Mosaicism implies the presence
of two or more distinct cell lines containing different karyotypes in the same individual.
Confined placental mosaicism is restricted to placental elements with complete absence in
the fetus and reflects the complexity of early placental development (Kalousek et al, 1987).
Once established the aberrant cell line has a similar rate of proliferation and maintenance to
that of a normal cell line. Level 1 and level 2 mosaicism is seldom confirmed in the fetus
and even level 3 mosaicism (multiple cells with the same cytogenetic abnormality in multiple
flasks) may not be truly representative of the fetal karyotype (Silverman and Wapner, 1992).
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The large European collaborative study on mosaicism at CVS, which involved 11,855 cases,
found that only 5.2% of villus biopsies complicated by mosaicism were confirmed by
amniocentesis. Verjeslev and Mikkelson (1989) reported that the most common autosome
mosaics involved chromosomes 3, 7, 8, 13, 15, 18, 20 and 21 but 45, XO was the most
frequently observed mosaic cell line. Table 2.1 shows that a mosaic diagnosed at CVS
involving one of the common trisomies is not necessarily reliable and certainly warrants
further testing (usually amniocentesis).
Table 2.1. Analysis of chromosome mosaics at CVS (Verjeslev and Mikkelson, 1989)
Mosaic at CVS Number Normal fetal Mosaic Not reported
karyotype Confirmed
Chromosome 21 8 3 (38%) 4 (50%) 1 (12%)
Chromosome 18 10 6 (60%) 1 (10%) 3 (30%)
Chromosome 13 9 4 (44%) 4 (44%) 1 (11%)
Chorionic villus sampling is an invasive procedure, carrying a risk to the pregnancy.
Jackson et al (1992) reported that the fetal loss rate for transabdominal- or transcervical-
CVS was similar at approximately 2.4%. Smidt-Jensen et al (1992) reported that post¬
procedure unintentional fetal loss (up to 28 weeks') was 7.63% for transcervical CVS and
2.34% for transabdominal CVS which was similar to amniocentesis. They concluded that
transabdominal CVS was the diagnostic technique of choice because of the success rate, it's
safety and the earlier gestation at which it could be performed (compared to amniocentesis).
It is certainly a more dignified approach than the transcervical technique and, for
obstetricians, an easier one to learn as they are usually already familiar with transabdominal
amniocentesis.
Amniotic membrane rupture and chorio-amnionitis are rare following CVS. Maternal
serum a-fetoprotein rises post-CVS, implying that fetomaternal haemorrhage has occurred
and anti-D immunoglobulin is indicated in rhesus-negative women. However, this iatrogenic
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rise has usually fallen to normal by 16-18 weeks' gestation and this biochemical marker can
still be used to screen for neural tube defects.
The association between CVS and the rare oromandibular-limb hypogenesis (OLH)
syndrome (with characteristic hypoglossia and hypodactyli) and transverse limb reduction
defects remains controversial. The incidence of OLH syndrome is 1 in 175,000 live births.
Experimental evidence suggests that it is due to a vascular insult resulting in incomplete
distal perfusion of an appendage, in early pregnancy. Firth et al (1991) reported five cases in
289 CVS procedures (or 1 in 58) between 56 and 66 days' gestation but Jackson et al (1991)
found no such association. Miny et al (1991), in the same correspondence columns, reported
an association between the severity of the lesion and the gestational age at CVS. They
recommended that CVS should be performed only after 11 weeks' gestation. Firth et al
(1994), in a follow-up analysis of their original paper reported 75 cases of limb reduction
defects associated with CVS and also suggested the same inverse association with
gestational age. Although the standard deviation was large, more severe lesions were
associated with earlier sampling. From our personal data in the West of Scotland, there were
78,866 births and 47 reported LRDs though none was associated with CVS (Gaudoin and
Mackenzie, 1997). Furthermore, in the World Health Organisation CVS Registry there were
48 cases in 80,051 births following CVS, an incidence very similar to our rate in the untested
population. However, until this question is resolved it seems prudent to perform CVS as late
as is possible whilst still obtaining results within the first trimester.
One possible solution to sampling as late in the first trimester as possible might be to use
fluorescence in situ hybridisation with chromosome-specific probes. This will be discussed in
Chapter 7.
Chorionic villus sampling is a valuable tool in the obstetrician's repertoire as it enables
diagnoses to be made reliably in the first trimester. However, in contemplating invasive
testing, the advantage of earlier diagnosis must be weighed against the slightly higher
unintentional pregnancy loss when compared to second trimester amniocentesis, the
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possibility of false positive diagnoses and the possibility of oromandibular-limb hypogenesis
syndrome.
2.4 Cordocentesis (fetal blood sampling)
Cordocentesis involves needling the umbilical cord under ultrasound visualisation. Less
than 17 weeks' gestation it is technically difficult with an associated 5% fetal loss rate though
this improves as pregnancy advances (Orlandi et al, 1990). From 17 to 39 weeks' gestation
overall losses, usually within 2 weeks of the procedure, are around 1.1%. The loss rate is
greater with inadvertent arterial puncture and after intravascular transfusion (Weiner et al,
1991). Losses are dependent on the experience of the operator and the indication i.e.
increasing if the fetus is already compromised and after intravascular transfusion (Nicolini
and Rodeck, 1992).
Cordocentesis for rapid fetal karyotyping has been superseded largely by the increasing
use of amniocentesis or CVS in later pregnancy but it may still be indicated in cases of
known morphological abnormality or intrauterine growth restriction where genetic
abnormality is suspected (Nicolaides et al, 1992). It is also indicated in circumstances such
as fetal hydrops though these instances are rare.
It has provided enormous insight into fetal physiology and pathophysiology but, ironically,
it has to some extent been a victim of its own success. Assessment of fetal acid-base status
may still be an indication but the values of the various biochemical parameters measured
are similar in those cases which survive compared with those that die in the perinatal period.
Furthermore, the information provided by cordocentesis has validated non-invasive methods
of fetal evaluation, such as the fetal biophysical profile and Doppler velocimetry, which have
been shown to correlate equally well with adverse fetal outcome.
Therefore, because of the inherent dangers, the limited indications and the availability of
other technologies, the role of cordocentesis as a diagnostic technique is diminishing (Fisk
and Bower, 1993).
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2.5 Diagnostic Ultrasound Scanning
Until the advent of ultrasound scanning (USS) the uterine contents hid most of its secrets.
Ultrasound relies on the pulse-echo principle: a transducer emits a short pulse of ultrasound
and the time taken for the echo to return to the same transducer is analysed. Depending on
the tissue, the reflected signal is altered and a composite image of the object can be built up.
The state-of-the-art machines give excellent images but are expensive and require highly
trained operators. Importantly, fetal internal organ systems, such as the urinary tract, can be
imaged.
Although acoustic energy passing through tissues is attenuated and dissipated as heat, to
date there have been no confirmed reports of fetal damage. However, Newnham et al (1993)
reported that infants who were intensively monitored by ultrasound in utero weighed 25g less
than the control group. Furthermore, there were significantly more babies born in this group
who weighed below both the 10th and 3rd percentiles.
In general, screening tests are not diagnostic but USS is peculiar as diagnoses of
structural fetal anomalies are possible. If congenital malformations can be detected and the
pregnancy terminated, one would expect the perinatal mortality rate (PNMR) to fall.
However, studies on the effect of routine second trimester USS on the PNMR are conflicting.
In a large study of almost 9000 patients, Chitty et al (1991) detected 40.9% of all structural
abnormalities and, more importantly, 74.4% of all abnormalities were detected in those
patients undergoing USS. In their study the PNMR was significantly lower in this group as
termination of pregnancy was offered and performed in the majority. However, if
aneuploidies are considered specifically, in the USS group only 3 of 23 cases were detected.
Sixteen were undetected because there were no obvious anatomical markers and three with
anatomical markers were not identified. Three with anatomical markers were detected but
two refused karyotyping and in the other the association between fetal abnormality and an
abnormal karyotype was not made. There were also two false positive diagnoses (a possible
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tracheo-oesophageal fistula and another with possible cystic adenomatoid lung
malformation).
In a similar sized study involving an unselected population in the mid-second trimester,
the incidence of anomalies was 1.9% (including minor renal tract anomalies) and 85% of
these were detected (Luck, 1992). There were two false positive results (specificity, 99.9%)
but many abnormalities went undetected. Specifically, 64% of cardiac anomalies were
missed as were 60% of diaphragmatic hernias and 40% of skeletal abnormalities. Cardiac
and skeletal abnormalities in particular may be associated with fetal aneuploidy and USS
alone would not have detected many cases.
Even in a highly selected group with a known structural abnormality, if there was one
anatomical abnormality only 2% of cases had a chromosomal abnormality. In the presence
of multiple abnormalities 29% showed a chromosomal abnormality (Nicolaides et al, 1992).
Trisomy 18 is usually the most easily identified because of characteristic skeletal
abnormalities. However, only 33-44% of Down's syndrome cases have a significant
anatomical abnormality and these are less easily identified because the defects (particularly
short bones and cardiac anomalies) are more subtle and interpretation that much more
difficult (Nyberg et al, 1990). In their highly selected patients, Nicolaides et al (1992)
detected respectively only 57.2%, 54.2% and 71.0% of trisomy 21, trisomy 18 and trisomy
13 cases less than 24 weeks' gestation.
In 1984 a report by the Royal College of Obstetricians and Gynaecologists concluded that
routine USS for fetal abnormality was cost effective and this was endorsed by the Northern
Regional Survey Steering Group (1992). It concluded that nearly half the total decline in
PNMR over the period 1982-1990 was due to the increased antenatal detection, and
subsequent termination, of pregnancies involving fetal anomalies. However, the multicentre
RADIUS study (Routine Antenatal Diagnostic Imaging with Ultrasound), involving over
15,000 patients found no significant differences between the study and control groups in
adverse outcome measurements (death or periventricular haemorrhage) whilst the rates of
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preterm delivery and intrauterine growth restriction were very similar. Furthermore, only 17%
of fetal anomalies were detected before 24 weeks' gestation (Ewigman et al, 1993).
A number of groups have reported the potential of fetal nuchal translucency (NT) as a
first trimester screening test for fetal chromosomal abnormalities, particularly Down's
syndrome. The actual pathophysiology remains undetermined but screening for this "marker"
is extremely appealing. Pandya et al (1995) reported a prospective study of NT screening
based at two district general hospitals and a co-ordinating tertiary referral centre. Scans were
performed by trained ultrasonographers but importantly, implementation of the programme
did not require an increase in staff or the purchase of extra (expensive) machines. Scans
were performed at 10-13 weeks' gestation on 1763 fetuses (1673 singleton and 45 twin
pregnancies) and the maximum subcutaneous nuchal translucency was measured. Nuchal
translucency thickness increased with advancing gestation and overall 3.6% (63)
demonstrated an NT thickness of greater than 2.5mm. Sixty-two women were offered CVS
and 49 accepted. Of the 49 who underwent CVS, 45 showed a normal karyotype whilst 4
were abnormal: 3 cases of Down's syndrome and 1 case of Turner's syndrome (45, XO). The
other 13 cases which did not have CVS performed went on to deliver phenotypically normal
infants. Fifty-five women who had a negative first trimester screening ultrasound underwent
definitive antenatal diagnostic testing (usually by amniocentesis), because of advanced
maternal age or increased risk based on maternal serum biochemical screening. Of these,
there was one case of trisomy 21 in a 42 year old woman. The authors found that there was
a slight, but statistically insignificant, rise in fetal karyotyping rate over the study period.
If we consider only Down's syndrome, of 1763 fetuses there were 4 cases. Three might
have been detected by increased NT thickness (sensitivity, 75%). Similarly, of the 63
positive scans, 3 were true positives (positive predictive value, 4.8%; false positive rate,
3.4%). Likewise, the specificity was 96.6% (1699/1759) with a false negative rate of 25%
(1/4). Given that screening for Down's syndrome would involve large numbers of women, the
numbers involved in this study are relatively small. That said, the data compare very
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favourably with detection rates from maternal serum biochemical screening (chapter 2.8)
which also requires invasive testing to confirm the suspicion of fetal aneuploidy.
Furthermore, biochemical assays for Down's syndrome are not as reliable for twin
pregnancies compared with singleton pregnancies.
Pandya et al (1995) reported that many older women "were reassured by the decreased
risk for trisomies associated with nuchal translucency < 2.5mm and decided against invasive
testing". However, until larger datasets have been evaluated, we must exercise caution in
prematurely adopting such enthusiasm or, in the long term, we risk jeopardising the
implementation of what is an extremely promising development in the field (Gaudoin and
Mackenzie, 1997). Nevertheless, in time it may be possible to combine NT thickness with
other screening modalities, such as biochemical assays, to improve the predictive value
compared with each test being used alone.
Ultrasound machines and clinical expertise is costly. The structural lesion may be present
at the time of the scan but the ultrasonographic signs may only develop later e.g. duodenal
atresia. Moreover, the subsequent prognosis in some situations, such as choroid plexus
cysts, can be uncertain and this presents a dilemma to the counsellor. Enormous anxiety can
be generated with false positive diagnoses and, disastrously, even termination of pregnancy
may occur. There are technical problems such as obesity and many karyotypic abnormalities
have subtle or no anatomical markers so that false negative results inevitably occur.
Diagnostic ultrasound is non-invasive and, as far as is known, harmless to the fetus.
However, detection of fetal anomalies, particularly the early diagnosis of aneuploidies, is not
as yet very reliable and although a normal USS is reassuring, it is clearly not infallible.
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2.6 Coelocentesis
During the first 12 weeks' of intrauterine life the amniotic sac is surrounded by coelomic
fluid in the extra-embryonic coelomic cavity, a derivative of the extra-embryonic mesoderm.
Jurkovic et al (1993) reported sampling and cytogenetically analysing the cells from this
bright yellow fluid. Sampling was performed at 6-12 weeks' gestation, immediately prior to
termination of pregnancy and amniocentesis was performed simultaneously. The procedure
was not associated with alteration in fetal heart rate and there was no evidence of fetal
haemorrhage into the coelomic cavity based on ultrasound visualisation. Unfortunately,
attempts at culturing coelomic fluid and obtaining metaphase preparations were wholly
unsuccessful and only half of the amniotic fluid samples were successful. However,
fluorescence in situ hybridisation and polymerase chain reaction successfully predicted fetal
sex with 100% sensitivity and specificity. They suggested that, as the amniotic membranes
remain intact, the risk of fetal trauma was minimal. Furthermore, because the coelomic cells
are derived from the extra-embryonic mesoderm there may also be fewer problems with
pseudomosaicism compared to CVS. Moreover, as it does not involve direct trauma to the
definitive placenta, there is possibly less likelihood of limb reduction defects.
Findlay et al (1996) reported their experience with a fluorescent PCR technique to
provide results within five hours of coelocentesis, including DNA fingerprinting to exclude
maternal contamination. Although all sampling was performed prior to first trimester
termination, gender prediction was very accurate (p < 0.0004) though the false positive rate
was 20%. Makrydimas et al (1997) performed coelocentesis on four women at 7-9 weeks'
gestation, prior to termination of pregnancy (for non-medical reasons). The four couples
were known to be at risk of having a baby with (3-thalassaemia and DNA analysis in their
blood identified their individual mutations. Allele-specific polymerase chain reaction
identified the mutations in the DNA extracted from the coelomic cells and placental tissue.
Three fetuses were found to be carriers of either the paternal or maternal mutation, while
one was found to be affected by p-thalassaemia.
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Although the safety of this procedure is, as yet, undetermined, it offers an earlier and
potentially safer method of antenatal diagnosis than present first trimester techniques.
2.7 Cervical sump sampling
Shettles (1971) postulated that the villi of the chorion laeve simply exfoliated in early
pregnancy. He sampled the endocervical mucus, subjected the cells to quinacrine mustard
staining and accurately predicted fetal gender in 100% of cases (p<0.001). Rhine et al
(1975) blindly sampled the cells from behind the cervical mucous plug, the cervical sump
and, using Y-body fluorescence predicted 18 males and 18 females. All 18 male predictions
were correct though there were 5 false negatives i.e. 5 males in the group of predicted
females. Five of the samples were in the first trimester and six in the second and for these
trimesters gender prediction accuracy was not statistically significant. However, because
most were performed in the third trimester, the overall results were highly significant (p <
0.001).
Similar work was performed by Griffiths-Jones et al (1992) taking samples from the lower
uterine pole, prior to first trimester termination of pregnancy, using their Transcervical Cell
Retrieval technique (TRACER). The cells were identified as syncitiotrophoblasts both
morphologically and immunologically. Using PCR with a Y-chromosome repeat sequence
they compared the result of the retrieved cells to that of the abortus. They correctly identified
8 of the 9 male fetuses whilst in another Y-positive sample culture of tissue from the abortus
failed. However, the false positive rate was 6/16 though these were from vaginal and
endocervical swabs rather than from the lower uterine pole. Overall their results were not
significant and they suggested that contamination due to residual sperm from recent
intercourse or contamination from a male technician were possible reasons for the high false
positive rate. Bulmer et al (1995) also had variable recovery results when comparing
different sampling techniques. They too identified trophoblast cells immunologically but
found considerable antigenic heterogeneity in the cell populations, leading them to conclude
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that a panel of mAbs directed against various villus and extravillus trophoblast populations
would be necessary to improve the predictive value of the subsequent cytogenetic analyses.
Adinolfi et al (1993) flushed the lower uterine pole with sterile saline prior to first trimester
termination of pregnancy. In an attempt to avoid the exquisite sensitivity and hence potential
drawback of polymerase chain reaction, they subjected the recovered cells to fluorescence
in situ hybridisation (FISH) and primed in situ DNA synthesis (PRINS) using Y-chromosome-
specific sequences. In their study, gender prediction accuracy was 90.1% (p<0.006).
However, the proportion of fetal-specific cells was very small and the range very large (2-
33%), and there was considerable overlap between the percentage of cells bearing a Y-
signal in male and female pregnancies. One case involved a trisomy 18 fetus that had been
diagnosed previously by transcervical CVS and termination of pregnancy was about to be
performed. The recovered cells were subjected to FISH using a chromosome 18-specific
probe and 65% of cells appeared to be trisomic. Although encouraging, the proportion of
fetal cells was much greater than with the other samples suggesting that the numbers may
have been increased iatrogenically by the initial diagnostic technique (Gaudoin, 1993b).
Disappointingly, Bahado-Singh et al (1995) could only recover trophoblast cells in 50% of
cases and cultures were successful in only 20%. Similarly, Adinolfi et al (1995) had variable
results using chromosome-21 -specific small tandem repeat sequences. Using this approach,
Overton et al (1996) reported that although gender prediction accuracy was statistically
significant using PCR or FISH, the high false positive rates, particularly in the PCR group,
rendered cervical sump sampling unreliable for prenatal diagnosis.
More recently, Sherlock et al (1997) obtained first and second trimester samples prior to
termination of pregnancy, morphologically identified these cells as trophoblasts, and
correctly identified a variety of aneuploidies using FISH. Chang et al (1997) immunologically
identified trophoblast cells in 12 of 14 cases and subjected these to FISH analysis with 100%
gender prediction accuracy. Using a chromosome 13/21 a-satellite probe they also correctly
identified a trisomy 21 conceptus. In the two remaining cases, FISH failed to identify a male
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conceptus thus emphasising the importance of positive identification of fetal cells prior to
cytogenetic analysis, in order to avoid a false-negative results. Importantly, some of the
pregnancies were allowed to continue and, to date, no maternal or fetal complications have
been reported. Encouragingly, Falcinelli et al (1998) reported that gestation did not influence
transcervical cell recovery.
A potential criticism of these studies is that they were performed without the aid of
ultrasound to determine the placental position and in many cases, particularly in early
pregnancy, the placenta might have been biopsied directly. Furthermore, a recurring point is
that positive identification prior to cytogenetic analysis is an absolute necessity to improve
the predictive value of the test. However, the limited data on pregnancies which were
allowed to continue suggests that further investigation and longitudinal studies of
pregnancies should be encouraged as it may prove safer than the obvious comparative
technique, chorionic villus sampling.
2.8 Maternal serum biochemical screening for Down's syndrome
Approximately 5% of pregnant women are more than 35 years old but give birth to only
30% of Down's syndrome babies. Therefore, maternal age alone is an inadequate indicator
of trisomy risk (chapter 1). Furthermore, in effect, only 15% of Down's syndrome cases are
detected as fewer than half these women undergo a definitive antenatal diagnostic
procedure (Wald and Cuckle, 1987).
Although not a diagnostic test, maternal serum screening has contributed significantly to
the antenatal detection of Down's syndrome and, therefore, discussion of antenatal diagnosis
is incomplete without it's inclusion. Moreover, using appropriate algorithms, it may be used
to screen for other aneuploidies as well.
In 1983 Davenport and Macri reported an association between low maternal serum a-
fetoprotein (MSAFP) and late abortion. A year later Merkatz et al (1984) reported an
association between very low MSAFP and fetal trisomy. They noted an undetectable
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MSAFP in a woman who subsequently delivered a trisomy 18 fetus and retrospectively
analysed 41 cases of autosomal trisomy from which serum was still available. In those cases
MSAFP was significantly lower than that of 3862 controls. In their study, if only the
autosomal trisomies were considered, then 17% had values less than 0.25 x MoM (multiples
of the median), compared with 5.3% of the normal population and 28% had a MSAFP less
than 0.4 x MoM, compared with 11.3% of the normal population. If MSAFP was used as the
sole indicator for amniocentesis, 11% of the pregnant population would require
amniocentesis to detect a similar proportion of aneuploid pregnancies as screening based on
age alone and the authors suggested that a further discriminating marker was necessary.
The principles and application of maternal serum biochemical screening are excellently
summarised by Reynolds and Penney (1989). For any variable parameter, there is a
continuum of measurements which follow a Gaussian distribution. Provided the Gaussian
distributions for a given parameter are known for both unaffected and Down's syndrome
pregnancies, then the chance of a Down's syndrome-associated pregnancy is the ratio of the
heights of the Gaussian distribution for affected and unaffected pregnancies. The screen
need not be limited to biochemical data but may include other parameters such as maternal
age and nuchal thickness. Using matrix algebra, any number of variables can determine the
risk of a pregnancy being affected. In devising such algorithms (or "decision trees"), so
called "decision limits" are set. For example, if the risk of a woman carrying a Down's
syndrome fetus is 1 in 250, then she is offered amniocentesis. If the risk is less than this, say
1 in 300, then she is not. The limitations to the complexity of these algorithms are the
inevitable trade-off in sensitivity, specificity and predictive values of the test and hence an
acceptable balance must be struck.
A number of biochemical factors are altered in pregnancies bearing Down's syndrome
fetuses. Because the cell cycle of trisomy 21 cases is longer than for normal karyotypes,
they are physiologically different so that, for instance with trisomic fetuses, mean corpuscular
volume is increased relative to gestational age (Sipes et al, 1991). Aneuploid fetal and
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placental development is different from euploid pregnancies and one might therefore expect
that the pattern of production of placental proteins is altered as well. However, why this
difference exists remains undetermined.
In Down's syndrome, the geometric mean level of human chorionic gonadotrophin (hCG)
is raised whilst AFP and unconjugated oestriol (uE3) are decreased (Wald and Cuckle,
1992). Wald et al (1988) predicted that screening based on Age + hCG + AFP + uE3 could
detect 60% of Down's syndrome cases if 4.7% of pregnant women underwent
amniocentesis. In their prospective study involving over 12,000 patients, Wald et al (1992)
reported that 48% of Down's syndrome cases were detected with a 4.1% false positive rate,
and 43 amniocenteses were performed to detect one case. Although not as good as their
original prediction, it still represented considerable improvement when compared to age-
based screening. They calculated that the cost of detecting a case of Down's syndrome was
£38,000, considerably less than the life-time cost of care of a Down's syndrome patient.
Zeitune et al (1991) in a retrospective study attempted to identify trisomy 21, 13 and 18
simultaneously. They analysed 113,000 unaffected and 142 trisomy pregnancies and found a
significantly reduced MSAFP. When this was combined with maternal age they would have
detected 37% of affected pregnancies with a 6.6% false positive rate. However, closer
analysis suggests that they would have detected only 12% of trisomies in the 25-29year age
group compared with 71% in the 35-37year age group. In common with many algorithms,
detection is weighted in favour of older women (Gaudoin, 1993c). Although the authors
developed an algorithm which encompassed the three common autosomal trisomies
simultaneously, it was not much better than using maternal age alone.
Palomaki et al (1992) in a prospective multivariate analysis, again using the combination
of hCG, AFP and uE3, specifically addressed the detection of trisomy 18 (Edward's
syndrome) which is associated with reduced levels of all three biochemical parameters.
Although 25% of Edward's syndrome show elevated AFP levels (due to a co-existing neural
tube or ventral abdominal wall defect), and these were missed by their algorithm, they
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should be detected by standard AFP protocols and detailed ultrasound scanning. They
correctly detected 6 cases (85%) but, because of the small numbers in the study population,
the 95% confidence interval for detection was 40-95%. They only required to perform 14
amniocenteses for every diagnosis, though again the 95% confidence limits were very broad
(7-41 amniocenteses).
Accurate gestational dating by ultrasound can improve detection rates by almost 10% and
a number of other biochemical markers might in the future be included in analyses (Wald
and Cuckle, 1992). Maternal serum pregnancy-specific b-1 glycoprotein (SP1), human
placental lactogen, progesterone and thyroid antibody levels are all raised in Down's
syndrome pregnancies. Urea-resistant neutrophil alkaline phosphatase is raised and is an
extremely effective marker for Down's syndrome. Unfortunately, it cannot yet be
incorporated into clinical practice as it is labour intensive and currently requires subjective
interpretation of neutrophil stippling (Wald and Cuckle, 1992).
Inhibin is a heterodimer with an a- and a p-subunit. The p-subunit may be either a pA- or
a pB-subunit, (inhibin A and inhibin B, respectively). Aitken et al (1996) in a case-controlled
study retrospectively evaluated an algorithm incorporating maternal age, AFP, intact HCG or
free pHCG (FpHCG) and inhibin A from 528 pregnant women in the West of Scotland. Of
these, 58 were Down's syndrome pregnancies, 32 were trisomy 18 samples and 438 were
control samples. There was no difference between affected and unaffected pregnancies in
the first trimester but after 13 weeks' gestation inhibin A levels in affected pregnancies were
significantly greater. They estimated that they might detect 75% of Down's syndrome cases
(60-87% confidence interval) whilst maintaining a 5% amniocentesis rate. This promising
data will require large prospective studies to determine if inhibin A is as promising as this
retrospective data suggests. If so, it will be a substantial step forward in second trimester
prenatal serum screening.
Another approach is first trimester aneuploidy identification by biochemical markers that
would allow confirmation by CVS and subsequent first trimester termination of pregnancy.
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Kratzer et al (1991) designed an algorithm incorporating first trimester hCG, ahCG and
progesterone. They developed an 'aneuploidy index' and estimated that they could have
detected 9 of 17 Down's syndrome cases (53%) with only a 4.5% false positive rate.
Unfortunately all similar studies are too small and a large prospective study is required.
Unfortunately, in the United Kingdom, particularly in the older pregnant population,
invasive methods remain the first-line screening test (Mutton et al, 1993). However, using
maternal serum screening in the second trimester, it might be possible to detect around 50-
70% of Down's syndrome cases and it is clear that there is potential for improvement. The
best combination of biochemical parameters has yet to be defined but inhibin A is a
promising development. At present, screening is most discriminatory in the mid-second
trimester but in time it may be possible to incorporate physical parameters, such as nuchal
thickness, as well.
69% health boards now offer some kind of biochemical screening programme but
problems remain. All have experienced difficulty in counselling and educating patients (and
care-givers themselves) and, in particular, conveying the message that a negative result
does not necessarily mean that the woman is not carrying a Down's syndrome baby.
Furthermore, and not least, the biochemical suggestion of fetal aneuploidy requires an
invasive procedure thereafter to confirm or refute the possible diagnosis.
2.9 Discussion
It is clear that each antenatal diagnostic method has its benefits and limitations. None is
infallible and for definitive diagnoses, an invasive procedure is necessary which inevitably
carries a risk to the pregnancy.
However, as the field has developed, there has been a trend to earlier and/ or less
invasive methods. In particular, ultrasound in the mid-second trimester can detect many
structural anomalies but is poor at detecting Down's syndrome. First trimester ultrasound has
enormous potential and is being investigated further. Maternal serum screening has
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improved the detection rate of Down's syndrome, particularly in women less than 35 years
old. Unfortunately biochemical screening is not diagnostic and many invasive procedures are
still required to detect an affected pregnancy.
With this background knowledge it is easy to appreciate why the detection and
cytogenetic analysis of fetal cells from maternal blood is such an appealing concept.
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Chapter 3. Isolation of Fetal Cells from Maternal Blood
3.1 Introduction
In 1893 Schmorl, described multinucleated syncitiotrophoblast cells in the pulmonary
vasculature of women who had died of eclampsia but it was only in 1969 that Walknowska et
al proposed that fetal cells isolated from maternal blood might be used for prenatal
diagnostic purposes. Such a suggestion, however, was only possible because of recent
developments and better understanding of cell biology. In particular, it was possible to
culture human leukocytes and arrest mitosis in metaphase and Levan (1956) demonstrated
that human diploid cells possessed 46 chromosomes. Three years later Lejeune et al (1959)
showed that Down's syndrome was due to an extra small acrocentric chromosome (now
called chromosome 21).
Since Walknowska's original idea, enthusiasm for the possibility of cytogenetically
analysing fetal cells from maternal blood has waxed and waned as encouraging results have
been tempered by unlikely reports. However, in recent years intense interest has once more
been rekindled, largely because of further scientific progress. Fluorescence activated cell
sorting and, more recently, immunomagnetics have furthered cell enrichment possibilities
whilst fluorescence in situ hybridisation and polymerase chain reaction have made possible
more detailed genomic analysis. The principles and application of these techniques are
explained at this juncture as constant referral is made to them in much of the following text.
3.1.1 Fluorescence activated cell sorting
The use and capabilities of fluorescence activated cell sorting (FACS or flow sorting), are
excellently summarised by Parks and Herzenberg (1982), the latter of whom is one of the
pioneers in this field.
Cells are labelled with a monoclonal antibody (mAb) with an attached fluorescent marker.
As the cells pass across a laser beam the fluorescent molecules are excited and the emitted
light is collected by a photomultiplier system and converted into an electrical signal. When a
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cell is detected which fulfils the necessary conditions in light scatter and fluorescence,
droplets containing that cell are electrically charged. The droplets pass through an electric
field which draws charged droplets out of the stream and these are collected as sorted
samples. FACS can be applied to any cell which can be obtained in single-cell suspension
and can use any fluorescent label capable of being excited by laser light. Moreover, different
mAbs reacting to different antigens on the same cell may be used simultaneously. Each type
of mAb may be labelled with a different fluorochrome so that cells may be sorted with
greater discrimination. In addition, cells can be differentiated by their light scattering
properties based on their size and cytoplasmic characteristics. Such multi-parameter flow
sorting allows highly specific subsets of cells to be collected whilst other cells, which do not
fulfil the necessary criteria, are said to be gated out. In this way FACS has allowed rare cells
to be separated accurately from cells of no interest.
The sensitivity of the technique is dependent on the excitation efficiency of the marker
and the background fluorescence of unstained cells. For markers such as fluorescein, cells
with only 10,000-20,000 dye molecules can be distinguished and currently the number of
markers is limited by the excitation and detection systems available. The increasing
availability of fluorochromes suitable for use with solid-state lasers heralds the next phase in
this technology by allowing greater numbers of parameters to be gated so that the selection
may be even more specific (Battye and Shortman, 1991).
Although the viability and functional capacity of cells may be affected by FACS, it is
possible to use polymerase chain reaction and fluorescence in situ hybridisation to
investigate fetal cells isolated by this method from maternal blood (vide infra).
Although FACS is the gold standard and reference point for all other cell separation
procedures, it has limitations. Failure to detect a particular antigen does not necessarily
imply absence of the antigen. For instance, minor glycosylation in the case of carbohydrate
moieties might render the antigen 'hidden' and there is sometimes arbitrary distinction
between negative and positive cells. If cells are too close together in suspension then rare
positive cells may be missed and yields from FACS can be variable (Sieff et al, 1982).
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Moreover, the capacity of FACS to handle large numbers of cells is limited. Basic machines
can only sort at a rate of 2000-3000 cells/ second though more recent flow sorters are
claimed to sort at 10,000 cells/ second. However, this is relatively slow if one considers that
in 20ml of blood there are more than 1010 cells. Furthermore, usually about 0.1-1% of all the
sorted cells are collected and considerable numbers of cells may need to be collected.
Hence, the ability of FACS to detect rare cells is limited by the specificity of labelling and the
time to sort for them. Furthermore, FACS machines are extremely expensive, requiring
considerable expertise and technical back-up to be maintained (Manyonda et al, 1992).
If the isolation and cytogenetic analysis of fetal cells from maternal blood is to become a
screening tool, applicable to all early pregnancies, the necessary enrichment techniques
must be robust and relatively inexpensive and FACS probably does not fulfil these criteria.
Although these limitations are recognised, it must be acknowledged that much of the recent
groundwork and advances in the field of fetal cell retrieval remains dependent on FACS.
3.1.2 Advances in Molecular Biology
One of the major issues is to confirm that cells isolated from maternal blood are actually
fetal and the majority of published data involves identifying male DNA (the Y-chromosome)
to demonstrate this.
3.1.2.1 Quinacrine Mustard (QM) staining
The heterochromatin q12 region of the Y-chromosome can be stained with quinacrine
mustard (QM) and is seen as a fluorescent spot when viewed appropriately. Unfortunately,
QM autosome fluorescence is seen on chromosome 3 and chromosome 13 so there is a
high false-positive rate. There is inter-male variability in the size of the Y-chromosome
heterochromatin and, as with many techniques, the method is subject to the vagaries of
inadequate sample preparation and staining conditions (Jonasson, 1986). Kirsch-Volders et
al (1980) found that in 20% of women, 0.02% of cells were QM-positive. All males showed
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positive cells though only 55.7 ± 4.0% of all male nuclei were positive. Clearly, QM -staining
is not an ideal method for accurate sex determination.
3.1.2.2 Fluorescence in situ hybridisation (FISH)
This will be described in greater detail in Chapter 7 but suffice to say at this stage that
FISH involves hybridising a probe which is complementary to nucleic acid sequences
(whether DNA or RNA) in the cell. The probe is labelled with a reporter molecule that allows
subsequent visualisation by immunological development in much the same way as
immunocytochemistry. Using chromosome-specific probes, the number of signals within the
nucleus reflects the number of copies of that chromosome in the nucleus.
3.1.2.3 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) involves amplification of specific DNA sequences so
that, for instance, Y-chromosome-specific DNA from male fetal cells in maternal blood might
be detected. PCR uses two oligonucleotide primers which are complementary to a specific
sequence at the ends of a stretch of DNA. The DNA and primers are heat denatured and
allowed to reanneal with primers hybridising to opposite strands of DNA, one on either side
of the target sequence to be amplified. The primers allow DNA polymerase to start working
only at these specific sites. The DNA polymerase adds nucleotide primers in a 5' to 3'
direction so that extension progresses along the strands of the primers in opposite directions
(figure 3.1). In theory each round of amplification doubles the amount of DNA so that
amplification is exponential rather than simply linear. In practice PCR is about 85% efficient
after 20 cycles. In order to detect the DNA sequence, the PCR products may be digested
with restriction enzymes and the DNA fragments subjected to agarose gel electrophoresis
with ethidium bromide added to the gel to intercalate with the DNA fragments. Smaller
fragments move faster through the gel and their sizes can be compared to known standard
DNA fragments by visualising the ethidium bromide (and hence the DNA fragments) under
ultra-violet light.
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PCR may be used on single cells (Li et al, 1988) but the corollary of such exquisite
sensitivity is the increased likelihood of false positive results. Therefore, as with all molecular
biological techniques, it is important to have both positive and negative controls and strict
adherence to protocols.
It can be appreciated that non-specific binding occurring early in the PCR process will be
amplified to a much greater extent than non-specific binding occurring later, giving a
stronger false-positive signal. This may be limited by "nesting". Nested PCR involves
amplifying a sequence of DNA using "external" primers. PCR is performed again using
another set of "internal" primers within the original primers. This is advantageous as the
initial pair of primers might be similar to other sequences in the genome which, too, will be
amplified. Therefore if there are relatively few target cells e.g. fetal cells in maternal blood,
the fetal sequence will be swamped by amplification of maternal sequences. In fact, most
sequences between mother and fetus will be common and only certain regions of the Y-
chromosome are unique. However, by amplifying the sequence within the original sequence,
non-specific (maternal) sequences will not be amplified any further (figure 3.2).
Nested PCR provides greater amplification potential and higher specificity. Even so, if
there is any contamination from extraneous sources, e.g. from a male technician, because of
the exquisite sensitivity this will be amplified and false positive results may still be obtained.
It is unlikely that a pure population of fetal cells will ever be obtained from maternal
blood. Therefore, maternal DNA will always be in excess. If we consider cells from a Down's
syndrome fetus in maternal blood, the difference between the normal maternal constitution
and the fetal constitution is simply one of dosage - 2:3 copies of chromosome 21. Using
PCR, it would be impossible to diagnose Down's syndrome because the slightly elevated
chromosome 21 dosage could not be demonstrated. However, if fetal cells can be identified
positively and a pure cell population obtained, they may be subjected to quantitative PCR
which might overcome this problem (chapter 10).
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In the published data, most analyses have determined the probability of sexing a series of
pregnancies based on the presence of Y-chromosomal DNA. Assuming that a fetus is as
likely to be male as female, the chance of correctly assigning fetal sex is 0.5 in any one case
and the chance of incorrectly assigning sex is also 0.5.
The following formula was used in all of the cited studies to determine the statistical
significance of gender prediction where "N" is the total number of patients in the series, and
"n" is the number of cases where fetal sex was wrongly assigned.
p = N! (0.5)N + N! (0.5)N + N! (0,5)N + N! (0.5fN
(N-0)!0! (N-1)!1! (N-2)!2! (N-n)ln!
The equations below have also been used to determine the sensitivity, specificity and
other statistical parameters for prospective gender prediction. The Test result' was the sex
assigned by the test so that, for instance, 'a' was the total number of cases in which the test










Sensitivity = Total number of true positives in the test
Total number of all positives in the population (a+c)
a
Specificity = Total number of true negatives in the test





Number of true positives in the test
Total number of positives seen in the test (a+b)
a
Negative = Total number of true negatives in the test




False positive rate =
Number of false positives
Total number of negatives in the population
b = 1 - specificity
(b+d)
False negative rate =
Number of false negatives
Total number of positives in the population (a+c)
c 1 - sensitivity
Finally, before considering the approaches used by different groups to enrich for fetal
cells from maternal blood, it is important to consider the scale of the task.
3.1.4 The scale of the problem
Parks and Herzenberg (1982) cannulated placental blood vessels in Rhesus monkeys and
transfused radiolabeled erythrocytes into the fetus. These could be topped up via the
cannula. Once confident that continuing transplacental haemorrhage was not iatrogenic they
estimated the daily transplacental haemorrhage of fetal blood to be 0-2pl. Eventually a
steady state developed where cells were entering the maternal circulation at the same rate
as they were removed. The most recent sensible estimates suggest there is perhaps 0.04-
0.2pl of fetal blood in 20ml of maternal blood (Hamada et al, 1993). Table 3.1 shows that
even if this higher figure is accurate, in 20ml of maternal blood at 15 weeks' gestation there
might only be 420 fetal erythroblasts (0.2pl x 2.1 x109 erythroblasts/l) and 270 fetal
lymphocytes. In 20ml of maternal blood there are 101° cells, or one nucleated fetal cell for
every 108 nucleated maternal cells. Therefore, looking for fetal cells in maternal blood is like
looking for the proverbial needle in the haystack.
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Table 3.1. Mean fetal erythrocyte and leukocyte values (Millar et al, 1985)
Weeks' gestation 15 16 17 18 19 20 21
Total erythrocytes (x10TZ/l) 2.43 2.68 2.74 2.77 2.92 3.12 3.07
Mean cell volume (fl) 143 143 137 135 129 126 123
Erythroblasts (x109/l) 2.1 3.6 2.5 2.2 1.7 1.2 0.8
Total leukocytes (x109/l) 1.6 2.4 2.0 2.4 2.5 2.6 2.7
Neutrophils (x106/l) 113 198 127 161 134 129 192
Lymphocytes (x109/l) 1.36 2.17 1.70 2.12 2.16 2.33 2.33
Note the relative reduction in erythroblast concentration with increasing gestation compared
to leukocytes.
Knowing the enormity of the task, the possibility of isolating fetal cells from maternal
blood can be considered. Importantly, when reviewing the published studies it must be borne
in mind that there is a tendency not to publish negative findings and to report only successful
studies. Consequently, optimistic reports must be viewed with a degree of caution.
For simplicity the historical evidence will be considered according to cell type and in a
chronological fashion. Although each is described in isolation, different groups have been
working on enrichment of different cell types simultaneously. Throughout the narrative, when
a certain number of "weeks' gestation" is quoted, it implies the number of weeks of
amenorrhoea.
The large number of published studies by necessity compels omission of some and
inclusion of others and studies on whole maternal blood will be discussed first.
3.2 Analysis of fetal cells from whole maternal blood
A number of groups have attempted to identify and analyse nucleated fetal cells from
whole maternal blood with minimal enrichment (initial removal of only erythrocytes).
Therefore, any type of nucleated fetal cell might be analysed.
Zilliacus et al (1975) searched for Y-chromatin-positive interphase cells based on QM
staining. They found that 0.02 - 0.16% of all lymphocytes appeared to be positive which
suggested that there were 103-104 maternal leukocytes for every nucleated fetal cell. They
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correctly identified 7 of the 11 male fetuses with one false positive result (p = 0.048). They
cultured the cells but could not identify any XY mitoses and could not find any non-nucleated
fetal erythrocytes although they expected to find considerably more of these cells compared
to nucleated cells. They concluded that if these cells were lymphocytes then they crossed
the placenta by some form of active and selective transport rather than by haemorrhage.
However, alternative explanations are that insufficient metaphase preparations were
examined, particularly as fetal cells are now thought to be rarer than they assumed or, more
likely, that the apparently high proportion of cells with a QM signal was due to false-positive
autosomal fluorescence associated with QM staining.
Using direct blood smears and QM staining, Siebers et al (1975) reported on one hundred
pregnant women none of whom had given birth to a male less than two years previously. In
early pregnancy they found large nucleated cells which they assumed to be lymphoblasts
and 77.8% of male-bearing pregnancies were Y-chromatin-positive by 12 weeks' gestation.
They suggested that the proportion of fetal cells did not increase significantly with advancing
gestation though closer scrutiny suggests that analyses were more reliable in the second and
third trimesters. Twenty-four cases involved first trimester pregnancies and sex prediction
was 75% accurate (p < 0.02). However, from the results of the second and third trimester
cases, sex prediction was 96.7% accurate (p < 0.0001). A mean of 3.75% of lymphocyte-like
cells were Y-chromatin positive and although the overall results were highly significant, the
absolute numbers of apparent fetal cells was unlikely. Such a large figure would represent
about 40ml of fetal blood in the maternal circulation and again, a more likely explanation is
the false positive results associated with QM staining.
Because of such unlikely data, particularly as the only analytical technique available at
that time was fraught with a high false positive rate, the interest in fetal cells in maternal
blood waned. However, it was reawakened by the development of polymerase chain reaction
(PCR).
In 1989 Lo et al analysed 19 pregnancies using nested PCR, amplifying a region of the
DYZ1 locus of the distal long arm of the Y-chromosome. In none of the seven female-
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bearing pregnancies was a Y-specific sequence identified but in all 12 cases involving male-
bearing pregnancies a band was detected (p < 0.0001). They found that at least 15 cycles
were required using the internal primers in late pregnancy whilst 20 cycles were required less
than 11 weeks' gestation. However, beyond 20 cycles false-positive results were consistently
obtained and in three non-pregnant female controls they had one false positive result.
Although women performed all experimentation, they conceded that "nesting" was liable to
detect even the tiniest amount of contaminating material and produce false-positive results.
An alternative explanation for the false-positive results is that a 323 bp segment, which
spanned the segment flanked by the external primers used is present in 10% of women
(Nakagome et al, 1990).
Lo et al (1990) then reported the nested technique with primers which were purportedly
more Y-specific. In 12 cases from 6-11 weeks' gestation, fetal gender prediction was 83.3%
accurate (p < 0.04). In all 27 cases, up to term, gender prediction was 77.8% accurate (p <
0.003). They failed to generate Y-sequences in 4 cases involving a male fetus, possibly
because there were very few or no circulating male fetal cells, and suggested that this may
be overcome by multiple sampling of women. However, logistically this may not be practical
and what is probably better is to determine the optimum time in early pregnancy when
sampling is likely to be most rewarding. Furthermore, although their primers were
purportedly more Y-specific, their false positive rate of 20% again demonstrated the extreme
sensitivity of PCR to potentially extraneous DNA.
Haemoglobin Lepore-Boston is a haemoglobinopathy caused by a hybrid 5p-gene. In
1990, Camaschella et al took blood from three mothers known to be carriers of p-
thalassaemia, who had partners known to be carriers of the haemoglobin Lepore-Boston
trait, and subjected it to gene sequence-specific PCR. Both cases of the condition were
correctly identified at 8-10 weeks' gestation with results confirmed by conventional invasive
methods. This was a major landmark as, for the first time, a genetic disease was diagnosed
prenatally by non-invasive means.
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However, the following year Nakagome et al (1991) reported their study of 18 patients
using nested PCR. From control experiments they detected one male cell in 25,000 female
cells. However, in none of the 8 cases involving a male fetus could they obtain a male-
specific sequence, suggesting a much lower ratio of fetal to maternal cells. Suzumori et al
(1992) investigated 100 women prenatally and 30 women immediately postpartum (15
males, 15 females). Using the original nested primers of Lo et al (1989) they correctly
predicted the sex in 30 of 45 males whilst 10 of the 55 female-bearing pregnancies were also
positive. Overall the gender prediction accuracy was 75% (p < 0.0001). In the postnatal
studies, all the women who gave birth to males were PCR-positive, suggesting a greater
volume of fetal blood in the maternal circulation following delivery. However, positive results
were also obtained in 7 out of the 15 women who gave birth to females and the authors
suggested that contamination from male workers and the previous birth of a male child might
account for this. However, the proportion of false positive results that could be attributed to
this latter factor (2 of the 10 antenatal patients and 3 of the 7 postnatal women) was small
when compared to the total number of false positive results. The other possible explanation
was the homology of the DYZ1 region with autosomal sequences which is only detectable
with dual amplification (Nakagome et al, 1990). Whatever the reason, it emphasised the
susceptibility of nesting to false positive results and better primers would be required if such
an approach was to be applicable clinically.
In 1993 Hamada et al subjected the mononuclear cells from 50 primigravidae to FISH
and nested PCR. Because they were mononuclear, any fetal cells were unlikely to be
syncitiotrophoblasts or polymorphs but may have been cytotrophoblasts, lymphocytes or
erythroblasts. By 15 weeks' gestation XY interphase cells were identified in all male
pregnancies and correlated with PCR though FISH had greater specificity as it was less
prone to false positive results. However, prior to 15 weeks' gestation, only two male (XY
interphase) cells were found in the eight women carrying male fetuses and two positive cells
were found in one of the 15 primigravidae carrying a female fetus.
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In the same year Langlois and Wilson (1993) used nested PCR on whole maternal blood
in 27 pregnancies at 10-11 weeks' gestation but gender prediction accuracy was poor (59%,
p > 0.05). Liou et al (1993) investigated 31 pregnancies at 8-14 weeks' gestation again with
nested PCR and they achieved 100% concordance in sex prediction (p < 0.0001). They first
identified male DNA at 8 weeks' gestation and by 13 weeks' gestation they had demonstrated
a Y-specific sequence in 95% of the male pregnancies.
Lo et al (1993) used PCR to amplify for the Rhesus D gene in Rhesus-negative women.
They accurately predicted the fetal Rhesus status in 16 of 21 pregnancies (p < 0.02) and
showed that fetal genotype implicated in fetal diseases could be demonstrated in maternal
blood.
Thomas et al (1994), using nested PCR, accurately identified the fetal sex in all 5 in vitro
fertilisation pregnancies before 6 weeks' gestation (less than 27 days' post-embryo transfer)
which is probably the earliest demonstration of fetal DNA in maternal blood. This study
continued to a total of 30 patients and, astonishingly, gender prediction from whole blood
was 100% accurate (p < 0.0001). No male DNA could be detected eight weeks postnatally
suggesting that regardless of the cell type analysed, there did not appear to be any
persistence of fetal DNA which might confuse results in subsequent pregnancies (Thomas et
al, 1995).
Smid et al (1997) employed nested PCR with the Y-specific sequence, DYS14, in 27
women taking samples from each trimester and their data suggested that the concentration
of fetal cells in maternal blood was highest in the first and third trimesters. Although quite a
small study, it was encouraging because the subsequent management of a complicated
pregnancy is most easily planned from an early stage.
Bianchi et al (1997) took blood from 199 women carrying chromosomally normal fetuses
and from 31 women with a male aneuploid fetus and subjected the blood to quantitative PCR
with Y-chromosome-specific primers. Although there were false-positive DNA products
detected in pregnancies bearing a female fetus there were quantitatively more products in
male-bearing pregnancies (p < 0.01). Clearly this was neither a prospective nor blinded study
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but significantly more fetal cells were detected in maternal blood when the fetus was
aneuploid. This may have been because the invasive procedure used to initially diagnose
the abnormality had increased the deportation of fetal cells in to the maternal circulation
(Jansen et al, 1997) or that fetomaternal transfusion is increased because placentation is
abnormal when the fetal karyotype is abnormal (see also chapter 7).
These studies suggest that fetal DNA sequences (usually male) may be found in maternal
blood in early pregnancy which might be useful in X-linked recessive conditions or in cases
where a gene is carried by the fetus but not the mother. However, the inability of PCR to
detect fetal aneuploidies in cells from whole maternal blood is a significant limitation to its
application. Furthermore, using PCR with the same primers, different groups have arrived at
entirely different results, suggesting significant variation in fetomaternal transfusion and also
highlighting the methodological problems associated with analysis of rare cells.
When the published studies are considered together, the large range of sensitivities (0-
100%) without any preselection method underlines the need for an enrichment step.
However, to achieve this, the enrichment technique must be reliable and probably enrich for
a particular cell type to the exclusion of other potential nucleated fetal cells. The possibilities
lie with fetal leukocytes, trophoblast cells or erythroblasts and each will be considered in turn.
3.3 Lymphocytes
Walknowska et al (1969) cultured maternal blood using the lymphocyte mitogen,
phytohaemmaglutinin (PHA), and reported that 0-1.5% of the metaphase preparations
showed 5 small acrocentric chromosomes. They presumed these corresponded to the two
copies of chromosomes 21 and 22 and a Y-chromosome and of the 21 women who
demonstrated this phenomenon, 19 gave birth to boys (p < 0.0002).
Because the cells resembled lymphocytes and responded to PHA, and normal placentae
do not contain lymphoid cells, they suggested that they were fetal blood cells which found
their way into maternal blood. If haemorrhage was the entry mechanism, the proportion of
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putative fetal lymphocytes would be equivalent to more than 100ml of fetal blood. They did
not believe that such a large volume could have resulted from a single episode of bleeding
and suggested that small, recurrent bleeds were more likely. The alternative, or additional,
explanation was that lymphocytes migrated through vascular endothelium from fetus to
mother whilst other fetal blood cells could not breach this interface. They went on to suggest
that the proportion of fetal lymphocytes was so high because they may be more sensitive to
PHA, favouring their presence as mitotic cells over maternal lymphocytes. Furthermore, fetal
lymphocytes might survive for longer in the maternal circulation so that a small but chronic
transfer resulted in large numbers in maternal blood. Hence, the absolute volume of fetal
blood in the maternal circulation might be small and yet the proportion of fetal lymphocytes
could be quite high. Moreover, they suggested that lymphocyte transfer might actually be
necessary for successful pregnancy outcome. As lymphocytes express HLA antigens, their
escape into the maternal circulation may have some bearing on the mother accepting the
fetus as "self'.
The authors attributed the two false positive results to artefacts such as a broken
chromosome but conceded that the persistence of XY cells from previous pregnancies due
to fetal-maternal chimerism was a possibility. Their explanation of the three false negative
results was that very few cells were cultured in these cases and so finding fetal metaphase
spreads was less likely. However, closer analysis suggests that in these three cases a mean
of 590 metaphase spreads were examined (range, 470 - 700) compared to 440 metaphase
preparations overall (range, 192 - 900). If the "male" spreads were truly fetal, it is more likely
that either the ratio was less than one in 900 or that there were no fetal cells in the original
negative blood samples.
Schroder et al (1977), again using quinacrine staining on cultured lymphocytes in
metaphase failed to predict fetal sex with any accuracy and concluded that fetal
lymphocytes, if present, were unresponsive to the commonly used mitogens. However, they
also suggested that the interphase cells which had been analysed by other groups might
have been placental cells and not lymphocytes.
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As long ago as 1962 Payne had established that HLA antigens were expressed on fetal
lymphocytes from the twelfth gestational week. In 1979 Leonard Herzenberg and colleagues
used fluorescence activated cell sorting (FACS) to enrich for HLA.A2-positive lymphocytes
from HLA.A2-negative pregnant women, known to be carrying a male fetus (from prior
amniocentesis). In 5 cases they found 2-7 cells which were quinacrine-positive and neonatal
studies showed all five babies to be HLA.A2-positive. In the other cases no Y-chromatin cells
were identified and all seven babies were HLA.A2-negative (p < 0.0003).
Kirsch-Volders et al (1980) cultured lymphocytes from 18 women from 6 weeks' gestation
to term and using QM staining they found that 0.04-0.23% of peripheral blood mononuclear
cells were positive, representing about 10ml of fetal blood. From metaphase preparations
gender prediction was 89% accurate (p < 0.004). The first true positive Y-chromatin cell was
at 10 weeks' gestation though, in fact, both false positive results were from cells at earlier
gestations. They pointed out that this approach might only be practical in primigravidae
because of lymphocyte longevity and the possibility of persistent fetomaternal chimerism
(Ciaranfi et al, 1977). Importantly, they also emphasised that it was impossible to
differentiate between a mother and her female fetus.
The group headed by Leonard Herzenberg then reported a further, much larger and
complex study (Iverson et al, 1981). Of 108 women, 48 were HLA.A2-negative and known to
be carrying a male fetus. Twenty-one of these had HLA.A2-positive partners. 20ml of
maternal blood was flow sorted using an anti-HLA.A2 mAb and in all eight cases where the
neonate was subsequently found to be HLA.A2-positive, between 1-7 Y-chromatin-positive
cells were identified. The first positive cells were recovered at 15 weeks' gestation. In 1 case
where the baby was HLA.A2-negative, they found two Y-chromatin-positive cells whilst in
none of the other 12 cases (HLA.A2-negative male newborns) did they find any positive
cells. In no instance where both parents were HLA.A2-negative did they find any positive
cells. The remaining 19 HLA.A2-negative women gave birth to girls and in only one case
were any Y-chromatin-positive cells found. Although this baby was HLA.A2-positive,
quinacrine staining of her cells did not show any positive interphase signals. Of these
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women, 13 had given birth to boys in the past. The authors concluded that fetal lymphocytes
did not persist for any length of time in maternal blood and previous reports of this kind were
probably due to autosomal fluorescence associated with quinacrine staining. These results
were highly significant (p < 0.0001) and they estimated that there was 1 fetal lymphocyte to
1000-5000 maternal lymphocytes which was compatible with realistic minor, chronic
transplacental haemorrhages. Although the sorted cells resembled lymphocytes they
suggested that they could also be fetal haematopoietic progenitors as these also express
HLA antigens.
Selypes and Lorencz (1988) then reported a novel enrichment technique. They subjected
blood to conventional culture techniques and also to their "air culturing" technique. Using QM
staining, sex prediction was 84.8% accurate (p < 0.0001). Based on the ratio of Y-chromatin-
positive cells to maternal cells, they found "air culturing" to be superior (p < 0.01) and
suggested that this technique preferentially cultured fetal cells. To date no-one has
confirmed the improved results using "air" culturing, and an open mind must be kept about
its applicability.
Tharapel et al (1993) enriched for fetal lymphocytes using FACS based on HLA
differences between pregnant women and their partners. Using standard lymphocyte culture
techniques they could not find any XY metaphase spreads in any male pregnancy and
attempted to explain these negative findings in a number of ways. The numbers of fetal cells
in maternal blood may vary depending on the cell type and gestational age so that at
particular gestations it might be appropriate to enrich for particular cell types. Alternatively,
fetal lymphocytes may be unresponsive to the standard mitogens. Using FACS they found
that up to 2% of maternal cells which were negative for the mAbs used actually bound the
antibody so that the relative enrichment of fetal lymphocytes was minimal. They only
examined a mean of 135 metaphase preparations per sample (range, 0-613) and, given
that fetal cells are very rare and enrichment was minimal, insufficient numbers of metaphase
preparations were probably examined. Of course how fetal lymphocytes in maternal blood
respond to the usual mitogens is unknown but we obtained umbilical cord blood from a
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second trimester Down's syndrome fetus at termination of pregnancy and cultured the cells.
We confirmed the 47 XX, +21 karyotype and, from our own first hand experience, it would
seem that fetal lymphocytes in the second trimester are responsive to phytohaemmaglutinin
(unpublished data). Tharapel et al's final point was that fetal cells in the maternal circulation
may not be lymphocytes but erythrobiasts. Fetal erythroblasts express HLA antigens in low
density and if present might have been enriched by their technique. However, they probably
do not respond to lymphocyte mitogens and they did not report interphase cytogenetic
analysis.
It is apparent that the data regarding fetal "lymphocyte" interphase or metaphase
cytogenetic analysis is conflicting. Quinacrine staining suggested implausibly large numbers
of fetal lymphocytes in maternal blood but this may be due to its poor specificity. Moreover,
the possibility that fetal lymphocytes persisted from previous pregnancies might confuse
karyotyping. Morphologically fetal lymphocytes are indistinguishable from maternal
lymphocytes and detailed HLA typing is probably impractical as a routine screening
procedure for all pregnant women. Finally, lymphocyte surface antigens have never
unequivocally identified the cell types actually analysed in these studies and some have
suggested that they might be haematopoietic progenitors. For these reasons the isolation of
fetal lymphocytes from maternal blood is probably not a practical solution to the problem.
3.4 Granulocytes
To date there has been only one report investigating fetal granulocytes in maternal blood
(Wessman et al, 1992). Erythrocyte-depleted blood was subjected to absorption in situ
hybridisation using a Y-chromosome probe and visualised with diaminobenzidine
tetrachloride and overall, gender prediction accuracy was 90.9% (p < 0.01). In this study
0.13 ± 0.08% of polymorphs showed a Y signal and the authors proposed polymorphs as a
fetal cell type suitable for enrichment because they have a short half-life so that persistence
to a subsequent pregnancy is unlikely.
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However, closer analysis is required. If we consider the data from Table 3.1, the
estimated number of fetal granulocytes in the maternal circulation represented over 150ml of
fetal blood. This is highly improbable. There is no evidence that polymorphs are actively
transported across the placenta and the most likely explanation is the high false positive rate
associated with absorption in situ hybridisation compared to fluorescence in situ hybridisation
(Jonasson, 1986). This study was small and has yet to be corroborated by others.
Furthermore, it would be impossible to differentiate fetal from adult granulocytes and, at
present, enrichment of fetal granulocytes from maternal blood is not a realistic prospect.
3.5 Trophoblast cells
Trophoblast cells are in direct contact with maternal blood and, therefore, no breach in
the fetomaternal interface is necessary for these cells to enter the maternal peripheral
circulation.
In 1893 Schmorl described trophoblast cells in the lungs of women who had died of
eclampsia, now a well-documented phenomenon (figure 3.3). However, trophoblast
deportation may be a physiological phenomenon and possibly a prerequisite for successful
pregnancy. As trophoblast cells do not express Class I and Class II MHC-antigens they may
antigenically "present" the fetus to the mother so that she does not reject it as "foreign"
(Adinolfi, 1992a). Furthermore, because they do not stimulate an aggressive immune
response, they may not be removed rapidly from the maternal circulation.
Douglas et al (1959) analysed whole maternal blood with no attempt at enrichment or
immunohistochemical identification. They found multinucleate cells in 61.5% of broad
ligament veins at Caesarean section but only in 9.1% when sampling the inferior vena cava.
They could not identify any trophoblast cells in 80 women following antecubital vein
sampling. Their work was corroborated by Attwood and Park (1961) who suggested that
trophoblast cells were removed rapidly by the pulmonary vasculature and did not circulate
for very long.
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Little was reported until Covone et al (1984) described a mAb, H315, which identified
cytotrophoblast and syncitiotrophoblast cells. It did not, apparently, stain blood cells. Using
FACS with H315 they isolated mononuclear and multinuclear cells in 50% and 80% of
pregnancies respectively. There was no relation to gestational age and no attempt was made
to sex the pregnancies prospectively. Unfortunately, 50% of controls also showed H315-
positive multinucleated cells. Pool et al (1987) found that H315 reacted strongly with
syncitiotrophoblast but variably with cytotrophoblast. Using FACS with this mAb they could
not isolate positive cells in 25% of pregnant women and the population of sorted cells was
not significantly different between pregnant and non-pregnant women. Furthermore, as the
FACS-sorted cells were negative for other trophoblast markers, they concluded that H315
was unreliable. In a follow-up to their original study, Covone et al (1988) flow sorted H315-
positive cells and using PCR with Y-specific primers, no Y-DNA fragment was observed in
any pregnancy with a male fetus. Following lymphocyte incubation with cellular elements
from chorionic villi they found that lymphocytes became H315-positive and suggested that
circulating maternal leukocytes adsorbed the placental antigen on to their surface and were
thus positively sorted.
In a slightly different approach, Adinolfi et al (1989) used immunomagnetic Dynabeads
conjugated to H315 mAb in an attempt to enrich for trophoblast cells. Following isolation and
PCR, no Y-DNA fragments were observed. They, too, suggested that H315 was unhelpful.
Mueller et al (1990) used Dynabeads with two mAbs to trophoblast surface protein
antigens. The isolated cells were subjected to PCR with Y-specific primers and overall
gender prediction was 92.3% accurate (p < 0.002). They suggested that the only false-
positive case may have been due to a "male vanishing twin" with the abortus shedding large
numbers of trophoblast cells into the maternal circulation. The group continue to screen for
trophoblast-specific mAbs but, because of commercial considerations, have not made these
available for testing by external laboratories.
Bruch et al (1991) used FACS with three anti-trophoblast mAbs (which did not react with
erythroblasts) and identified Y-DNA by PCR in two of the three women carrying a male fetus.
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In nine of twenty-three pregnant women, they failed to find any positive cells (p = 0.186) and
the sorted cells did not look like trophoblasts by either light or electron microscopy. They
suggested that perhaps trophoblast cells in maternal blood are altered morphologically and
that maternal leukocytes adsorbed trophoblast-antigens on to their surface. Of course it may
be that their mAbs were not trophoblast-specific and reacted with maternal blood cells as
well. The same group, in a case report, addressed the problem of leukocyte contamination
by a multiple stage enrichment process (Cacheux et al, 1992). Blood was taken from a
woman known to be carrying a 47, XYY fetus and the erythrocytes were removed by density
gradient centrifugation. The lymphocytes were removed immunomagnetically and the
remaining cells flow sorted with two of their original mAbs. Using FISH with a Y-chromosome
probe, 45 of the 1387 collected cells (3.2%) showed one Y signal and 14 (1%) showed two Y
signals. In the original amniocentesis sample 66% of scored nuclei showed two Y signals.
The false negative results might have been due to inefficient hybridisation (chapter 7.9.2)
but an alternative explanation is that the two Y signals in cells were false positive signals as
they did not report their results with control samples. In any case, in this situation PCR would
have been unhelpful as it would not have permitted discrimination between one and two Y
signals in the cells. From this example, the need for FISH to diagnose autosomal trisomies is
apparent.
Thomas et al (1994, chapter 3.2) investigated 5 in vitro fertilisation pregnancies which
had undergone pre-implantation sexing and, using nested PCR, they accurately identified
both male-bearing pregnancies before 6 weeks' gestation. Fetal vessels are only present in
the villus stroma from 8 weeks' so it was unlikely that fetal blood elements could escape into
the maternal circulation as early as 5 weeks'. Because of this physiological precondition,
they proposed that the most likely source of fetal DNA was trophoblast cells.
Durrant et al (1994) screened 19 oncofetal antibodies for trophoblast specificity but when
coupled to immunomagnetic beads, even the most trophoblast-specific of these could not
detect trophoblast cells in artificial admixtures. However, they subsequently reported their
experience using immunomagnetics and positive sorting for both fetal erythroblasts and
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trophoblast cells (Durrant et al, 1996). They subjected the potential trophoblast cells to PCR
and found that gender prediction was poor (p = 0.09) whilst if potential fetal erythroblasts
were analysed on their own, gender prediction was just significant (p < 0.03). However, if the
two were combined, prediction was greatly improved (p < 0.002) because of a reduction in
the large false negative rate associated with either cell types analysed on their own. They
argued that cytogenetically analysing fetal erythroblasts could act as an internal control if
confined placental mosaicism was suspected, although the problems associated with positive
selection are discussed further in chapter 6.
Of all the potential cells for enrichment, trophoblast cells are the only ones which are
fetal-specific and no breach is necessary for cells to enter the maternal circulation.
Unfortunately, generation of specific mAbs is difficult as antigens may be adsorbed on to
maternal leukocytes often resulting in a high false-positive rate. Furthermore, confined
placental mosaicism could prevent definitive diagnoses being made from a maternal blood
sample. All suspected aneuploid pregnancies would require invasive diagnostic testing
(chapter 2.3) which would defeat the aim of non-invasive prenatal diagnosis. In summary,
although isolating trophoblast cells has merits it also has considerable shortcomings and,
therefore, many groups are now focusing on fetal erythroblasts.
3.6 Fetal erythroblasts
In 1990 Diana Bianchi and her colleagues enriched for fetal erythroblasts from maternal
blood and there are a number of reasons why these might be good candidate cells for
enrichment.
a) Relative proportions of erythroblasts at different gestational ages.
In the first and early second trimesters, as placentation establishes, there is rapid
invasion of fetally-derived cells into maternal arterioles. Hence, it is plausible that around
this time frequent breaches occur in the fetomatemal vascular interface, allowing more fetal
blood cells into the maternal circulation. Erythroblasts are the most common type of
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nucleated cell in early pregnancy but their proportion, relative to other nucleated cells,
declines rapidly after 18 weeks' gestation as the main site of erythropoiesis switches to the
spleen and bone marrow (figure 10.2, table 3.1). Therefore, the majority of nucleated fetal
blood cells entering the maternal circulation from a minor transplacental haemorrhage in
early pregnancy, should be erythroblasts.
b) Adult erythroblasts in the peripheral circulation.
The bone marrow is a dedicated organ, efficient at retaining its progenitor cells and in
healthy pregnant woman, adult erythroblasts should not find their way into the peripheral
circulation. However, pregnancy places additional demands on erythropoiesis and there is
some evidence that maternal erythroblasts enter the peripheral circulation during pregnancy
(Slunga-Tallberg et al, 1995). This emphasises that erythroblasts are not fetal-specific but,
even so, if erythroblasts are recovered there remains a good chance that they are fetal.
There are a number of pathological conditions where erythroblasts escape into the
peripheral circulation (Table 3.2). Of all these, severe iron deficiency anaemia,
haemoglobinopathies and splenectomy are the most likely conditions to be encountered in a
pregnant woman and thus confuse analyses. The others are generally life-threatening and
the woman, in any case, is unlikely to conceive.
Table 3.2. Pathological conditions associated with peripheral erythroblasts (Harper,
1968)
• Post-splenectomy
• Severe anaemia: iron deficiency, megaloblastic, haemolytic
• Polycythaemia
• Haemoglobinopathies
• Di Guglielmo syndrome
• Leukaemias
• Neutrophilic leukaemoid reactions
• Leukocytoses with predominant neutrophilia (e.g. sepsis)
• Subacute or chronic haemorrhage




Cohen et al (1964), using an anti-Rhesus antibody, showed that the frequency of fetal
erythrocytes in maternal blood increased with advancing gestation and the likelihood of
finding fetal erythrocytes approached 100% if enough samples were taken. They suggested
that transplacental passage was an intermittent, recurrent event and a normal phenomenon
of pregnancy. This was substantiated by the model of Parks and Herzenberg (1982, chapter
3.1.4) and if their model is pertinent to humans then it would suggest that fetal erythroblasts
are escaping constantly into maternal blood. Fetomaternal haemorrhage probably increases
as pregnancy advances but at later gestations a greater haemorrhage would be required for
the same number of erythroblasts to find their way into the maternal circulation than at
earlier gestations.
d) Peripheral mitoses.
Fetal erythroblasts are capable of mitosis (Tipton et al, 1990) and if they enter the
maternal circulation they could be mitotically active and amenable to detailed cytogenetic
analysis.
e) Removal of fetal erythrocytes from the maternal circulation.
Adults receiving incompatible blood group transfusions remove the foreign blood rapidly.
However, it is possible that incompatible fetal blood does not initiate as great an immune
response. At least 500pl of Rhesus-positive blood is needed to initiate an immune response
as fetal erythrocytes have 75% fewer reactive A and B sites than adult erythrocytes (Voak
and Williams, 1971) and erythroblasts express even fewer antigen sites than erythrocytes
(Sieff et al, 1982). The Rhesus-D antigen is only expressed from the pronormoblast stage
onwards and antigen expression reaches a maximum only when the erythrocyte is fully
mature (Rearden and Chiu, 1981). Consequently, fetal erythroblast destruction may not be
as rapid as in adult-to-adult incompatible transfusions and they may persist for their natural
lifespan in maternal blood.
f) Erythroblast lifespan.
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Little is known of the maturation time of early fetal multipotential stem cells but
observations in adult bone marrow suggest a five day intramedullary maturation time
(Erslev, 1990). If this applies to fetal erythropoiesis, they should not persist for any length of
time in the maternal circulation. Therefore, if found consistently in maternal blood it implies
that fetal erythroblasts are constantly removed or become enucleated and are replaced by
chronic transplacental haemorrhage. This means that fetal erythroblast persistence to
another pregnancy is improbable and unlikely to confuse cytogenetic analyses in the index
pregnancy, offering a major advantage over fetal lymphocytes (chapter 3.3).
g) HLA incompatibility.
Erythroid precursors express HLA antigens but these are gradually lost during maturation
(Sieff et al, 1982). Of course this could mean that, because of HLA incompatibility, fetal cells
are removed rapidly from maternal blood. However, many groups have shown that fetal cells
can be enriched by exploiting HLA differences (chapter 3.3) so that either there must be a
degree of HLA-incompatible tolerance between mother and fetus and/ or a stable state of
removal and replacement of fetal cells exists.
h) Morphological identification.
Erythroblasts have a characteristic morphology and are easily distinguishable from other
cells. Fetal erythroblasts are large cells though their size decreases as pregnancy advances
(table 3.1). We believe figure 3.4 demonstrates a fetal erythroblast which was enriched from
the blood of a pregnant woman (chapter 6) as it is much larger than the surrounding adult
erythrocytes.
Chromosomally abnormal fetuses, especially trisomies, have a significantly higher mean
corpuscular volume than controls as they appear to have escaped normal erythropoietic
control mechanisms or lag behind by a matter of weeks (Sipes et al, 1991). Although this
phenomenon is unexplained, it represents an intrinsic red cell abnormality and this obvious
morphological difference might allow even easier differentiation of potential fetal
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erythroblasts on a microscope slide in karyotypically abnormal pregnancies, particularly if the
slide was scanned by a robot (chapter 10.4).
i) Positive identification of fetal erythroblasts.
If fetal erythroblasts can be identified immunologically as well as morphologically, it
would aid rapid identification of these cells on a slide and minimise false results with
subsequent cytogenetic analyses. The composition of haemoglobin in fetal erythrocytes
varies throughout gestation (figure 10.2) and if mAbs can be raised to embryonic
haemoglobin chains it should be possible to positively identify fetal erythroblasts and,
thereafter, subject them to cytogenetic analyses using fluorescence in situ hybridisation.
Enrichment of fetal erythroblasts from maternal blood
During cell proliferation, CD71 (transferrin receptor) expression increases 2-5 fold. CD71
is expressed on activated lymphocytes, a small proportion of other peripheral blood cells and
erythroid progenitors up to and including the reticulocyte stage (Sieff et al, 1982) but is lost
rapidly thereafter (Frazier et al, 1982).
Bianchi et al (1990) enriched for fetal erythroblasts by FACS based on CD71 expression
and, from an original 20ml of maternal blood, using PCR they accurately identified 6 of 8
male-bearing pregnancies (p < 0.003). They estimated recovery of about 1ng of fetal DNA,
equivalent to approximately 150 cells. At 17 weeks' gestation, 150 erythroblasts represents
approximately 0.04pl of fetal blood, equivalent to 10pl in the entire maternal circulation,
which is considerably less than other estimates (Parks and Herzenberg, 1982; Hamada et al,
1993). Enrichment procedures inevitably incur some cell loss and their calculations did not
take this into account. Consequently, there might be even more fetal blood in the maternal
circulation. Nevertheless, considerable enrichment is still necessary.
Glycophorin-A (GPA) is the erythroid-specific major membrane sialoglycoprotein and
appears at the erythroblast stage, reaching a maximum at the normoblast stage (Kansas et
al, 1990). There are no surface antigens which are erythroblast-specific and only glycophorin
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and the Rhesus antigens are erythroid-specific (Yokochi et al, 1984). Rhesus cannot be used
as a sorting parameter as it would only be appropriate for Rhesus-incompatible pregnancies.
GPA, however, in combination with CD71 should identify erythroblasts and reticulocytes.
The large size of fetal erythrobiasts (table 3.1) also allows size to be used as a gating
parameter with FACS. After enucleation, right-angle scatter of erythroid cells is increased,
possibly because of the acquisition of the biconcave disc shape (Loken et al, 1987), and
hence reticulocytes may be gated out of the sorted cells. Based on this rationale, Price et al
(1991) from Tennessee flow sorted on cell size, cytoplasmic granularity, transferrin receptor
and Glycophorin-A expression. They collected 0.4 ± 0.7% of cells from first trimester
samples and 2.2 ± 3.6% of cells from the second trimester samples. Most were reticulocytes.
Using nested PCR with Y-DNA primers on 18 samples they predicted fetal gender with
94.4% accuracy (p < 0.0001). Using FISH with a Y-chromosome-specific repeat sequence
probe, about 10% of sorted cells showed a Y-domain in male-bearing pregnancies but their
false positive rate was 25% and the false negative rate was 35.7%. Overall, gender
prediction was only 68.2% accurate (p > 0.05). They also sorted cells one week after a
patient underwent chorionic villus sampling and was found to be carrying a Down's syndrome
fetus. Twenty-four of 62 cells analysed showed three domains using a chromosome 21-
specific probe. Although many of these cells might have been introduced into the maternal
circulation by the invasive procedure, if fetal erythroblasts only have a five day lifespan then
those erythroblasts escaping at the time of CVS should have enucleated by the time
enrichment was attempted.
The group also took blood from a woman prior to first trimester CVS, flow sorted the cells
and performed FISH with probes for the Y-chromosome and chromosomes 18 and 21. From
a total of 681 cells reported, 8.7% of nuclei showed a single Y domain, 8.5% (25 of 295)
showed three chromosome 18 domains whilst only 3.0% (5 of 166) of cells showed three
chromosome 21 domains. From these results they predicted the 47 XY, + 18 karyotype
correctly. This report was a milestone. It demonstrated that fetal cells, probably erythroid,
could be isolated from maternal blood in early pregnancy and diagnoses of fetal aneuploidy
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could be made. The case report also illustrated that FISH, and not PCR, is necessary to
diagnose fetal aneuploidy and that simultaneous X and a Y-chromosome probes are required
to predict fetal sex accurately.
Bianchi et al (1991) amended their original protocol by removing leukocytes with FACS
and then collected CD71-positive cells. The sorted cells were subjected to PCR and
combining this data with that of their 1990 study, they suggested that Y-specific DNA
fragments were easiest to obtain up to 16 weeks' gestation and declined thereafter. It is
preferable to make a diagnosis of fetal abnormality early in pregnancy and, if these findings
are correct, it would be advantageous.
The Tennessee group then reported a prospective diagnosis of Down's syndrome (Elias
et al, 1992). In two cases, prior to first trimester CVS, they flow sorted maternal blood and
used FISH with a chromosome 21 probe. Each observer scored one hundred nuclei and in
one case 74% of the nuclei exhibited 3 signals. Using this probe in diploid cells, 7.5% (range
= 0-12%) of nuclei exhibited 3 signals and they used this level as a cut-off for karyotype
prediction. From their results they correctly predicted a 47, +21 karyotype. Unfortunately in
the other reported case only 2.9% of sorted nuclei exhibited three signals which would have
fallen below their threshold and, erroneously, the fetus would have been considered diploid.
However, their data must be interpreted with caution. In the "diagnostic" sample they
collected 37,000 nucleated cells and three independent observers each scored only 100
nuclei. It is highly unlikely that they examined the same cells and this would suggest that
there were over 27,000 fetal erythroblasts in 20ml of maternal blood. The issue of fetal
erythroblast persistence is unresolved but from current assumptions concerning their short
half-life, this would represent an unlikely figure of 5ml of fetal blood in the maternal
circulation.
Although, this report was encouraging, it illustrated a deficiency in FISH analysis. Cell
fixation strips away the cytoplasm to improve probe access and it is then impossible to
identify the sorted cells positively. Furthermore, the hybridisation efficiencies of individual
probes, particularly with regard to the cell type, must be determined. Karyotype assignment
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based on spot counts then becomes a statistical question related to the ratio of fetal to
maternal cells. The number of sorted maternal cells is likely to remain reasonably constant
from sample to sample but, as far as is known, there is considerable variation in the number
of fetal cells between pregnancies. Therefore, in aneuploid pregnancies, if there are very few
fetal cells they might not take the count of aneuploid cells above the threshold, as in the
second reported case. It is clear that positive identification prior to FISH is imperative to
allow cytogenetic analysis only of fetal cells.
Bianchi et al (1992) reported a case at 19 weeks' gestation involving a Down's syndrome
fetus (47XY, +21) diagnosed by prior amniocentesis. They enriched for cells by FACS based
only on CD71 expression and subjected the isolated cells to FISH using a probe for
chromosome 21 and the Y-chromosome. Only three cells showed a single Y domain and
three chromosome 21 domains simultaneously. One cell showed three chromosome 21
signals but no Y-probe signal. Because of the very small number of cells that suggested the
true fetal karyotype it would have been impossible to arrive at any meaningful conclusion.
Ganshirt-Ahlert et al (1992) used positive selection based on CD71 expression with the
Miltenyi magnetic activated cell sorting system (MACS). Their results are discussed in
greater detail in chapter 6.4.4 but even in model systems they found that the relative
enrichment of erythroblasts was poor. However, because of the expense and complexity of
FACS, such alternative strategies are necessary if fetal cell retrieval from maternal blood is
to become a routine early pregnancy screening procedure.
In 1993 Bianchi et al adopted a multiparameter approach to flow sorting to prospectively
sex fetuses with PCR. Again they combined data from previous reports with newer data.
Using CD71 expression alone, gender prediction was poor (p = 0.28). They used an
additional marker, CD36, the thrombospondin receptor, which is apparently expressed from
the colony forming unit-erythrocyte stage of fetal but not adult erythrocytes. In these cases
gender prediction accuracy was 87.5% (p < 0.05). They enriched five maternal blood
samples based on GPA expression alone and gender prediction was 100% accurate (p <
0.05). They sorted five samples on both CD36 and GPA expression so that, in theory, only
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erythroid progenitors should be collected and again gender prediction was 100% accurate.
In the three final women they used CD71 and GPA and although gender prediction was
again 100%, these results could have arisen by chance. The authors found that 4.9-25.3% of
sorted cells expressed both CD36 and GPA whilst only 0.4-1.7% of cells expressed both
CD71 and GPA. They suggested that the dual antibody protocol identified different
subpopulations of cells though in fact the CD71/GPA-positive population could have been a
subset of the CD36/GPA population. If the 13 patients where GPA was used are considered
(regardless of other mAbs) the chance of predicting fetal sex with such accuracy was less
than 1 in 10,000. They concluded that, because the sorted fetal cells expressed GPA, it was
convincing proof of their erythroid origin.
Following their original communication, Ganshirt-Ahlert et al (1993) reported an improved
immunomagnetic enrichment method using a triple density gradient cushion (Bhat et al,
1993). The cells harvested at the upper interface were enriched further by MACS using an
anti-CD71 mAb and the recovered cells stained with a simple haematological stain. Their
data suggested that the number of fetal erythroblasts increased exponentially with advancing
gestation and as many as 500,000 erythroblasts were recovered which is surprising as
previous reports suggest far fewer cells. However, in seven cases they subjected the
recovered cells to FISH using a Y-chromosome repeat sequence probe. In the male-bearing
pregnancies a mean of 14% of nuclei showed a single Y signal and gender prediction was
100% accurate (p < 0.008). During pregnancy around 0.83% of maternal blood cells are
CD71-positive (Adinolfi, 1992a). However, the data of Ganshirt-Ahlert et al suggest that
around 0.1% of all nucleated cells in maternal blood should be fetal. This is extremely
unlikely and their results must be considered with caution. The authors also subjected
enriched cells from known or suspected fetal aneuploidies to FISH using appropriate
chromosome probes. They found that the mean percentage distribution of cells with three
signals in trisomic pregnancies did not overlap with the percentage distribution of cells with
three signals in normal pregnancies. However, in the ten trisomy 21 cases, only one of the
diagnoses was made prospectively i.e. prior to an invasive diagnostic procedure. Of the five
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trisomy 18 cases, only one of the diagnoses was made prospectively and even this was at 33
weeks' gestation. Of all the common aneuploidies, trisomy 18 has the most characteristic
ultrasound malformations (Nicolaides et al, 1992) and, given the late stage of diagnosis, fetal
abnormality was possibly suspected because of other clinical abnormalities such as
intrauterine growth restriction which may have prompted an ultrasound scan. Their data
suggested that more fetal cells escaped into the maternal circulation in aneuploid
pregnancies, a phenomenon which was also reported by Simpson and Elias (1993). In some
way aneuploid placentation differs from normal pregnancies, with associated altered
placental hormone production (chapter 2.8), and it may be that these placentae also allow
fetal cells to cross into the maternal circulation in greater numbers as well. They followed
patients postnatally to address the possibility of fetal erythroblast persistence in maternal
blood and, using FISH in aneuploid pregnancies, the percentage of putative trisomic cells fell
to control levels by 7-10 months postpartum. If the cells were fetal erythroblasts, and they do
not persist beyond 10 months postpartum, they should rarely confuse analyses in
subsequent pregnancies.
The same group reported that fetal erythroblasts could be identified from five weeks'
gestation. They found that, up to 16 weeks' gestation, as many as 10,000 fetal erythroblasts
in 91.3% of all pregnancies (Ganshirt-Ahlert et al, 1994). As so many putative erythroblasts
were found, the validity of these results must be questioned. Phagocytic cells should be
removed prior to MACS separation or they engulf the beads, the nuclei become pyknotic, the
cells assume an erythroblast-like morphology (using simple Romanowski stains) and they
are easily confused with true erythroblasts (Manyonda et al, 1992). The density gradient
media used by Ganshirt-Ahlert et al preferentially collected neutrophils and as they did not
use any other confirmatory test, such as immunocytochemistry or FISH, it might explain the
high numbers of putative erythroblasts they recovered. Although encouraging, it emphasises
that positive identification is imperative to minimise false results.
Zheng et al (1993) reported a study to prove simultaneously that the isolated cells were
both erythroid and fetal. Erythrocytes were removed by density gradient centrifugation and
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then the majority of leukocytes were removed with anti-CD45 and anti-CD32 mAbs using the
immunomagnetic MACS system. In their model experiments (spiking adult blood with fetal
erythroblasts), leukocyte removal was rather variable: relative to the number of leukocytes
before and after enrichment, erythroblast enrichment ranged from a factor of 18- to 184-fold.
However, from cytospin preparations of the enriched maternal blood samples, the remaining
cells were identified on slide using a mAb to y-globin (UCH y, Allen et al, 1987) with Vector
Red as the chromogen. The positions of the y-globin-positive nucleated cells were recorded
and the slides subjected to FISH using a repeat sequence Y-chromosome probe. The cells
were relocated and, if negative for a Y-domain, FISH was performed again but using an X-
chromosome centromeric repeat sequence probe. In five of the pregnancies (four males
and one female) between 2 and 11 positive cells were identified and in all of these gender
was correctly predicted (p < 0.03). In the other sample, no y-globin-positive cells were
identified. Immunocytochemistry prior to FISH reduced the hybridisation efficiency of the Y-
chromosome probe from 98% (non-erythroblast male cells) to 64% (erythroblasts subjected
to immunocytochemistry). They did not report the hybridisation efficiency of fetal
erythroblasts which had not undergone prior immunocytochemistry but the effects of the dual
procedures is discussed in greater detail in chapter 9.
Reading et al (1995) enriched for fetal erythroblasts using MACS by negative and then
positive sorting. They subjected the recovered cells to immunocytochemistry with an anti-
HbF mAb and thereafter FISH. In 5 of 40 cases there were no HbF-positive cells and in
23/40 FISH failed on the positive cells. Of the remaining 12 cases, gender prediction was
83.3% accurate (p < 0.02) but this must be taken in the context of the additional 28 cases
where no result was obtainable. Slunga-Tallberg et al (1995) reported that erythroblasts
could be enriched from 37 of 40 primigravidae in greater numbers than in non-pregnant
women. The nucleated cells were all glycophorin A-positive and all women were known to be
carrying a male fetus. They too found that hybridisation efficiency was reduced with
erythroblasts (see also chapter 7) and, concerningly, none showed an XY karyotype. They
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concluded that these cells must be maternal erythroblasts which enter the peripheral
circulation during pregnancy.
Bianchi et al (1996) flow sorted maternal blood for erythroid precursors and subjected the
collected cells to PCR for a Y-chromosome sequence. Both sensitivity and specificity were
poor (68% and 69% respectively) and the false-positive rate was 31%. They suggested that
the high false-positive rate was due to prolonged persistence of fetal DNA because of
microchimerism between fetal and maternal cells. However, an alternative explanation
would be contamination of the samples with DNA from male technicians but either way it
demonstrated the major limitation of PCR in this context. Furthermore, it illustrated that
absence of amplification products requires confirmation that fetal material is actually present
rather than the test being falsely negative.
Sohda et al (1997) enriched for erythrobiasts with FACS and subjected the recovered
cells to Y-chromosome FISH. Of the thousands of cells recovered, almost 5% displayed a
Y-chromosome signal. Although gender prediction was extremely accurate, given other
estimates of the frequency of fetal erythroblasts in maternal blood, this large number is
unlikely and again suggests that the cells should be identified positively in some way prior to
cytogenetic analysis. Campagnoli et al (1997) positively sorted for erythroblasts using the
immunomagnetic MACS system and correctly identified all seven male fetuses using Y-
chromosome FISH.
Mavrou et al (1998), also using the MACS system, enriched for erythroblasts by depleting
leukocytes and found between 1 and 15 y-globin-positive cells in 35 of the 40 women.
Unfortunately they managed to successfully perform FISH with sex chromosome probes in
only five cases which suggests that very few cells can be recovered and, also, that the
efficiency of FISH with fetal erythroblasts is poorer than with other cell types.
Bischoff et al (1998) reported their results on 40 women, from 10 to 27 weeks' gestation,
using FACS with a combination of negative and positive enrichment for fetal erythroblasts
and subsequent multi-colour FISH analysis. They only evaluated between 154 and 4212
cells from each woman and the gender prediction accuracy was only 72.5% because of the
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high false negative rate (68.7%) in assigning the fetus as male. There were two cases of
trisomy 21 and in both only one trisomic cell was identified in the 272 and 955 cells
evaluated from each case. Given the small number of positive cells, it would be impossible
to confidently assign the abnormal fetal karyotype. Furthermore, there was one case of
trisomy 18 and they enriched cells at 27 weeks' gestation. Trisomy 18 is characterised by
clinically detectable fetal growth retardation and pathognomonic ultrasound features and
confirmatory invasive testing would be offered. The text only states that one of the 40 cases
was performed because of abnormal ultrasound findings but, given the late gestation at
testing, it is reasonable to assume that this was the one. Unfortunately they failed to
diagnose the karyotype which is, of course, is concerning.
Al-Mufti et al (1999) reported positive immunomagnetic enrichment of erythroblasts on
230 pregnancies at 10-14 weeks' gestation, prior to invasive testing. Of these women, 36
(16%) were carrying a trisomy 21 fetus. The recovered cells were subjected to FISH with a
probe for chromosome 21 and, in 22 cases, over 5% of nuclei displayed 3 signals. These
data must be viewed cautiously as the 16% incidence of trisomy 21 is considerably higher
than any other reported series for prenatal diagnosis and the high proportion of trisomic cells
recovered from maternal blood is similarly much higher than other series even using FACS,
the acknowledged gold standard for cell separation.
Most recently, Wang et al (2000) reported a direct comparison of FACS and MACS. This
was simply a comparison as blood was taken immediately after termination of pregnancy
when a larger number of fetal erythroblasts might be expected to leak into the maternal
circulation. They subjected maternal blood to both FACS using an anti-y-globin mAb and
negative enrichment with MACS (depletion of CD45-positive cells) and staining the
remaining cells with the anti-y-globin mAb. The collected cells in both groups were subjected
to X- and Y-chromosome FISH and they found that the yield of fetal cells was better in the
FACS group. This confirmed that FACS remains the gold standard for enrichment but,
because of its technical disadvantages (vide supra), simpler, less expensive enrichment
methods must continue to be investigated.
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3.7 Summary
Although fetal cells can be found in maternal blood, they are extremely rare. Even the
most recent reports suggest that very few cells can be recovered which emphasises the
absolute necessity for positive identification of fetal cells prior to cytogenetic analysis. The
apparent absence of fetal DNA does not necessarily mean that fetal DNA is not present or,
vice versa, that cells which appear fetal morphologically, may actually be maternal.
PCR analysis of whole blood might allow the diagnosis of certain genetic disorders but is
prone to false-positive results and it cannot be used to diagnose fetal aneuploidies. FISH
analysis on whole maternal blood samples is impractical and some form of fetal cell
enrichment is necessary.
The original analyses on putative fetal lymphocytes were dogged by the lack of specificity
of both the enrichment and the cytogenetic techniques available at that time but, as these
techniques improved, it appeared that they could be isolated reliably from maternal blood.
Unfortunately, there is the possibility that fetal lymphocytes might persist from previous
pregnancies which could confuse karyotyping. Furthermore, detailed HLA typing would be
required to distinguish fetal from maternal lymphocytes which is impractical.
The only study analysing fetal neutrophils from maternal blood was flawed both
theoretically and methodologically and most groups have dismissed the potential of fetal
neutrophils as a candidate cell type.
Of all the potential cells, trophoblast cells are the only ones which are truly fetal-specific.
Furthermore, no vascular breach is necessary for trophoblast cells to enter the maternal
circulation. Unfortunately, generation of trophoblast-specific mAbs has proved extremely
difficult and as trophoblast cells have limited mitotic capability it may restrict the efficiency of
FISH. Finally, and most importantly, confined placental mosaicism could severely restrict the
potential for definitive diagnoses to be made from a maternal blood sample alone.
Current opinion suggests that erythroblasts are the most promising fetal cell type for
enrichment from maternal blood as transplacental haemorrhage appears to be a common,
and possibly physiological, phenomenon and erythroblasts are likely to cross over in greatest
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numbers in early pregnancy (Adinolfi, 1992b). They are morphologically and immunologically
distinctive cells and they appear to be mitotically active. Fetal erythroblasts also express
fewer antigens than their adult counterparts so they might not be removed rapidly from the
maternal circulation despite blood group incompatibilities. Furthermore, the volumes in the
maternal circulation might be insufficient to provoke an immune response. Unfortunately,
hybridisation efficiency appears to be poorer than with other cell types and whether fetal
erythroblasts persist for any length of time postnatally remains unresolved.
However, many of these statements are largely conjecture and the large number of small
studies with varying results attests to the problems of enrichment and cytogenetic analysis of
fetal cells from maternal blood.
3.8 Aims of this Thesis
If fetal cells isolated from maternal blood are to be used diagnostically, the test must be
at least as good as the invasive tests it replaces. If used as part of a screening test, it must
be as good as maternal serum and nuchal thickness screening.
Before this can happen, certain key questions must be answered. Can fetal cells be
recovered in all pregnancies? What is the optimal time for blood sampling? How many cells
can be recovered and how much maternal blood would be needed? How reliable is FISH on
the recovered cells? Is it possible to prove that the recovered cells are fetal and thereafter
to perform FISH on them? Are currently available cytogenetic techniques adequate to
obviate invasive diagnostic techniques and could gene disorders be diagnosed? And finally,
what factors may confound analyses? Because of the above factors, we have concentrated
our efforts on fetal erythroblasts and by doing so, address some of these questions.
This study aimed to develop a simple, inexpensive and automatable technique to enrich
for fetal erythroblasts from maternal peripheral blood and to cytogenetically analyse the
enriched cells using fluorescence in situ hybridisation. Attempts were also made to identify
the cells positively prior to FISH. The philosophy of automation was fundamental as only
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then could it ever be applicable on a large scale. Robotics and automation was beyond the
scope of this thesis but each of the steps had to be simple if this was to be achieved.
The methods were developed on models which were subsequently applied to maternal
blood samples and the problems encountered are discussed in the following chapters.
Although each of the chapters is described in isolation, it will become apparent that the
different aspects of enrichment and cytogenetic analysis are inter-related, and alteration of
one aspect had repercussions for subsequent steps in the procedure.
The techniques used throughout this project are described in a logical progression for the
novice who might wish to repeat some of this work and all experiments conformed to, and

















Figure 3.3 Trophoblast cell (arrowed) in a maternal pulmonary vessel at post
mortem
/
Figure 3.4 A fetal erythroblast (arrowed) enriched from the blood of a pregnant
woman
Note the large size of the erythroblast relative to adult erythrocytes
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Chapter 4. General Laboratory Techniques
4.1 Morphological Staining Techniques
4.1.1 May-Grunwald-Giemsa
Slide preparations (either whole blood smears or cytospin specimens) were fixed in 100%
methanol for five minutes, immersed in neat May-Grtinwald stain for 10 minutes and then
immediately in 12% Giemsa (in pH 6.8 distilled water) for five minutes. The slides were
rinsed in distilled water (pH 6.8) and air dried prior to mounting.
4.1.2 Reticulocyte stain
New methylene blue (1g) in 100ml of citrate-saline solution. Equal volumes of stain and
whole blood were mixed in an Eppendorf tube and incubated at 37°C for 15 minutes. The
blood film was examined at x100 magnification.
4.2 Cell counts
4.2.1 Nucleated cell count.
Diluting fluid: 2% acetic acid in distilled water (to lyse erythrocytes) with 3 drops of methyl
violet to stain the nuclei. 50pl of whole blood was aspirated and the external surface of the
pipettor tip carefully wiped clean. The blood was ejected into 950pl of diluting fluid and fluid
was repeatedly drawn in and out of the pipettor tip to wash all the cells into the diluting fluid.
This was then thoroughly mixed for five minutes. A drop of suspension was drawn under the
coverslip of an improved Neubauer Counting Chamber by capillary action. The number of
nuclei were counted in the four large squares at the corners and the central large square and
this figure was multiplied by 40 to calculate the nucleated cell count x 103/ml.
4.2.2 Erythrocyte count
Diluting fluid: Sorenson's buffered saline with 1% formalin (to fix the cells). 5pl of whole
blood was added to 995pl of diluting fluid in the same manner as for a nucleated count and
mixed thoroughly. A drop was drawn under a Neubauer coverslip and the number of
erythrocytes were counted in the four small corner squares and the central small square of
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the central large square of the counting chamber. This figure was expressed as the total
number of erythrocytes x 107/ml.
4.3 Immunocytochemistry
4.3.1 Principles of immunocytochemistry
Many of the methodologies described in subsequent chapters are dependent on
immunological techniques and exploitation of monoclonal antibodies. Hence, an overview of
the principles is given at this stage.
All tissues express certain antigens to which specific "monoclonal" antibodies (mAbs)
may be raised. The primary mAb, often mouse anti-human, when incubated under
appropriate conditions, will bind firmly to it's target antigen. The binding site can be
visualised using a secondary antibody (perhaps a rabbit anti-mouse antibody with a marker,
or chromogen, attached) directed against the original mAb. The chromogen may be a
fluorescent marker or one visualised by enzyme precipitation to leave a known coloured
stain. Because the secondary antibody has multiple binding sites many secondary antibodies
bind to the primary mAb. The more secondary antibodies clustered around the original tissue
antigen site, the greater the signal produced. Layers can be built up like an inverted pyramid
depending on the intensity of signal required (figure 4.1). An indefinite number of layers can
be developed but as secondary antibodies are often polyclonal they may react with different
antigens, non-specifically binding to other tissues and increase "background" staining. At
best this will confuse the picture but at worst can be misinterpreted as target antigen. Hence,
there is a balance between signal intensity versus background staining, a dilemma


















In order to minimise non-specific binding of the secondary antibody to other tissue
antigens, the species of blocking serum should be of the same species as the secondary
antibody (e.g. normal rabbit serum with rabbit anti-mouse secondary antibody). Phosphate
buffered saline with 1% bovine serum albumin should be used if there are multiple layers
involving different species.
Assessment of signal intensity is subjective but generally follows a plateau distribution i.e.
at very weak and very high primary mAb concentrations, signal intensity is poor whilst the
greatest but equivalent signal intensities are seen over a broad band of mAb dilutions. If the
primary mAb is too concentrated steric hindrance may result as too many mAbs compete for
the same antigen. As a result of this crowding, the secondary antibodies cannot bind
adequately and the subsequent signal intensity is reduced. Conversely, if the mAb is too
dilute, too little binding also results in a weak signal. Hence, for economy, the weakest
primary mAb concentration should be used without compromising the final signal.
The monoclonal antibodies used will be discussed in detail in the appropriate chapters.
4.3.2 Immunocytochemistry Method
All immunocytochemistry experiments were performed with a positive control (to ensure
that the process had worked) and a negative control (no primary mAb) to ensure that
secondary antibody binding was specific.
For best results, slides were fixed in methanol: acetone 50:50 for five minutes and air
dried. Slides were washed in tris buffered saline (TBS) for 15 minutes and incubated with
normal rabbit serum (NRS) for 10 minutes. The primary mAb was added for 30 minutes at
room temperature and washed off with TBS for 10 minutes. The slides were then incubated
with the secondary antibody for 30 minutes and washed again in TBS for 10 minutes. If the
secondary antibody was directly-labelled with a fluorochrome the slides were mounted in
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Vectashield/DAPI and viewed using a Zeiss Axioplan microscope. Images were captured on
an Apple Macintosh Quadra 950 using IPLab Spectrum 2.4 software.
If the secondary biotinylated antibody required enzyme development the slides were
incubated with streptavidin alkaline phosphatase for 30 minutes, washed in TBS for 10
minutes and then developed with the DAKO New Fuchsin kit for 20 minutes as per the
DAKO protocol. The slides were rinsed for 5 minutes in tap water, air dried and
counterstained with Giemsa before mounting in glycergel (DAKO).
The above method, with necessary adaptations, was used repeatedly throughout the
following chapters and will be discussed in detail where appropriate.
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Chapter 5. Density gradient removal of mature erythrocytes
The ratio of fetal erythroblasts to all maternal cells is estimated at 1 in 108-1010 (Chueh
and Golbus, 1991; Simpson and Elias, 1993). The majority of blood cells are non-nucleated
erythrocytes and hence enormous enrichment is necessary to reduce this to a more
manageable figure.
Strategically it was logical to remove the major contaminating cell type (mature
erythrocytes) as the first enrichment step and this was the object of density gradient
centrifugation.
5.1 Principles of Separation
The relative density of different blood cell types increases from platelets, to monocytes,
lymphocytes, basophils, neutrophils and eosinophils whilst non-nucleated erythrocytes are
the most dense. Therefore, when centrifuged, erythrocytes gravitate most readily and a
"buffy coat" of leukocytes and platelets collect at the top of the cell column.
In a continuous density gradient column, the density of the medium is greater at the
bottom than at the top. Cells form layers where their densities are less than the underlying
medium and this level is known as the isopyknic point. A discontinuous gradient has a
constant density throughout the fluid column.
5.2 Development of separation media
The reaction between two compounds can be increased if it occurs at an interface and
centrifugation promotes further the collisions necessary for such reactions to occur.
B0yum (1964) created an iodine-based medium of known specific gravity, "Natrii" (N-
methyl-3,5-diacetoamido-2,4,6-trijodbenzoas) and added methylcellulose to encourage red
cell aggregation through interaction with carbohydrate moieties on the cell membrane. The
resultant rouleaux were more dense and passed through the medium leaving unaggregated
nucleated cells above the medium.
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The degree of erythrocyte removal can be manipulated by altering the relative density,
the methylcellulose concentration, the pH or the osmolality of the medium. Unfortunately, the
trade-off is in target cell recovery which must be maximised for rare cells such as fetal cells
in maternal blood. Moreover, the densities of a particular cell type follow a Gaussian
distribution and there is overlap in densities between the most dense of one cell type and the
least dense of another. Therefore, there will always be some contamination by unwanted
cells.
Histopaque (Sigma) is a mixture of an iodinated compound, sodium diatrizoate, and the
polysaccharide, ficoll 400. The proportion of diatrizoate can be varied to selectively enrich
for particular cell types. Ficoll improves erythrocyte removal by rouleaux formation but
because of this erythroblasts may also be removed.
Nycodenz is a non-ionic tri-iodinated derivative of benzoic acid with three aliphatic
hydrophilic side chains. It lacks any red cell aggregating agent so that erythroblasts should
not be lost in the red cell pellet if they are less dense than the medium. The relative density
of Nycodenz can be specified depending on the proportions of Nycoprep and Nycodenz
buffer.
A number of different density gradient media and different types of centrifugation tube
were investigated to determine which removed most non-nucleated erythrocytes whilst
maximising fetal erythroblast recovery.
5.3 Methods
The initial model involved umbilical cord blood taken at delivery, collected in EDTA tubes
(Local Ethics Committee approval having been obtained) and three different density gradient
media were investigated.
Erythrocyte and leukocyte counts and a differential cell count were determined with the
differential count always based on the first 1000 nucleated cells in consecutive high power
microscope fields.
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5.3.1 Density gradient media on model systems
5ml of whole blood was carefully layered on to 3ml of density gradient medium and
centrifuged at 500 x g for thirty minutes. The cells were harvested at the plasma/ gradient
interface, washed in 2% (w/v) bovine serum albumin in phosphate buffered saline [2% (w/v)
BSA in PBS] for two minutes and the supernatant centrifuged at 250 x g for fifteen minutes.
The washing process was repeated twice more and the cells resuspended in 2% (w/v) BSA
in PBS up to the original volume of 5ml.
Erythrocyte and leukocyte counts and a differential count were determined from the
harvested cells, which allowed the proportion of recovered nucleated cells and fetal
erythroblasts to be calculated.
The efficiency of separation using whole or washed blood was also compared. Whole
blood was divided into equal aliquots and one aliquot was diluted in 2% (w/v) BSA in PBS,
washed for five minutes and then the cells pelleted at 350 x g for fifteen minutes. The
washing process was repeated once more and the pellet resuspended to its original volume
in 2% (w/v) BSA in PBS. This sample and the original whole blood aliquot were then layered
on to equal volumes of the density gradient medium and centrifuged as previously
described.
Model systems of cord blood mixed with varying proportions of adult blood from healthy
volunteers were investigated and again the efficiency of centrifugation was determined.
Samples were also obtained from the products of conception at first trimester suction
termination of pregnancy (with Ethics Committee approval and informed patient consent).
The whole sample was diluted in 2% (w/v) BSA in PBS and filtered through nylon stockings
to remove solid matter leaving a fluid which was relatively rich in erythroblasts. Inevitably it
also contained maternal blood. Cell and differential counts were determined. The samples
were then mixed with varying proportions of adult blood from healthy volunteers as it was
hoped that this model would simulate whole maternal blood more realistically. The minimum
dilution investigated was 5pl of termination blood (fetal and maternal) diluted in 10ml of
healthy, non-pregnant female volunteer blood.
88
In the later stages of the project, another gradient medium, Nycodenz, relative density of
1.085, was also investigated on fetal blood from these samples.
5.3.2 Centrifugation tubes
Using Histopaque 1119, four different centrifugation tubes were compared directly:
conical Sterilin centrifugation tubes (catalogue number, AS144), Falcon polypropylene tubes
(catalogue number, 2096) and translucent polystyrene tubes (catalogue number, 2099) which
were claimed by the manufacturers to be smoother, facilitating erythrocyte removal. A major
disadvantage of density gradients is the time and care required to layer whole blood without
disturbing the interface. Greiner polypropylene LeucoSep tubes (catalogue number, 163290)
have a porous filter fixed transversely towards the bottom of the test tube which allows whole
blood to be poured on to the filter without disturbing the interface.
5.3.3 Maternal blood
15ml of venous blood was drawn from the antecubital fossa of pregnant woman at 7-15
weeks' gestation and collected in EDTA tubes (with Ethics Committee approval and informed
patient consent). Whole blood was subjected to density gradient centrifugation using
Histopaque 1119 as above and resuspended in 2% (w/v) BSA in PBS. The cell suspension




Tables 5.1 - 5.5 present the results of the different variables investigated. The results are
presented as mean values (± 1 standard deviation), where "n" is the number of samples
studied and the results are tabulated for easier comparison of data. Student's t-test was used
for statistical analysis and the 95% confidence intervals for the data were determined using
SPSS (version 8.0) statistical programme.
Table 5.1 details the differential nucleated cell count from term cord blood, the results
being similar to those published previously (Playfair et al, 1963).
Table 5.1 Cell and differential counts in term cord blood
Cell type Cell count
Erythrocytes 4.43 (±0.38) x 10a/ml
Nucleated cell count 9.4 (± 1.0) x 10b/ml !
Polymorphs 59.0 ± 7.5%
Lymphocytes 35.3 ± 6.5%
Monocytes 0.2 ± 0.2%
Erythroblasts 5.6 ± 4.5%
Cells stained with May-Grunwald-Giemsa stain (n = 105).
Table 5.2 details the efficiency of erythrocyte removal and recovery of leukocytes and
fetal erythroblasts. Both ficoll-hypaque and Histopaque 1077 resulted in better erythrocyte
removal than Histopaque 1119 (p < 0.001) but Histopaque 1119 recovered significantly more
erythroblasts (p < 0.001). This latter result is probably more important as, given the small
number of fetal erythroblasts expected in maternal blood, maximum erythroblast recovery at
each stage of the enrichment process is necessary.
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Blood centrifuged at room temperature at 500 x g for thirty minutes.
*p < 0.001, erythrocyte removal comparing density gradient medium with Histopaque 1119.
**p < 0.001, leukocyte recovery comparing density gradient medium with Histopaque 1119.
Tp < 0.001, erythroblast recovery comparing density gradient medium with Histopaque 1119
95% confidence intervals in parentheses.
Washing blood prior to density gradient centrifugation resulted in poorer recovery of both
leukocytes and erythroblasts (table 5.3) although this did not reach significance.
Table 5.3 Comparison of the effect of washing blood prior to density gradient
centrifugation on nucleated cell recovery in term cord blood
Medium Percentage recovery
of nucleated cells (%)
Percentage recovery
of erythroblasts (%)
















Blood washed prior to centrifugation in 2% (w/v) BSA in PBS and then centrifuged at room
temperature at 500 x g for thirty minutes (n = 8, each group).
95% confidence intervals in parentheses.
In direct comparisons of Histopaque 1119 with Nycodenz 1.085, the former appeared to
be more efficient at removing erythrocytes although this did not reach statistical significance
(p > 0.05, table 5.4). However, Nycodenz 1.085, because it lacks a red cell aggregating
agent resulted in better erythroblast recovery (p < 0.001).
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Table 5.4 Direct comparison of Histopaque 1119 and Nycodenz 1.085 using artificial





















P NS NS < 0.001
Centrifugation at room temperature at 500 x g for thirty minutes (n = 10 each group)
NS = not significant. Note the superior erythroblast recovery with Nycodenz (95% confidence
intervals in parentheses).
Direct comparisons using different centrifugation tubes showed that there was little
difference in erythrocyte removal or leukocyte recovery (p > 0.05) except that Greiner tubes
recovered fewer leukocytes compared to the Sterilin tubes (p < 0.001, table 5.5).
Table 5.5 Comparison of different centrifugation tubes using H1119
Centrifuge tube Erythrocytes removed (%) Leukocytes recovered (%)
Sterilin 99.98 ± 0.01 46.6 ± 5.7*
(99.97 - 99.99) (46.5 - 46.7)
Greiner 99.97 ±0.03 30.8 ± 1.7*
(99.95- 99.99) (29.8-31.8)
Falcon (2099) 99.99 ±0.01 36.1 ±22.7
(99.97 - 99.99) (23.3 - 48.9)
Falcon (2096) 99.98 ± 0.01 42.5 ±21.5
(99.97 - 99.99) (30.3 - 54.7)
Centrifugation at room temperature at 500 x g for thirty minutes (n = 12 each subgroup)
95% confidence intervals in parentheses.
*p < 0.001, difference between Sterilin and Greiner tubes on leukocyte recovery
5.5 Discussion
The experiments in model systems showed that ficoll-containing density gradient media
resulted in good erythrocyte removal and the more dense the medium, the better the
recovery of erythroblasts. Non-aggregating media resulted in poorer erythrocyte removal
(though this was not significant) but better erythroblast recovery.
Washing resulted in increased loss of erythroblasts presumably because cells adhered to
the test tube walls and/or clumped. Inevitably the more washing steps, the greater the
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losses. Because fetal erythroblasts are extremely rare in maternal blood, and every effort
must be made to maximise their recovery, washing was abandoned.
There were only marginal differences in erythrocyte removal using the different types of
tubes. The Greiner tubes were easiest to use, but least efficient at erythrocyte removal (as
erythrocytes tended to stick at the porous filter and were collected with the nucleated cells).
They also recovered fewer leukocytes. The polystyrene Falcon tubes (2099) were best at
removing erythrocytes but nucleated cell loss was greater. Erythrocyte removal and
nucleated cell recoveries were similar for the Sterilin and polypropylene Falcon tubes (2096)
but leukocyte recovery (and, presumably fetal erythroblast recovery) was more predictable
using the Sterilin tubes.
Bhat et al (1990) enriched for fetal lymphocytes from homogenised fetal livers using a
discontinuous dual density gradient system of Histopaque 1077 (H1077) on Histopaque 1119
(H1119). They found that lymphocytes preferentially collected at the plasma/H1077 layer
whilst erythroblasts collected at the H1077/H1119 interface. Although the upper interface
was relatively free of erythroblasts (less than 0.5% of the nucleated cells) overall 17.4% of
all erythroblasts collected at this interface. They subsequently used a discontinuous triple
gradient of H1077, H1107 and H1119 to enrich specifically for erythroblasts in model
systems (Bhat et al, 1993). Erythroblasts express the transferrin receptor, CD71, and they
examined the cells according to CD71 and leukocyte antigen (CD45 and CD13) expression.
At the H1077/H1107 interface, 19.3% of nucleated cells were CD71-positive and leukocyte
antigen-negative, suggesting that they were of erythroid origin. 1.1% of the nucleated cells at
the plasma/ H1077 interface were erythroid, whilst at the H1107/H1119 interface, 1.5% of
the nucleated cells were erythroid. They suggested that erythroblasts preferentially collected
at the H1077/H1107 interface and, if enriching from maternal blood, harvesting this layer
might be most rewarding. Unfortunately the authors did not report the absolute number of
cells recovered at each interface. If, for instance, ten times as many cells were collected at
the lower interface compared to the one above, the total number of fetal erythroblasts would
be similar in each layer. In considering rare cells, such data is necessary as it could have
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significant bearing on the density gradient used. Hahn et al (1999) compared a triple
gradient with a single gradient and concluded that the latter was simpler and resulted in
better recovery of fetal erythroblasts. Huber et al (1996), using an analytical proprietary
liquid chromatography gradient, suggested that up to 80% of fetal erythroblasts were lost in
the red cell pellet if relatively low density ficoll-hypaque was used, including gradients used
currently by many groups. This is much greater than our experience with H1119 although our
large standard deviation is testimony to the very large proportion of erythroblasts which can
be lost. However, it confirms our belief that a single higher density gradient is simpler than
dual or triple cushions and would maximise erythroblast recovery (although at the expense of
slightly greater erythrocyte contamination).
The inclusion of an aggregating agent in H1119 resulted in better, and more predictable,
erythrocyte removal than Nycodenz 1.085 which lacked an aggregating agent (table 5.5)
although this did not reach statistical significance. However, Nycodenz resulted in
statistically better erythroblast recovery. Unfortunately there were also almost three times as
many contaminating erythrocytes after centrifugation which more than offset the
improvement in erythroblast recovery as this many erythrocytes would occupy considerable
space on microscope slides. Sekizawa et al (1999) compared two different densities of
percoll (relative density 1.083 and 1.090) which does not contain an aggregating agent and
found they could recover significantly more erythroblasts by using the denser medium.
However, they also found that the proportion of contaminating cells was also increased. It
would be ideal to use a medium such as Nycodenz to recover as many erythroblasts as
possible but to do so would depend on removing the remaining contaminating erythrocytes at
a later stage (chapter 10.1).
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5.6 Summary
Histopaque 1119 was the best compromise for erythrocyte removal and erythroblast
recovery. We concluded that blood should not be washed prior to density gradient
centrifugation and centrifugation should be performed using conical based Sterilin tubes.
As expected, density gradient centrifugation was insufficient and the enrichment process
was continued with immunomagnetic Dynabeads (chapter 6).
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Chapter 6. Immunomagnetic enrichment of Erythroblasts
6.1 Principles of Immunomagnetic separation
Explanation of the principles of immunomagnetic separation is given here to allow better
understanding of the methodologies that are described immediately after. Basically,
immunomagnetics utilises magnetic particles onto which are attached specific antibodies.
The antibodies are directed against cell surface antigens and when placed adjacent to a
magnet the magnetic beads are drawn to the magnet, dragging with them any attached cells.
6.1.1 Dynabead constitution
Dynabeads are 4.5pm diameter particles consisting of a styrene divinylbenzene core and
magnetite. The core is coated with a hydrophilic polymer containing epoxy and hydroxyl
groups which binds the secondary antibody covalently. The secondary antibody can then
bind the Fc portion of a primary monoclonal antibody (mAb). The magnetite in the bead is
attracted to the magnet (Lea et al, 1985). Because of their size, Dynabeads are visible under
the light microscope and also autofluoresce.
Dynal now produce beads which have IgG subclass-specific, species-specific secondary
antibodies so that the subclass of the primary immunoglobulin determines the variety of
bead to be used. This improved the efficiency enormously (table 6.3).
6.1.2 Methods of binding the secondary to the primary antibody
There are essentially two approaches - the indirect and direct methods.
The indirect method involves incubating the cells with the primary mAb, washing the cells
to remove excess mAb and then incubating the cells with the Dynabeads. The beads attach
to those cells that have bound the primary mAb and the cells are subsequently removed
from suspension. The indirect approach has certain disadvantages. In tissues with high
antigen expression, primary mAb crowding may reduce secondary antibody binding because
of steric hindrance (chapter 4.3). Alternatively, the primary mAb may bind in a configuration
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that is inaccessible to the secondary antibody. In these situations the direct method improves
separation (Gee et al, 1991).
The direct approach involves first attaching the primary mAb to the secondary antibody
and then incubating the beads with the cells. Once the beads have bound to the cells, the
test tube is placed adjacent to a magnet, housed in the proprietary "magnetic particle
separator". The beads are drawn to the magnet, taking attached cells with them (figure 6.1).
Whenever a new primary mAb was obtained, using the direct method the optimum
concentration needed to be determined to maximise bead efficiency and the following
strategy was used.
After removal of erythrocytes (chapter 5), differential and quantitative leukocyte counts
were ascertained and immunocytochemistry performed using the primary mAb. This allowed
the proportion and the absolute numbers of cells binding the specific mAb to be calculated.
Varying concentrations of the new antibody had been previously made up with beads and the
individual aliquots of beads incubated with equivalent samples of the leukocyte preparation.
Following removal of the beads, a cell count and differential of the supernatant was made
and immunocytochemistry using the same primary mAb again performed. Those
preparations, post-immunocapture, which showed the fewest cells expressing the antigen
suggested the optimum mAb concentration for maximal bead efficiency. The method was
largely empirical and there was a relatively broad plateau for the optimal mAb concentration
before efficiency was reduced significantly. In this way the lowest concentration of mAb
could be used without compromising bead efficiency.
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6.1.3 Optimising the number of beads per cell
If too few beads were used, cell removal was reduced. Using too many beads simply
increased costs without improving cell removal and the mass movement effect of large
numbers of beads increased the non-specific loss of erythroblasts (chapter 6.2.7). The direct
approach was more economical with respect to both mAb and beads than the indirect
method and, after initial comparisons between the two, all separations were performed using
the direct approach.
6.1.4 Methods of cell enrichment
Two methods were tested for fetal erythroblast enrichment: positive and negative
selection. Positive selection implies that the antibody used isolates the cell of interest. We
used a monoclonal antibody to the transferrin receptor (CD71). Negative enrichment implies
removing unwanted cells (leukocytes), leaving the desired cells (fetal erythroblasts) and
contaminants in suspension (figure 6.2).
6.2 Method for Dynabead Preparation
1 ml of beads was resuspended in 10ml of 2% (w/v) BSA in PBS/0.02% azide (2%
BSA/PBS/azide) and placed in the magnetic particle separator for two minutes. The
supernatant was pipetted off and the beads resuspended in 10ml of 2% BSA/PBS/azide,
mixed for two minutes in an SB1 end-over-end blood tube rotator (Stuart Scientific Co. Ltd.)
and then placed in the magnetic particle separator again. The washing process was repeated
for a total of five washes to remove any unbound secondary antibody.
For a 1 in 10 dilution of primary mAb, 1 ml of the mAb was added to 4 x 108 of the
appropriate IgG subclass-specific Dynabeads and made up to 10ml with 2% BSA/PBS/azide.
The beads and mAb were mixed at 4°C for at least 30 minutes, though usually overnight,
and could be left in this state for several weeks. Using the direct technique, table 6.1 shows










The Principle of Immunomagnetics
The bead draws the attached cells to the magnet
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Figure 6.2. The Principles of Negative Selection
Beads with cell
attached
The cells which are attached to the beads are retained on
the magnet and discarded, leaving the target cells
(erythroblasts) in suspension.
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Table 6.1. Optimum primary monoclonal antibody dilutions and number of Dynabeads
per cell
Antigen Monoclonal Monoclonal Optimum number
antibody antibody dilution of beads/ cell
CD71 BER-T9 1 in 50 5
CD18 HIG.125 1 in 10 4
CD2 RFT-11 1 in 10 3
CD3 UCHT1 1 in 10 3
CD45 EBZ17 1 in 10 4
HLA.DR DA6.231 1 in 30 3
See Appendix II for mAb source.
Dynabeads and primary mAb incubated at 4°C in 2% BSA/PBS/azide.
6.2.1 Preparation of Dynabeads for cell enrichment
Following density gradient centrifugation, the total number of leukocytes were determined
and an appropriate quantity of beads was washed five times in phosphate buffered saline
(PBS). Suboptimal washing did not remove all the unbound primary mAb resulting in
competition between bound and unbound mAb for antigen sites, so decreasing bead-cell
binding.
6.2.2 Estimation of Dynabead efficiency
The major drawback of positive selection was the difficulty in detaching beads from the
cells (vide infra) and, therefore, the inability to examine the selected cells morphologically.
The only way to determine which cells had been selected was to analyse the cells left in
suspension. Although less than ideal, by inference the cells which had been removed could
be estimated. Using negative enrichment this was not a problem as the cells left in
suspension included fetal erythroblasts.
Every deposition method incurs cell loss. This was not expected to be cell-specific but
across all cell types. Simply by making a direct estimation of the number of nuclei that were
deposited on to slides resulted in an overestimation of the efficiency of beads. Calculation of
Dynabead efficiency, using either positive or negative selection, was therefore likely to be no
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more than an estimate. However, a strategy to make this as accurate as possible was
developed.
Cytocentrifuge preparations were made following Histopaque and immunomagnetic
enrichment and then stained. The ratio of nucleated cells to erythrocytes following these two
stages was calculated and from these ratios the percentage of fetal erythroblasts recovered
or selected (in the case of positive selection) and leukocytes removed was determined.
Because ratios and not absolute cell numbers were calculated, the results were likely to be
more accurate. This method to calculate bead efficiency has been reported previously by
Ganshirt-Ahlert et al (1993).
6.2.3 Optimising conditions for cell and bead incubation
(i) Incubation temperature
Samples of cells were taken from the same original cell suspension and mixed
simultaneously in exactly the same way but at 4°C and 22°C. Using negative selection, the
results of fetal erythroblast recoveries and leukocyte removal were determined.
(ii) Cell-bead mixing methods
The cell suspension was made up with 2% (w/v) BSA in PBS and using an equal amount
of beads conjugated to anti-CD18, anti-CD2 and anti-CD3 mAbs, different methods of cell/
bead mixing were investigated.
(a) Peristalsis technique. The tip of a 1 mm bore soft plastic tube was placed at the
bottom of the test tube containing the cell suspension at 22°C and an aliquot of beads was
added. A Minipuls 2 peristaltic pump (Gilson) generated small air bubbles that rose through
the suspension at 1 bubble/ second, encouraging the beads and cells to mix. After 20
minutes the test tube was placed in a magnetic particle separator. The supernatant was
decanted into a fresh test tube, another aliquot of beads added and the process repeated for
four incubations.
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(b) Dropping technique. Dynabeads, being denser than cells, gravitate faster. 75pl
aliquots of beads were dropped every two minutes into a static upright test tube containing
the cell suspension and allowed to descend under unit gravity until all the beads were
exhausted.
(c) Rotor mixing. The cell suspension filled the test tube to approximately 70%. The
cells were incubated with four sequential aliquots of beads, each for 20 minutes, at 22°C
using an end-over-end blood tube rotator, SB1 (Stuart Scientific Co. Ltd.) angled at 30° to
the horizontal, rotating at 26 revolutions per minute.
(d) Spiramix technique. The Denley Spiramix 5 was easiest to use as test tubes could
be added and removed without having to stop the motor. The test tubes were approximately
70% full and the cells were incubated with four sequential aliquots of beads, each for 20
minutes, with the barrels rotating at 48 rpm.
Cell counts and differentials were calculated for each of the different mixing methods to
determine the most efficient method of cell removal.
(iii) Length of incubations and the number of aliquots of beads
Two approaches to the length of time cells were mixed with beads were investigated.
Firstly all the cells were incubated with all the beads for a prolonged but defined period,
usually 90 minutes. Alternatively the same absolute number of beads were divided into
three, four or five equal aliquots and all the cells incubated with successive aliquots for a
shorter period (e.g. 20 minutes each) for approximately the same length of time overall.
6.2.4 Positive selection of fetal erythroblasts
An absolute quantitative leukocyte count, differential count and reticulocyte count was
made of the cells after removal of erythrocytes by density gradient centrifugation.
A ratio of 5 beads, coated with anti-CD71 mAb (BER-T9), to one nucleated cell was
optimal in model experiments. The beads were divided into 3 equal aliquots and these were
incubated sequentially with the leukocyte suspension for 20 minutes at 22°C on the end-
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over-end rotator. After magnetic bead removal the remaining supernatant was carefully
pipetted into another test tube, the next aliquot of beads was added and the incubation
repeated.
Following the three incubations, a reticulocyte and quantitative leukocyte count and
differential cell count were calculated on the bead-free supernatant. A cytospin preparation
was also subjected to immunocytochemistry using the original BER-T9 mAb to assess the
efficiency of beads at removing CD71 -positive cells.
Two effects were soon apparent. Firstly, a sizeable proportion of leukocytes, particularly
polymorphs, appeared to be selected. Secondly, the morphology of the cells that were
positively selected could not be determined as overlying beads obscured them (figure 6.3).
In maternal blood samples, if this population included erythroblasts, cytogenetic analysis
using fluorescence in situ hybridisation would be impossible.
To determine why so many leukocytes were removed, cell suspensions were incubated
with raw beads and those cells remaining in suspension were analysed.
An attempt was made to detach the beads from the cells with Dynal proprietary "Detach-
a-beads" using the manufacturer's protocol or by simply "flooding" the positively selected cell
population with a 1 in 50 dilution of anti-CD71 mAb. This was performed by incubating BER-
T9 with the beads for twenty minutes, placing the test tube in the magnetic particle separator
and then making cytospin preparations to see which cells detached from the beads.
6.2.5 Miltenyi Magnetic activated cell sorting
In 1992 Ganshirt-Ahlert et al reported using the Miltenyi Magnetic Activated Cell Sorter
(MACS) to enrich for fetal erythroblasts from cord blood. In an attempt to repeat their work,
we obtained the MACS system from Becton-Dickinson.
Using the indirect method and BER-T9 (using the 10ml syringe columns and the protocol
detailed by Miltenyi) three passes of the column were made. The bead-free supernatant was
collected and cell counts and cytospin preparations made for morphological and
immunocytochemical staining. The syringe column was removed from the magnetic bracket
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and the steel wool flushed three times. The cells in the eluent were collected and analysed in
the same way. From this, the removal and recoveries of fetal erythroblasts by MACS were
calculated.
6.2.6 Negative enrichment for Erythroblasts
Following density gradient separation the total number of nucleated cells was determined
and the absolute numbers of beads necessary were prepared (table 6.1).
The aliquot of anti-CD18-beads was divided into four equal aliquots and the first aliquot
was incubated with the cell suspension for 20 minutes at 22°C on an end-over-end blood
tube rotator. Following magnetic particle separation the supernatant was carefully pipetted
off and placed in another test tube whilst the beads were discarded.
The anti-CD2- and anti-CD3-beads were divided into three aliquots and the individual
aliquots and the anti-CD18-beads were added to the cell suspension for three more
sequential incubations, each for 20 minutes. The supernatant became progressively clearer
as more leukocytes were removed.
After the anti-CD18/CD2/CD3 mAb cocktail, approximately 80% of the remaining
mononuclear cells were CD19-positive, indicative of B-cells. B-lymphocytes and activated T-
lymphocytes express HLA.DR antigens and, therefore, an in-house mAb DA6.231 was added
to target the B-cells (Guy et al, 1982).
After the final incubation the supernatant was placed in a sterile test tube. 500pl were
removed, a cytospin preparation was appropriately stained and a differential count
determined.
6.2.7 Investigation of erythroblast loss associated with negative enrichment
From the model systems it was apparent that fetal erythroblasts were lost at the bead
stage. This appeared to be dependent on the length of incubation and the mAbs used and
resulted in the different protocol permutations.
Cells were inevitably left on the walls of the test tube when the supernatant was removed
but another possible mechanism of erythroblast loss was at the magnet stage. When the test
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tube was placed in the magnetic particle separator, it was plausible that erythroblasts were
literally "caught in the back and pushed" to the test tube wall because of the mass movement
effect of the beads.
This was investigated by washing the beads three times in 2% (w/v) BSA in PBS and then
replacing the test tube against the magnet. It was hoped that cells that were not
immunologically bound would separate from their beads during the resuspension and
thereafter remain in suspension rather than being pushed to the side wall again. The
supernatant (of unbound cells) was pipetted off into a clean test tube and centrifuged to
pellet the cells. A differential count and nucleated cell/ erythrocyte ratio were determined to
calculate the number of erythroblasts in this supernatant.
6.2.8 Combining negative and positive enrichment
Neither positive nor negative enrichment gave completely satisfactory results and the two
methods were combined in an attempt to reduce the final absolute number of cells. Firstly,
leukocytes were removed and then CD71 -positive cells were selected with BER-T9-
conjugated beads using the protocols as above. The bead-cell conjugates were fixed in
suspension in fresh methanol: acetic acid (3:1) to lyse the cell membranes so that the bare
nuclei separated from the beads which were subsequently drawn to the magnet. The
suspension was drawn off and centrifuged to pellet the nuclei. This was resuspended in a
small volume of methanol: acetic acid for later in situ hybridisation.
6.3 Results of Immunomagnetic enrichment techniques
6.3.1 Positive selection
Table 6.2 shows that 70-83% of cord erythroblasts were CD71-positive and demonstrates
the efficiency of positive selection of the positive cells. These data show that enrichment was
only to one order of magnitude. Furthermore, raw beads (without a primary mAb attached)
appeared to remove both polymorphs and lymphocytes possibly by phagocytosis or by
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binding of the secondary antibody to cell surface antigens. Furthermore, the attached beads
(figure 6.3) obscured the morphology of the positively selected cells.
Table 6.2. Positive selection with anti-CD71 mAb (BER-T9) (n=25)
CD71-positive cord erythroblasts (%) 70-83
Removal of CD71-+ve erythroblasts (%) 93.2 ± 10.7 (89.0-97.4)
Removal of leukocytes (%) 62.5 ±24.4 (52.9-72.1)
Removal of polymorphs with raw beads (%) 74.9 ± 11.0 (70.6-79.2)
Removal of lymphocytes with raw beads (%) 34.4 ±9.5 (30.7- 38.1)
Dynabeads incubated with erythrocyte-depleted nucleated cells at room temperature.
95% confidence intervals in parentheses
Using the proprietary Detach-a-beads only 3.7% of all the CD71-bound cells could be
detached and the final recovery, from all starting fetal erythroblasts, was only 0.8%. By
flooding the beads with BER-T9 mAb, 7.5% of all the bound cells could be detached and the
final recovery from all starting fetal erythroblasts was 15.3%.
6.3.2 Results using the Miltenyi Magnetic Activated Cell Sorter
We found that 56.7 ± 17.9% of fetal erythroblasts (n = 6) escaped immunocapture.
However, of these, approximately 40% appeared to be CD71-negative. Furthermore, over
70% of leukocytes (particularly polymorphs) were not in the negative fraction and many of
these came through with the positive eluent. More importantly, only 24.0 ± 5.7% of the
selected fetal erythroblasts could be recovered from the steel wool column.
6.3.3 Negative selection
The ratio of beads to cells varied and generally, the more beads used, the greater the
leukocyte removal. However, this increased the costs and, importantly, non-specific
erythroblast loss.
Data is presented as the percentage removal of leukocytes from the total number of
leukocytes after density gradient centrifugation and, similarly, the recoveries of erythroblasts
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is presented as a percentage of fetal erythroblasts recovered after density gradient
centrifugation.
HIG.125 is an lgG2a mAb. Table 6.3 compared the old Dynabeads (where the secondary
antibody was a polyclonal antibody) and the newer Dynabeads, where the secondary
antibody is immunoglobulin subclass-specific. It demonstrates that leukocyte removal was
more efficient with the newer Dynabeads (p < 0.001) but there was no difference in
erythroblast recovery.
Table 6.3. Direct comparison of different Dynabeads using anti-CD18 mAb (HIG.125)
on efficiency of negative enrichment












P < 0.001 NS
Dynabeads with polyclonal or sub-class-specific secondary antibody bound to HIG.125
incubated with cells at room temperature.
NS = not significant. 95% confidence intervals in parentheses.
Using different T-cell mAbs with the subclass-specific beads the possibility of additional
mAbs was addressed. Table 6.4 shows that RFT-11 mAb was more efficient at removing T-
cells than the mAb, UCHT1 (p < 0.001) but neither removed erythroblasts.
Table 6.4. Direct comparison of individual anti-T-cell mAbs on efficiency of T-cell
removal
Primary antibody n T-cell Erythroblast
removal (%) recovery (%)
RFT-11 (anti-CD2) 5 84.9 ±2.3 98.7 ±2.1
(82.9 - 86.2) (96.9- 100)
UCHT1 (anti-CD3) 5 65.4 ±6.0 99.4 ± 1.3
(60.1 - 70.7) (98.3- 100)
P <0.001 NS
Incubations at room temperature. 95% confidence intervals in parentheses.
A single aliquot of EBZ17-coated Dynabeads (anti-CD45) was compared with sequential
incubations of equal aliquots of beads, using the same total number of beads (Table 6.5).
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Although additional aliquots improved leukocyte removal, this did not reach significance.
However, using 5 aliquots of anti-CD45-coated beads significantly reduced the recovery of
erythroblasts compared to one or three aliquots (p < 0.001) and fetal erythroblast recovery
was substantially poorer when compared to the anti-CD18 mAb (p < 0.001).
Table 6.5 Comparing incubations using single and multiple aliquots of beads coated
with anti-CD45-mAb (EBZ17)
No. of aliquots n Leukocyte removal (%) Erythroblast recovery (%)
1 aliquot 60 97.6 ± 3.6 25.9 ±21.5
(90 minute incubation) (96.7 - 98.5) (20.5-31.3)
3 aliquots 19 98.3 ±2.2 23.8 ± 12.9
(20 minute incubations) (97.3 - 99.3) (18.0-29.6)
5 aliquots 10 98.9 ±0.6 6.7 ± 3.0*
(20 minute incubations) (98.5-99.3) (4.8 - 8.6)
Incubations at room temperature. Note the fall in erythroblast recovery with increasing
leukocyte removal. 95% confidence intervals in parentheses.
*p < 0.001, erythroblast recovery compared to 1 or 3 aliquot incubations.
Table 6.6 shows that the addition of an anti-HLA.DR mAb significantly increased
leukocyte removal (p < 0.001) but that erythroblast recovery was dramatically reduced (p <
0.001). This latter result was more important because such losses would be intolerable given
the small number of fetal erythroblasts expected in maternal blood.
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Table 6.6. Efficiency of negative selection with diflferent mAb cocktails
mAb cocktail Anti-CD18/CD2/CD3 Anti-CD18/CD2/CD3/HLA.DR P
n 35 44










Incubations at room temperature. 95% confidence intervals in parentheses.
Note the fall in erythroblast recovery with increasing leukocyte removal.
Using the two stage process of Histopaque 1119 and negative enrichment with
Dynabeads, it was possible to recover fetal erythroblasts from a starting ratio of 1 fetal
erythroblast: 108 maternal cells (1 in 106 leukocytes), approaching the ratios which are
estimated in maternal blood. Overall, the final erythroblast recovery from whole blood was
approximately 32%.
6.3.4 Estimation of erythroblast loss with negative enrichment
The results are presented from assays using only anti-CD18- and anti-CD3-mAbs. At
each stage when the test tube was placed in the magnetic particle separator and the beads
were drawn to the magnet, approximately 2-3% of the original number of erythroblasts could
be recovered by washing the beads and dislodging any immunologically unbound cells.
Overall, therefore, only around 6-10% of fetal erythroblasts might be recovered by washing
the beads.
6.3.5 Comparison of incubating methods
Table 6.7 illustrates the relative efficiencies of the different incubation methods at 22°C
using beads coated with anti-CD18, anti-CD2 and anti-CD3 mAbs.
Clearly the two formal mixing techniques (end-over-end mixer and Spiramix) were
superior to either the peristalsis or dropping techniques (p < 0.001). However, compared to
the Stuart end-over-end rotor, the Denley Spiramix was easier to use and leukocyte removal
was also superior (p < 0.001).
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Table 6.7 Comparison of incubation methods
Incubation method n Leukocyte removal (%)
Peristalsis technique 8 43.2 ± 15.6 (32.4- 54.0)
Dropping technique 8 16.3 ±6.4 (11.9- 20.7)
Stuart SB1 end-over-end rotor 12 99.2 ±0.2 (99.1- 99.3)*
Denley Spiramix 5 12 99.6 ±0.1 (99.5- 99.7)*
95% confidence intervals in parentheses.
*p < 0.001, comparison of end-over-end rotor with Denley Spiramix using Dynabeads bound
to anti-CD18, CD2 and CD3, incubated at room temperature.
6.3.6 Results of combining negative and positive enrichment
In model experiments, following leukocyte removal, an average of 43.7% of fetai
erythroblasts were removed from the supernatant by the anti-CD71 -conjugated beads.
Therefore, using this three-stage approach, the final erythroblast recovery from whole blood
was approximately 15%.
6.4 Discussion
6.4.1 Optimising the incubation method
(i) Bead-cell binding
The direct approach (incubating cells with Dynabeads with the primary mAb already
attached to the beads) was superior to the indirect approach (data not shown). Beads could
be prepared several weeks in advance and experimentation was more rapid on the day. It
had the additional advantage of subjecting the ceils to fewer washes and centrifugations,
resulting in reduced cell loss. Finally, the direct method was more economical for both
primary mAb and beads.
(ii) Incubation temperature
The laboratory was not equipped with a 37°C room but incubation at 22°C was more
efficient than at 4°C. Antibodies work most efficiently at 37°C but at this temperature
phagocytes may also be activated. At 4°C mAb-epitope binding is less efficient but bonds
are stronger and hence if beads attach to a cell, there is a greater chance of dragging the
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cell to the magnet. The greater efficiency at 22°C was probably a reflection of the mAb
binding at a temperature nearer to its optimal working temperature.
(iii) Cell-bead mixing methods
It is desirable to encourage as many antibody-antigen collisions as possible to maximise
the possibility for antibody binding and clearly the formal mixing methods were superior. It
was hoped that the gentler mixing techniques would provide a longer time for antibody-
antigen interaction and, as there was no sudden mass movement effect as beads were
drawn to the magnet, non-specific fetal erythroblast loss would be minimised. However,
mixing the supernatant on rotating barrels (Denley Spiramix 5) gave the best and most
reproducible results. Because the mixer did not need to be stopped to remove the test tubes,
it was also the easiest to use and was adopted as the incubation method of choice.
(iv) Length of incubations and the number of aliquots of beads
Theoretically only one bead is required to remove a cell but three beads is optimal (Pilling
et al, 1989). For a finite number of beads, short incubations of multiple aliquots was superior
to longer but fewer incubations (Table 6.5). Particular mAbs may have a greater affinity for
certain cells and as more beads bound to that cell there were fewer beads available to react
with the remaining cells. These higher affinity mAbs removed many cells with the initial
aliquots and in subsequent aliquots there were relatively more beads to react with the
remaining cells.
The length of each incubation period was crucial. The longer the incubation period, the
greater the number of beads bound per cell. However, this also increased non-specific
binding and phagocytosis of beads. This was especially important when the anti-HLA.DR
mAb was used (Chapter 6.4.6).
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6.4.2 Positive selection (CD71)
The rationale for using CD71 to enrich for fetal erythroblasts has been detailed in chapter
3.6. For live cell separation only cell surface markers can be used (unlike FACS analysis)
and, therefore, it would seem that immunomagnetic separation is an ideal modality for fetal
cell enrichment.
Removal of 93.6 ± 12.0% of CD71-positive cord fetal erythroblasts (almost 70% of all
fetal erythroblasts) represented efficient selection. Frazier et al (1982) calculated that the
available transferrin binding sites were less than predicted by radio-immunoassay because
some of the receptor molecules were either embedded in the membrane or were intracellular
and hence unavailable for transferrin binding. This might explain why a proportion of fetal
erythroblasts was not selected with Dynabeads. However, it is also true that beads can never
be 100% efficient at selecting cells.
However, the selection of over 60% of leukocytes was very disappointing and overall the
relative enrichment of fetal erythroblasts, even in cord samples, was poor. Activated
lymphocytes and other dividing cells are CD71 -positive and removal of these cells might be
expected. However, even during pregnancy approximately only 0.83% of leukocytes are
CD71-positive (Adinolfi, 1992a). Therefore, immunological selection should not account for
the large proportion of leukocytes removed. Raw beads (with no primary mAb) removed a
substantial proportion of leukocytes probably by non-specific binding, engulfment of beads
by phagocytic cells and activation of cells because of harsh collisions. In the leukocyte-rich
layer following Histopaque 1119 centrifugation, polymorphs represented the greatest
proportion of leukocytes. Many of these were removed by the anti-CD71-conjugated
Dynabeads and accounted for the apparent selection of CD71-negative leukocytes.
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6.4.3 Detachment of positively selected cells
Unfortunately our attempts at detaching selected cells from the beads were disappointing.
The proprietary Dynal Detach-a-beads use an anti-Fab goat anti-mouse antibody that binds to
a site between the hinge and the actual antibody-binding site of the primary mAb.
Rasmussen et al (1991) found that Detach-a-beads left no primary mAb (B-cell, anti-CD19
mAb) on the cell surface. However, other groups have reported difficulties with Detach-a-
bead efficacy (Pilling et al, 1989; Manyonda et al, 1992) and Dynal admit that they are not
very effective with CD71-positive cells (Roy Edward, Dynal, personal communication).
Attempts to detach selected cells by competitive inhibition using BER-T9 (antiCD71) were
more successful but it was wasteful of antibody and only 15.3% of fetal erythroblasts were
finally recovered.
Because of the poor relative enrichment (because of non-specific leukocyte binding), the
inability to identify the selected cells after immunocapture and the inability to reliably and
efficiently detach the Dynabeads from the cell surface, positive selection was abandoned.
6.4.4 Magnetic Activated Cell Sorting (MACS)
MACS beads do not interfere with proliferation assays, can be used with flow cytometry
and the extremely powerful magnet means that few beads per cell are required to remove
cells. Most importantly, because of their size, the beads do not obscure cell morphology so
the selected cells can be investigated subsequently by immunocytochemistry or FISH.
Using MACS with anti-CD71 mAb over half the fetal erythroblasts escaped
immunocapture, though two-fifths of these were CD71-negative. Moreover, of the
erythroblasts that were selected, three-quarters could not be recovered from the steel wool
and when dealing with rare cells, this degree of loss was intolerable. The areas of loss were
thought to be from the multiple washing/ centrifugation steps and fetal erythroblasts
remaining trapped in the steel wool. As with Dynabeads, a large proportion of leukocytes
was also removed so that the relative enrichment was poor.
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Although MACS and Dynabeads were not compared directly, the time required for
processing was considerably longer with MACS (although with increased familiarity this may
not be so pronounced). Moreover, fetal erythroblast removal was superior with Dynabeads.
However, it must be remembered that the results for Dynabeads were calculated from
inference of what was left in the supernatant (whereas the results using MACS were direct
analyses) and subsequent cytogenetic analysis of the selected cells was impossible with
Dynabeads.
Manyonda et al (1992) compared MACS with Dynabeads for positive and negative
selection of CD45RO-positive cells. Dynabeads were more efficient and there was
significantly greater cell loss with MACS because of the increased number of separation
steps. Cell losses and recoveries varied more with MACS and it was much slower because
of the greater number of washing steps required by the protocol. Finally, in a cost-benefit
analysis, they found MACS to be much more expensive.
Ganshirt-Ahlert et al (1992) reported that using MACS on cord blood they could only
enrich for fetal erythroblasts by a factor of 1.4 to 10.8, similar to our results and insufficient
for the needs in maternal blood. Although some groups continue to investigate positive
selection of erythroblasts using MACS, we did not pursue this avenue further.
6.4.5 Negative enrichment for fetal erythroblasts
Negative enrichment has been used successfully for different applications. Bertoncello et
al (1991) used a cocktail of mAbs simultaneously to remove bone marrow cells and enrich
for primitive haematopoietic cells and because of the problems of positive selection,
negative enrichment was investigated.
Pilling et al (1989) found that the addition of mAbs directed against different epitopes of
the same antigen did not improve the efficiency, but when two mAbs directed against
different antigens on the same cell were used, depletion efficiency was better. Because of
the mechanical and spatial factors of antigen distribution, two beads binding to different
antigens can act synergistically to facilitate removal. They also found that negative
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enrichment gave a higher yield of cells than positive selection, an important consideration
with rare (fetal) cells. These principles allowed us to develop a cocktail of mAbs
systematically.
6.4.6 Choosing the best monoclonal antibody cocktail
The anti-CD18 mAb, HIG.125, removed 97.3 ± 1.4% of leukocytes. It is an lgG2a mAb
directed against the common p-chain (CD18) of the a/p heterodimer of the leukocyte
adhesion molecule (LAM-1, CD11a/CD18). As such it has pan-leukocyte activity
(Uciechowski and Schmidt, 1989). It was developed in-house by Dr. Veronica van Heyningen
and colleagues and obtained as a culture supernatant.
The anti-CD2 mAb, RFT-11, removed 84.9 ± 2.3% of T-cells. CD2 is a transmembrane
single chain 50 kDa glycoprotein expressed on resting and activated T-lymphocytes. It is
involved in cell adhesion and the alternative pathway forT-cell activation (Meuer, 1989).
RFT-11 is an IgGi subclass anti-CD2 mAb, and was obtained free of charge from the
Scottish Antibody Production Unit (SAPU) as a culture supernatant.
The anti-CD3 mAb, UCHT1, removed 65.4 ± 6.0% of T-cells. CD3 is a receptor complex
of at least five chains with molecular weights ranging from 16 to 28 kDa. It is involved in T-
cell activation and signal transduction and has pan-T-lymphocyte expression (Kurrle, 1989).
The mAb, UCHT1, an IgG-i subclass immunoglobulin, was also obtained free of charge from
SAPU as a culture supernatant.
The anti-CD45 mAb, EBZ17, removed 98.3 ± 2.2% of all leukocytes. CD45 is a single
chain glycoprotein present on all leukocytes and is involved in signal transduction by
modifying signals from other surface molecules. There are four isoforms with molecular
weights of approximately 185 kDa, 200 kDa, 215 kDa and 230 kDa. T-cells express all four
chains whilst B-cells express mainly the 230 kDa chain (Thomas, 1989). The mAb, EBZ17,
also obtained from SAPU as a culture supernatant, blocks all four glycoprotein chains (Smith
et al, 1985).
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It was puzzling that although EBZ17 and HIG.125 removed similar proportions of
leukocytes, erythroblast recovery was substantially less with EBZ17 (table 6.6) and
frequently erythroblasts were found with a bead attached (Figure 6.4).
The leukocyte adhesion molecule (CD11a/CD18) is expressed on all leukocytes but not
on erythroid lineage cells (Kansas et al, 1990). Therefore HIG.125 should not react with fetal
erythroblasts. The mAb, HLe-1 (Beverley et al, 1980), recognises the 200 kDa chain of CD45
and also reacts with epitopes on red cell precursors (Loken et al, 1987). Hence, CD45 is
expressed on erythroid cells at a low level and even after CD71 expression has peaked
(Kansas et al, 1990). Presumably, as more leukocytes were removed by the mAb cocktail,
there were fewer cells which were strongly CD45-positive and the EBZ17-beads attached to
any cell with low CD45 expression. It would certainly account for the difference in recoveries
between the two pan-leukocytes mAbs and because of this anti-CD45 mAbs were
abandoned.
This reduction in fetal erythroblast recovery was not seen with multiple incubations using
the anti-CD18, anti-CD2 and anti-CD3 mAbs and the principle of multiple aliquots of beads
was maintained.
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Figure 6.3 Positive selection of fetal erythroblasts using Dynabeads
Cytospin preparation. Note that the morphology of the selected cells (stained nuclei) is




Figure 6.4 Fetal erythroblast with anti-CD45-conjugated bead (EBZ17) attached
Cytospin preparation. Note that the erythroblast (arrowed) has an immunomagnetic bead
attached to it. Hence, it could be drawn to the magnet and removed from suspension.
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The addition of the anti-HLA.DR mAb, DA6.231, improved the leukocyte removal but
substantially reduced erythroblast recovery (table 6.6). DA6.231 is an IgGi mAb and was
made in-house (Guy et al, 1982). It is directed against the p-subunit of HLA class-ll
molecules and was added specifically to target B-cells. However, erythroid precursors also
express HLA.A, B, C and DR antigens and, using FACS, HLA.DR was demonstrated on
28.0% (range, 9.3-34.0%) of erythroblasts (Sieff et al, 1982). The authors pointed out that
FACS will not detect very low antigen expression and an even greater proportion of
erythroblasts might express undetectable HLA.DR. As more leukocytes were removed,
there were fewer leukocytes to react with DA6.231-conjugated beads and these could react
with any other HLA.DR-expressing cells, including erythroblasts. This would certainly explain
the decline in recovery with increasing leukocyte removal when DA6.231 was included in the
mAb cocktail. Although leukocyte removal was improved, because of these results, the use
of DA6.231 was discontinued. However, it should be possible to use a different anti-B-cell
mAb that does not react with fetal erythroblasts to improve enrichment if this is necessary.
6.4.7 Estimation of erythroblast loss during negative enrichment
The detrimental mass movement effect of beads "pushing" erythroblasts to the magnet
was likely to be greatest in a small volume containing a high concentration of beads.
Manyonda et al (1992) found that cell loss in this way amounted to a fairly consistent 12%.
Unfortunately, these conditions maximised the number of collisions between beads and
target cells. Diluting the cell/ bead supernatant prior to magnetic separation only recovered
about 6-10% of fetal erythroblasts and other cells came away as well, reducing the relative
enrichment. Considering what was required, it was not felt that the return from this fraction
warranted the additional steps. However, if insufficient numbers of fetal erythroblasts are
recovered from maternal blood after the complete enrichment process, retrieval of these
trapped erythroblasts may be necessary.
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6.4.8 Enrichment of other fetal cells
Negative selection should enrich for trophoblast cells as they do not express antigens to
which the mAbs used were directed (figure 6.5). To date unequivocal syncitiotrophoblast
cells have not been identified. Multinucleate cells have been encountered but, following
FISH, the individual nuclei have shown two X chromosome signals and no Y signal. In one of
these cases XY interphase cells were also found and the woman subsequently delivered a
male. It is most likely that these were megakaryocytes. Of course it is possible that
mononuclear cytotrophoblast cells have been analysed by FISH but they have not been
identified positively. However, because of potential confined placental mosaicism (chapter
2.3), it is arguable whether enrichment of trophoblast cells is, in any case, desirable.
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Figure 6.5 Multinucleated syncitiotrophoblast enriched from an artificial admixture of
termination and adult blood.
The syncitiotrophoblast cell (solid arrow) is surrounded by several erythroblasts (dashed
arrows).
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6.4.9 Combining negative and positive enrichment
Using this approach, just over 40% of fetal erythroblasts were removed from the
supernatant and in model experiments, 61.6% of the cells showed a Y-chromosome signal
(in the case of a male fetus). However, given that almost 60% of fetal erythroblasts
remained in the unselected fraction the absolute recovery of fetal erythroblasts was poor.
Following fixation and lysis in methanol: acetic acid it was impossible to identify the fetal
erythroblasts positively and we were unable to determine exactly how many cells were
actually dislodged from their beads. Therefore, although the ratio of male fetal cells to
maternal cells was large, the absolute numbers of recovered fetal erythroblasts was small
and this three-stage method of enrichment was unsuitable for the required task.
6.5 Summary
Using the described negative enrichment technique in model systems, it was possible to
recover fetal erythroblasts from a starting ratio of 1 in 108. Unfortunately, it is not known what
fetal erythroblasts in maternal blood look like, how they behave or how frequently they occur.
Therefore, enrichment from maternal blood can only be approached asymptotically by the
models we have designed.
Figures 6.6, 6.7 and 6.8 demonstrate the enrichment from whole blood, through density
gradient centrifugation to removal of leukocytes. Note the reduction in the relative number of
erythrocytes (following density gradient centrifugation) and then their relative increase once
the majority of leukocytes have been removed by Dynabeads. Figure 6.9 suggests
hypothetical results based on current knowledge and our results which, overall, represents
enrichment by three orders of magnitude.
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Figure 6.6 Whole blood
Note the large ratio of erythrocytes to nucleated cells
n
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Figure 6.7 Blood following density gradient centrifugation with Histopaque 1119




«■' «* % * * *% w. *» A * 'I
* * %■ V* %■* 4k X> J* V ***» " * j f *♦ kV»
e
#S *«%?»-« ? <0
.. »* n «, *, ' \ » <« * <• */
. -x ^ •*
# '
»,** J* 4hft ■ • W
i*«« .
44 •> A' . *
£ '#'1. » ■ •' :*P
Figure 6.8 Cells recovered after complete negative enrichment
Enriched fetal erythroblast is arrowed. Note that there are now very few nucleated cells and












Total number of erythrocytes 1 x 1011 5x10' 5x10'
Total number of leukocytes 1 x 10° 5x10' 5 x 10b





1 x 10b 1.25 x 10b 1.6 x104
Ratio of
Erythroblasts: All cells
1 x 10a 2.5x10' 1.6 x 10b
It would be ideal to deposit the remaining cells on to as few slides as possible, prior to
FISH, whilst minimising the cell loss during deposition. This could allow positive identification
of fetal erythroblasts but it presents us with a predicament. Optimal probe access requires
removal of cytoplasmic and perinuclear proteins but this would prevent using cytoplasmic
markers for positive identification.
Each of these issues will be addressed separately. Cytogenetic analysis of fetal cells was
the primary goal and will be dealt with first. However, it must always be borne in mind that
the key areas of enrichment, deposition, positive identification and cytogenetic analysis were
complexly inter-related.
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Chapter 7. Cytogenetic analysis of fetal erythroblasts
7.1 Introduction
Even with the best enrichment, maternal cells far outnumber any putative fetal cells. If
the primary goal is aneuploidy detection then polymerase chain reaction is inappropriate and
in situ hybridisation is necessary to determine the copy number of specific chromosomes in a
nucleus (chapter 3).
Fluorescence in situ hybridisation (FISH) involves hybridising a probe which is
complementary to a nucleic acid sequence (whether DNA or RNA) in the cell. The probe is
labelled with a reporter molecule which allows subsequent visualisation by immunological
development in much the same way as immunocytochemistry. Using chromosome-specific
probes, the number of signals within the nucleus reflects the number of copies of that
chromosome in the nucleus.
The proceeding sections will outline the principles and methods of fluorescence in situ
hybridisation so that its application to enriched maternal blood samples can be better
understood. The reagents are listed in Appendix II, with abbreviations in Appendix I.
7.2 Overview of in situ hybridisation
Non-radioactive in situ hybridisation, especially fluorescence in situ hybridisation (FISH),
has certain advantages over radioactive in situ hybridisation. FISH is faster, gives better
spatial resolution of individual hybridisation signals and signals are more stable. The entire
genome, entire chromosomes, chromosomal subregions or single-copy sequences can be
targeted specifically depending on the complexity of the probes used and as the technology
has developed, the sensitivity of FISH is now approaching that of isotopically labelled probes
(2-5 kbp). Furthermore, a variety of probe-labelling systems allow simultaneous detection of
different probes in the same nucleus using different fluorochromes. FISH can be performed
on metaphase or interphase cells, including cells fixed in suspension so that the three
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dimensional structure of the cell can be preserved. These probe-labelling and detection
systems are commercially available and the quality of microscopes and cooled charged
coupled device (CCD) cameras has improved steadily resulting in excellent images (Trask,
1991).
Plasmids are circular self-replicating molecules. The DNA probe is inserted and the
plasmid can then infect a bacterium such as E. coli which, as it multiplies, replicates the total
number of plasmids and hence the total number of probes. The probe can then be purified
from its vector. Cosmids are very large plasmids. Phage-A. has a Cos (cohesive) site at each
end with an area of DNA in the middle which can be removed using specific enzymes and
the probe-DNA inserted. Once replicated, another enzyme can be used to recognise and
break the Cos sites, releasing the probe.
To improve the specificity of the final signal, hybridisation of the labelled probe to
repetitive DNA sequences in the genome can be suppressed by prehybridising with
unlabelled genomic DNA, for example with Cot1 DNA. This is crucial for localisation of
unique sequences contained within large insert probes such as cosmids.
7.3 Preparation of Probes
7.3.1 Plasmid DNA purification and preparation
7.3.1.1 Bacterial culture
E. coli glycerol stock (with incorporated plasmid) was plated on L-agar containing
Ampicillin (50pg/ml) and incubated overnight at 37°C. Individual colonies of E. coli were
placed in separate sterile culture tubes containing 5ml LB-broth (with 1:100 phosphate and
ampicillin 1:1000 dilution) as per Sambrook et al (1989) and incubated at 37°C overnight in a
culture shaker.
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7.3.1.2 TELT method for DNA purification
1ml of the culture suspension was centrifuged in an Eppendorf centrifuge and the
supernatant discarded. The bacteria were resuspended in 200pl of TELT buffer. Lithium
chloride in the buffer removed RNA and protein aggregates from lysates. Fresh lysozyme
(10mg/ml) was made up in TELT buffer and 10pl added to the bacterial suspension to
destroy the bacterial cell membranes. The Eppendorf tubes were heated to 100°C for 1
minute on a hot-block and then plunged deep into ice and allowed to cool for 5 minutes.
Following high speed centrifugation, the supernatant was decanted into fresh Eppendorf
tubes and an equal volume of propan-2-ol (i.e. approximately 200pl) was added to
precipitate the DNA. This was ice cooled for 20 minutes, centrifuged and the supernatant
decanted off without disturbing the pellet at the bottom of the tube. The remaining propan-2-
ol was evaporated in a spin vacuum, resuspended in 50pl of Tris-EDTA (pH 8.0) and
dissolved in a 37°C waterbath for 30 minutes. The DNA was digested with the appropriate
restriction endonuclease and gel electrophoresis performed to confirm the presence of the
DNA insert (probe).
For the X-chromosome probe, pSV2neoX5 the following reagents were used:
BAM Hi restriction endonuclease 0.5pl





We made up 20pl of digest. Spermidine stabilises DNA enzyme complexes. The DNA
was digested at 37°C in a waterbath for 60 minutes. From in-house experience, Haelll
restriction endonuclease worked best with Buffer M for the Y-chromosome probe, pHY2.1.
Standard gels were 0.7% solution of agarose in Tris-EDTA with ethidium bromide. The
gel loading buffer contained bromophenol blue (0.25%), xylene cyanol FF (0.25%) and ficoll
(15%) in distilled water (Sambrook et al, 1989). Ficoll increased the density to encourage
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sinking and EDTA stopped the enzyme reaction. The dye allowed direct visualisation of the
migration front.
10pl of a known ^-marker, e.g. Hindlll, and the DNA digests were added to the wells and
subjected to 50mV for 60 minutes. Internal controls of uncut DNA, i.e. no restriction enzyme,
were run simultaneously to estimate the size of the entire vector and confirm that the insert
had been cut from the vector. The bands corresponding to DNA fragments were visualised
under UV light and the size determined by reference to the ^.-standards used. Large amounts
of DNA probe could then be purified.
7.3.1.3 Maxiprep. Preparation of large quantities of probe.
DNA purification was performed using the Promega Wizard Maxiprep Purification
System. There were minor modifications based on in-house experience and hence the
method is given in full.
The culture tube with the colony shown to be containing the vector was cultured overnight
in 500ml LB-broth in a shaker at 37°C. The broth (with no added magnesium) contained a
1:10 dilution of phosphate supplement and ampicillin (50pg/ml) 1:1000 dilution. The
following morning the broth was poured into sterile Sorvall High Speed Centrifuge Pots and
accurately balanced on weighing scales. The pots were centrifuged at 14,000 x g at 20°C for
15 minutes, the broth decanted off and the pellet of bacteria resuspended in 15ml of Cell
Resuspension Solution until no clumps were visible. 15ml of Cell Lysis Solution was added
and the cells mixed by inversion until the solution became very viscous and then cleared.
This was put on ice for 20 minutes and then transferred to Falcon tubes where 15ml of the
Neutralisation Solution was added and mixed. The solution became very viscous again. This
was put on ice for a further 20 minutes and then centrifuged at 14,000 x g at 4°C for 15
minutes.
The cleared supernatant was carefully decanted to a clean Falcon tube, avoiding the
white precipitate, and 0.6 x volume of propan-2-ol was added and mixed. This was left to
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stand at room temperature for one hour and then centrifuged at 14,000 x g at 4°C for 15
minutes. The supernatant was decanted off and discarded and the DNA pellet resuspended
in 75% ethanol. This was centrifuged at 14,000 x g at 4°C for ten minutes. The ethanol was
decanted off and the Falcon tube turned upside down and placed on filter paper to
encourage the remainder of the ethanol to drain off to allow the DNA to dry completely.
The Wizard Maxiprep DNA purification resin was mixed thoroughly and 10ml added to
the DNA. It was mixed by swirling until it got quite viscous. The Maxicolumn tip was inserted
into the vacuum manifold and the resin/DNA mix poured in. The vacuum was applied to pull
the resin through the Maxicolumn. To transfer all the DNA/resin mix to the Maxicolumn,
13ml of the column wash solution was added to the Falcon tube which contained the
DNA/resin mix, swirled and immediately poured into the Maxicolumn. The vacuum was
applied again, a further 12ml of the column wash solution was added and the vacuum
applied again. 5ml of 80% ethanol was added to the Maxicolumn and the vacuum applied to
rinse the resin which was dried by continuing to draw the vacuum for a further 10 minutes.
The Maxicolumn was placed in its original sterile Falcon tube and 1,5ml of preheated
Tris-EDTA (65-70°C) was added for one minute. This was centrifuged at 1300 x g for 5
minutes, the Maxicolumn was removed and the purified DNA eluate was left in the bottom of
the Falcon tube.
7.3.1.4 Spectrophotometry
A 1:100 dilution of DNA/Tris-EDTA (pH 7.4) was made up in an Eppendorf tube and the
spectrophotometer set to 260nm (the wavelength necessary for DNA analysis). A quartz
cuvette for DNA analysis was always used. The control Tris-EDTA (with no DNA) was put in
the cuvette, allowing the spectrophotometer to be zeroed. The diluted DNA was substituted
and the optical density (OD) determined. 50pg/ml of double-stranded DNA has an
absorbence of 1 at 260nm and hence an OD of 1 corresponded to approximately 50pg/ml of
double-stranded DNA. Bearing in mind that it is usual to only label about 500ng of DNA at a
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time, a large amount of very pure DNA was generated using this method. The DNA was
diluted in Tris-EDTA and stored at -20°C in individual aliquots (to avoid repeated freeze/
thawing of DNA) for future labelling.
To ensure that the probe had been purified a midi-gel was run as described previously.
7.3.2 Principles of Nick Translation
7.3.2.1 Probe labelling by Nick Translation
Deoxyribonucleic acid, DNA, is made up of four nucleotides in varying sequences:
adenine, guanine, cytosine and thymidine with a polysugar-phosphate backbone. Nick
translation was described by Langer-Safer et al (1992) whereby occasional thymidine bases
are replaced with deoxyuridine triphosphate (dUTP) bases on to which a reporter molecule is
attached. The reporter permits visualisation of the binding site and is often biotin or
digoxigenin, but occasionally direct labelling using a fluorochrome such as fluorescein
isothiocyanate (FITC) may be used.
DNase-1 "nicks" the DNA reasonably randomly and the number of "nicks" is proportional
to the amount of DNase added. If too much DNase-1 is used, then the DNA fragments will
be too small and the optimal amount should give 500bp fragments. When the DNA-
polymerase (Pol-1) sees a nick it repairs it with a similar base, chews the next base away
and replaces it with the appropriate base. It stops chewing/ repairing when it gets to the next
nick. Thymidine bases may be replaced by dUTP. Biotin is a small molecule so every
thymidine base is replaced by a biotin-dUTP base. Digoxigenin is large, so only 2 in 5
thymidine bases are replaced by digoxigenin-dUTP and the other 3 thymidine bases are
replaced by dTTP. For direct-labelled probes, FITC is a large molecule so only 2 in 5
thymidine bases is replaced by FITC-dUTP.
Normally 500ng of probe was labelled. Probes were clean as the method is very sensitive
to contaminants and all reagents were kept on ice and labelling performed in an unhurried
but efficient manner.
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10 x Nick Translation Salts (2.0|jl), dATP (2.5|jl), dCTP (2.5pl), dGTP (2.5|jl), biotin-16-
dUTP (2.5pl), 1.0|jl of 1:1000 diluted DNase, 500ng of probe and a volume of distilled water
to make the total volume up to 19gl were mixed in an Eppendorf tube. 1 pi of Pol-1 was
added and the Eppendorf put in a 15°C waterbath for 90-120 minutes. The reaction was
stopped by adding 2.0pl of 0.2M EDTA (to mop up the magnesium) and 1.0pl of SDS (a
detergent which denatured the enzymes). After the labelling reaction had been stopped, the
probes were separated from the unincorporated nucleotides by Pharmacia Nick Spin
Columns.
7.3.2.2 Nick Spin Columns
Nick Spin Columns contain G50 sephadex beads that have tiny pores. These pores
permit the penetration of unincorporated nucleotides, thus retarding their elution from the
column. The fluid was allowed to drain out of the column and 3ml of Tris-EDTA added and
allowed to drain through. The excess was discarded and the column centrifuged at 500 x g
for 4 minutes.
Because of the theoretical risk of diluting out the EDTA/SDS and reactivating the pol-1,
only at this stage was the probe made up to 75-1 OOpI with Tris-EDTA. It was immediately
layered on top of the Sephadex beads and the column centrifuged at 500 x g for 4 minutes.
The probe was collected in a labelled Eppendorf tube at the bottom of the test tube.
7.3.2.3 Estimation of Probe concentration
Nitrocellulose filters were prepared according to standard methods by washing in distilled
water for two minutes and then in 20xSSC for twenty minutes and air-dried. 1: 103 and 1:
104 dilutions of the probe were prepared in Tris-EDTA (pH7.5) and dotted on to the filter
papers to give concentrations of 20pg/pl, 10pg/pl, 2pg/pl and 1 pg/pl.
The 7-standard was diluted to the same concentrations and dotted on to the filter paper in
their corresponding positions. The filter paper was placed in a Biorad GS Gene ultraviolet
(UV) cross-linker and subjected to 250mJ UV radiation. Biotin or digoxigenin probes were
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detected with streptavidin alkaline phosphatase and anti-digoxigenin alkaline phosphatase
respectively using BCIP/NBT Vector kit protocols (Vector). The filter paper was sealed and
incubated in the dark at room temperature overnight and the probe concentration
subjectively determined by comparing the colour intensity of the probe with that of the X-
standards.
7.3.2.4 Principles of probe hybridisation and visualisation
Cot-1 DNA is a highly repetitive, widely occurring genomic DNA sequence. Especially
with contiguous cosmid probes, it is frequently necessary to pre-incubate the probe with cot-
1 to bind complementary areas of DNA on the probe. This prevents the repeat-containing
areas of the probe from binding to genomic DNA which has the same sequence, thus
improving probe specificity (reducing background staining), and is termed preannealing.
Denaturation allowed the double-stranded genomic and probe DNA to separate. The
length of incubation and any refining steps (the stringency) then depended on the assay.
After washing to remove any unbound probe the hybridisation bodies were visualised
using fluorescent affinity agents. Texas Red and FITC were the only fluorochromes used.
From the above, it can be seen that FISH employs the principles of indirect
immunofluorescence (chapter 4) and a schematic representation is given in figure 7.1.
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Figure 7.1 The principles of fluorescence in situ hybridisation
1. Double-stranded nuclear DNA and probe DNA (labelled with a reporter molecule e.g.
biotin) are heat-denatured.
2. Single-stranded probe and nuclear DNA are hybridised overnight under stringent
conditions.
3. Unbound probe is washed off.
4. The probe-nuclear DNA binding site is visualised by incubating with an anti-reporter
molecule (e.g. avidin) which has a fluorochrome attached (e.g. FITC).
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7.4 Fluorescence in situ hybridisation using chromosome-specific repeat sequence
probes.
These are repetitive DNA sequences that hybridise to specific areas on specific
chromosomes and are ideal for interphase analysis as the signals are large, intense and
well-localised. However, there may be similar sequences in other chromosomes increasing
the potential for false-positive results.
Both repeat sequence probes used in this study were made in-house, allowing limitless
supplies at minimal cost and, importantly, our scientists were already familiar with their use.
They were always tested with uncultured diploid cells as controls. Stimulated, cultured
lymphocytes are frequently arrested in mitosis which may result in multiple nuclear signals
and misrepresent the ploidy of the cell. Hybridisation efficiency is never 100% so that four
copies of a chromosome may only be represented by three FISH signals and will falsely
suggest a trisomic cell. Our experiments always involved uncultured cells as controls to
minimise this risk, particularly as the cells from maternal samples were also uncultured.
As the nucleus is a three dimensional structure, FISH signals may be at different planes.
Therefore, although a cell is trisomic, the third signal might be on a different plane and not
seen and the cell wrongly considered diploid. This will, of course, increase the false-negative
rate.
The Y-chromosome probe used was pHY2.1 (Cooke et al, 1982) and the X-chromosome
probe used was pSV2neoX-5 (Waye and Willard, 1985).
7.4.1 Y-chromosome probe, pHY2.1
The long arm of the human Y-chromosome carries 2000 copies of a tandemly repeated
2.47kb sequence constituting about 20% of Y-chromosome DNA. This heterochromatin,
which fluoresces brightly with quinacrine, is not involved directly with sex determination as it
is occasionally found in women. Within the 2.47kb sequence is a 2.1 kb sequence flanked by
Haelll sites. pHY2.1 (Cooke et al, 1982) was labelled with digoxigenin and visualised with
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anti-digoxigenin-Texas Red. There are about 100 copies of a very similar 2.0kb sequence
on autosomes (notably: 2q, 3p, 5p, 6p, 7q, 10p, 11 p, 13p, 14p and 14q, 15p, 18p, 21q, 22q
and also Xp and Xq) which can give much smaller, "background" signals.
7.4.2 X-chromosome probe, pSV2neoX-5
When DNA is run out on a caesium chloride gradient there is a large band and then
smaller satellite bands, one of which is known as the "a" band, a-satellite DNA is repeat
sequences in the pericentric regions of all chromosomes.
The pericentric region of the human X-chromosome is characterised by a tandemly
repeated family of 2kb DNA fragments of which there are approximately 5000 copies. These
fragments are each made up of twelve a-satellite monomers, each approximately 171 bp in
length. These monomers are 65-85% identical in sequence to each other which permits a
consensus monomer sequence. pSV2neoX-5 is a 242bp fragment (i.e. spans one-and-half
monomers) within the 2kb fragment. It is exclusive to the human X-chromosome so that
under conditions of high stringency there should be little or no cross-hybridisation (Waye and
Willard, 1985). Direct labelling of pSV2neoX-5 with FITC gave large, reliable signals with
very little background fluorescence.
7.4.3 Method for fluorescence in situ hybridisation using chromosome-specific repeat
sequence probes
Formamide is irritant and potentially teratogenic and gloves were always worn.
200ml of 2xSSC with 2ml of thawed RNase was warmed to 37°C and 200ml of 2xSSC
was kept at room temperature. The slides were incubated in the warmed 2xSSC/RNase for
one hour. Slides were immersed in the remaining 2xSSC and then sequentially dehydrated
through 70%, 90% and 100% alcohol for two minutes each. They were then dried in a
vacuum for 5 minutes. If slides were more than ten days old, they were subjected to
proteinase K (PK) treatment. If the slides were more than three weeks old FISH was
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unreliable. 400ml of PK buffer was divided into two 200ml aliquots and one aliquot heated to
37°C. Proteinase K digested proteins from around and within the nucleus, effectively
opening up the nucleus and improving probe access. If cells were left in PK for too long then
non-specific DNA binding, and hence background signals, were increased. 10pl of stock PK
was added to the buffer at 37°C, slides immersed for two minutes and then immediately
immersed in the PK-free buffer. They were sequentially dehydrated through 70%, 90% and
100% alcohol each for two minutes followed by vacuum drying. The amount of probe
necessary for each coverslip was determined from the estimate of the probe concentration
(chapter 7.3). For repeat sequence probes approximately 20ng of probe was applied per
22mm x 22mm coverslip and 60ng for a 22 x 50mm coverslip. The neat probes were put in
an Eppendorf centrifuge tube. 0.5mg of salmon sperm DNA per 10pl of the final calculated
volume of the hybridisation mixture and double the volume of absolute alcohol was added.
The alcohol was evaporated in a vacuum centrifuge for one hour.
100pl of hybridisation mixture was made up of Formamide (55pl); 20xSSC (5pl); Tween
20 (1pl); distilled water (19pl) and dextran sulphate (20pl). This was added to the dried down
probe and left to dissolve for one hour at room temperature. Coverslips were kept in
absolute alcohol with 1% concentrated hydrochloric acid to remove grease and destroy
bacteria. 10pl of the hybridisation mixture was placed on a clean 22 x22mm coverslip or
30pl on to a 40 or 50 x 22mm coverslip. Slides were mounted in the hybridisation mixture,
bubbles expelled and the coverslip sealed around the edges with "Tip Top" rubber solution.
The slides were laid in an enamel tray, covered with tin foil and placed in a 70°C waterbath
for 5 minutes to denature the chromosomes and the probes. The tray was then transferred to
a 37°C waterbath and the chromosomes and probes left to hybridise overnight.
If a-satellite probes were used, overnight hybridisation was performed at 45°C to increase
the stringency (reduce background staining). Other options to increase stringency were (a)
increasing the concentration of formamide in the hybridisation mixture, (b) decreasing the
salt (SSC) concentration in the hybridisation mixture, (c) washing the slides the following
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morning at a higher temperature and lower salt concentration (e.g. O.lxSSC at 60°C) and (d)
decreasing the concentration of the probe to reduce non-specific binding.
7.5 Fluorescence in situ hybridisation using contiguous cosmid probes.
7.5.1 Chromosome 21 contiguous cosmid probe, cCMP21.a
Single-copy sequence probes allow identification of very specific areas of chromosomes.
The smaller the probe, the more chromosome-specific it becomes but there is less reporter
molecule available so that the signal is not as large. However, the signal size and reliability
can be increased by using contiguous cosmids. Here two cosmids, which are very close
together, or indeed whose ends overlap, are used simultaneously. Even if one of the
cosmids fails to hybridise, hopefully the other will hybridise to give a reliable signal.
Analysis of chromosome 21 in interphase is more difficult than for other chromosomes
because there is no reliable chromosome 21-specific repeat probe. A repeat sequence probe
is available but it hybridises to both chromosomes 21 and 13 which limits its use (chapter
7.10.2).
The 21q22 region (the 22 region of the long arm of chromosome 21) is the region which
confers "Down's syndrome" on an individual. In this study the chromosome 21-specific
probe, cCMP21 .a, the kind gift of Dr. Nigel Carter, was used (Zheng et al, 1992). cCMP21 a
was produced from two cosmids, cCMP21.2 and cCMP21.6 which overlap to give a 55kb
probe, highly specific for the 21q22 subregion. Because of its specificity, both signals could
be resolved in common Robertsonian translocations involving duplication of chromosome
21q.
7.5.2 Method for fluorescence in situ hybridisation using chromosome-specific
contiguous cosmid probes
The methodology for using cosmid probes required certain modifications compared to
repeat sequence probes.
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Slides were kept in a metal rack throughout the procedure to avoid altering the
temperature of the water baths dramatically and because glass racks may crack with sudden
temperature changes. The probe concentration was around 50ng per small coverslip.
Sequences occurring within the cosmid probe and occurring elsewhere in the genome were
competed out with excessive Cot-1 human DNA (1pg/pl/22mm x 22mm coverslip). Salmon
sperm DNA was added to achieve a final concentration of 0.5mg/ 10pl of hybridisation
mixture. Twice the total volume of absolute alcohol was added and the probes vacuum
dried.
FISH using cosmid probes was performed at lower stringency and hence a hybridisation
mixture containing only 50% formamide was used. This was added to the dried down probe
and left to stand for one hour. 200ml of 70% formamide: 2xSSC was heated to 70°C. 70%
alcohol was made up and put on ice. Cellular DNA was denatured in a 70°C oven for 5
minutes, immediately put in the 70% formamide: 2xSSC at 70°C for 3 minutes and then
immediately transferred to the ice-cold 70% alcohol. The timing was crucial as this stopped
the denaturation reaction. After the vacuum-dried probe had dissolved it was put in the 70°C
waterbath (in a polystyrene floater) for 5 minutes. This allowed the double-stranded DNA of
both the probe and the cot-1 human DNA to become single-stranded. It was then transferred
to the 37°C waterbath for 15 minutes, allowing the single-stranded DNA to reanneal.
The probe was put on to a clean 22 x 22mm coverslip and mounted on the slide. Because
the cellular DNA and the probe had already been denatured, no further denaturation step
was required. The coverslip was sealed with "Tip Top" rubber solution, the slides laid in an
enamel tray and covered with tin foil. The tray was put in the 37°C waterbath for overnight
hybridisation. Cosmids were never hybridised at any higher temperature.
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7.6 Development of hybridisation signals
The following morning, regardless of the type of probe used, the protocol was the same.
From this stage onwards, care was taken to prevent the slides drying to minimise
background staining. The type of probe-labelling and the desired colour to visualise the
hybridisation bodies determined which antibodies were used. For biotin-labelled probes an
avidin molecule, with an appropriate fluorochrome attached, was used. The second layer
was a biotinylated anti-avidin goat monoclonal antibody and the third layer avidin-
fluorochrome again. For digoxigenin-labelled probes, two layers (a mouse-anti-digoxigenin
mAb and anti-mouse-FITC) permitted adequate visualisation with minimal background
staining. The antibodies were made up with blocking buffer (see appendix II) and
centrifuged at 4°C. 1ml of blocking buffer was also centrifuged to remove large conjugates.
The rubber seal was peeled off and the slides put in a rack. During the subsequent
washing, the coverslips fell off the slides. The slides were washed four times, each for three
minutes, at 45°C in 50% formamide/ 2xSSC, the washes repeated at 45°C in 2xSSC and
finally at 60°C in O.lxSSC. After the final wash the slides were put in 4xSSC/ Tween 20 at
room temperature and 2 litres of 4xSSC with 0.1% Tween 20 was warmed to 37°C. 10pl of
blocking buffer (to reduce non-specific background staining) was put on a fresh coverslip
(40pi for large coverslips) and mounted on the slide for five minutes. The coverslip was
flicked off and the first layer of antibodies applied to the same coverslip and remounted on to
the slide. The slides were laid in a sandwich box, containing benchcote moistened with
4xSSC/0.1% Tween 20, and put in a 37°C incubator for 30 minutes.
Following incubation the slides were washed three times in 4xSSC/ 0.1% Tween 20 at
37°C, each for 2 minutes, and the second layer of antibodies applied on clean coverslips.
The incubation and washing was repeated for the desired number of layers. The excess fluid
was drained off, 10pl of Vectashield/ DAPI/ propidium iodide was applied to a coverslip, the
bubbles were expelled and the coverslips sealed with rubber solution.
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7.7 Maternal blood samples
Using the enrichment process described in chapters 5 and 6 a prospective study of 15
women in early pregnancy was performed and prospective fetal sexing attempted.
Following enrichment, apart from some cytospin preparations, the remaining cells were
fixed in suspension in fresh methanol: acetic acid (3:1) and deposited on to clean
microscope slides. The cells were subjected to FISH, initially using only a Y-chromosome
probe and subsequently using X and Y-chromosome probes simultaneously. The Y-
chromosome, pHY2.1, was labelled with digoxigenin and visualised with anti-digoxigenin-
Texas Red and the X-chromosome probe, pSV2neoX-5, was directly labelled with FITC.
In two cases (patients 10 and 12) the women agreed to have blood taken from them
every two weeks from first presentation until twenty four weeks' gestation to see if there was
any trend in recovery of potential fetal cells as pregnancy advanced.
Blood was also taken from the antecubital fossa of a 39 year old woman prior to vaginal
prostaglandins and suction termination of pregnancy, seven days after CVS. CVS (for
advanced maternal age) performed at 11 weeks' gestation had demonstrated a 47.XX+21
fetal karyotype. The blood was enriched as previously described and the cells fixed in
methanol: acetic acid (3:1). The slides were subjected to FISH using the biotinylated
chromosome 21 contiguous cosmid probe, cCMP21.a, and the signal developed with avidin-
FITC.
7.8 Imaging
Slides were scanned manually using a Zeiss Axioplan fluorescence microscope with a
triple band-pass filter and images were captured on an Apple Macintosh Quadra 950 using
IPLab Spectrum 2.4 software.
Nuclei were inspected for a Y-hybridisation body and, when the two sex chromosome
probes were used simultaneously, for X and a Y-hybridisation bodies. If signals were
considered reliable then scanning was stopped for that particular maternal sample and the
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fetus was assigned as male. All the slides for any particular maternal sample were scanned
in entirety until such times as X and Y-hybridisation bodies were observed; if none was
found, then the fetus was assigned as female.
Using the contiguous cosmid probe, for the cell to be considered as showing two copies
of chromosome 21, the distance between the two signals had to be more than the diameter
of either of the two signals. Similarly, if three potential signals were identified then the
distance between two adjacent signals had to be more than the diameter of either of the two
adjacent signals.
The nucleus is a 3-dimensional structure with probe signals at different planes. Therefore,
the microscope objective had to be adjusted to examine the entire depth of each nucleus
and, despite enrichment, it took several days to scan a single maternal sample.
7.9 Results
7.9.1 Hybridisation efficiencies of the chromosome probes
The following data for chromosome probe hybridisation efficiencies was accumulated on
uncultured adult diploid leukocytes fixed in suspension in fresh methanol: acetic acid (3:1).
Table 7.1 shows that the repeat sequence probes, pSV2neoX-5 and pHY2.1, were highly
efficient.
Table 7.1 FISH analysis using single chromosome probes on adult leukocytes
Cell Karyotype Female Female Male
Chromosome X (pSV2neoX-5) Y (pHY2.1) Y (pHY2.1)
Probe
No. of samples 5 5 5
No. of cells 10,000 50,000 10,000
counted
2 signals 9520 0 0
(95.2 ± 2.7%) (0%) (0%)
1 signal 390 2 9630
(3.9 ± 2.0%) (0.01%) (96.3 ± 3.6%)
0 signals 90 49,998 370
(0.9% ± 0.4%) (99.99 ±0.01%) (3.7 ± 3.6%)
FISH performed using protocol detailed in Chapter 7.4 and 7.6.
95% confidence intervals in parentheses.
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Table 7.2 shows that the repeat sequence probes, pSV2neoX-5 and pHY2.1, for
chromosome X and Y respectively could be used reliably to assign gender in uncultured
leukocytes. Even so, there were false-positive results in female control samples and,
likewise, there were 'female' false-positive results in male control samples. This must be
borne in mind when attempting to assign gender in enriched maternal blood samples.
Table 7.2 FISH analysis using X and Y-chromosome probes simultaneously on adult
leukocytes
Cell karyotype Female Male
No. of samples 7 3
Total no. of cells counted 35,000 15,000
Chromosome Signal: XY 11 (0.03%) 13620 (90.8%)
Chromosome Signal: XXY 7 (0.02%) 180 (1.2%)
Chromosome Signal: XX 32819 (93.8%) 9 (0.06%)
Chromosome Signal: XO 2054 (5.87%) 90 (0.6%)
Chromosome Signal: OO 105 (0.3%) 675 (4.5%)
Chromosome Signal: OY 4 (0.01%) 426 (2.84%)
FISH performed using protocol detailed in Chapter 7.4 and 7.6.
Note the high hybridisation efficiency with adult leukocytes
Table 7.3 shows the hybridisation efficiency of fetal erythroblasts. These data
demonstrate that the hybridisation efficiency of erythroblasts is poorer than for adult
leukocytes when compared with the results in table 7.1 (p < 0.001, female cells using X-
chromosome probe alone; p < 0.001, male cells using Y-chromosome probe alone).
Table 7.3 FISH analysis using X or Y-chromosome probes on fetal erythroblasts
Erythroblast karyotype Female Male
No. of samples 9 3
Total no. of cells counted 18,000 6,000
Chromosome signal: XX 12,492 (69.4 17.5%) -
Chromosome signal: XO 3816(21.2 18.3%) -
Chromosome signal: OO 1692 (9.4 14.8%) 2304 (38.4 1 2.4%)
Chromosome signal: OY - 3696 (61.6 1 8.2%)
Chromosome signal: YY - 0
FISH performed using protocol detailed in Chapter 7.4 and 7.6.
Note the poorer hybridisation compared to leukocytes in Table 7.2
142
Table 7.4 shows that the hybridisation efficiency of the contiguous cosmid probe,
cCMP21.a, with uncultured adult leukocytes was not as efficient as the repeat sequence
probes. Only 66.2 ± 6.6% of cells showed two chromosome 21 signals simultaneously
although very few appeared to be trisomic.
Table 7.4. FISH signals using the chromosome 21 probe, cCMP21.a, on uncultured
adult leukocytes
0 signals 6880 cells (17.2 ± 5.1%)
1 signal 6602 cells (16.5 ± 5.2%)
2 signals 26,478 cells (66.2 ± 6.6%)
3 signals 12 cells (0.03 ± 0.02%)
4 signals 28 cells (0.07± 0,02%)
FISH performed using protocol detailed in Chapter 7.5 and 7.6.
7.9.2. Results of prospective in utero fetal sexing
In pregnancies involving a male fetus between 1 and 70 cells showed simultaneous X and
Y signals (figure 7.2) and table 7.5 shows the fetal sex assigned by FISH and the sex at
delivery (Gaudoin, 1995). Cases 1-7 used only the Y-chromosome probe whilst cases 8-15
used X and Y-chromosome probes simultaneously. Gender prediction was 86.7% accurate
(p < 0.004, 100% sensitivity, false positive rate 25%). However, the two false-positive results
emphasise the need for an additional test to confirm that the analysed cells were truly fetal in
origin.
The results of enrichment and FISH analysis in the two cases that were sampled serially
are summarised in table 7.6. It is tempting to suggest that the number of fetal erythroblasts
increase in maternal blood up to 14 weeks' gestation and decline thereafter (case 10) but,
unfortunately, because the pregnancy in the other case involved a female fetus, little can be
concluded from this data.
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1 8 PHY2.1 0 Female Female TN
2 12 PHY2.1 1 Male Female FP
3 12 PHY2.1 3 Male Male TP
4 14 PHY2.1 3 Male Female FP
5 12 PHY2.1 1 Male Male TP
6 10 PHY2.1 0 Female Female TN
7 10 PHY2.1 0 Female Female TN
8 15 pHY2.1,
pSV2neoX-5
3 Male Male TP
9 11 pHY2.1,
pSV2neoX-5
0 Female Female TN
10 14 pHY2.1,
pSV2neoX-5
70 Male Male TP
11 16 PHY2.1,
pSV2neoX-5
4 Male Male TP
12 16 pHY2.1,
pSV2neoX-5
0 Female Female TN
13 16 pHY2.1,
pSV2neoX-5
2 Male Male TP
14 11 pHY2.1,
pSV2neoX-5
1 Male Male TP
15 13 pHY2.1,
pSV2neoX-5
0 Female Female TN
FISH performed using protocol detailed in Chapter 7.4 and 7.6.
TP = true positive result, TN = true negative result, FP = false positive result, FN = false
negative result
Table 7.6. Results of serial maternal blood tests
Gestation in weeks at
sampling
8 10 12 14 16 18 20 22 24
No. of XY interphase nuclei
Case 10
0 2 5 70 38 2 2 0 0
No. of XY interphase nuclei
Case 12
0 0 0 0 0 0 0 0 0
FISH performed using protocol detailed in Chapter 7.4 and 7.6.
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7.9.3 Results from first trimester Trisomy 21 case
In the case of the woman carrying a Down's syndrome fetus over 200 trisomy 21 cells
were counted from less than one slide alone. Analysing 2000 consecutive nuclei, 16 nuclei
(0.8%) showed three signals (Gaudoin, 1995; figure 7.3). When comparing this maternal
sample with the control, using the %2 test, the difference in proportions is highly significant (p
< 0.001).
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Figure 7.2 XY interphase ceils enriched from the blood of pregnant women
X-chromosome probe labelled with FITC, Y-chromosome probe labelled with Texas red.
Ill
Figure 7.3 Trisomy 21 cells enriched from the blood of a woman carrying a Down's
syndrome fetus
Chromosome 21 probe labelled with FITC. Note that the three-dimensional structure of the
nucleus means that not all the probe signals are clearly visible in a single plane.
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7.10 Discussion
7.10.1 FISH used to analyse putative fetal cells in maternal blood
Despite enrichment, it is unlikely that a pure sample of fetal cells from a maternal blood
sample can be obtained and FISH is necessary to diagnose fetal aneuploidy in such
circumstances.
As our attempts at prospective fetal sexing were significant (correctly assigning fetal sex
in 13 of 15 cases), it suggests that fetal cells can be enriched from maternal blood in early
pregnancy, albeit in small numbers. In the first seven maternal cases, FISH was performed
with only the Y-chromosome probe and there were two false-positive results. It is very
unlikely that these cells were lymphocytes from previous pregnancies (chapter 3.3) as both
women were purportedly primigravidae and, furthermore, enrichment specifically depleted
lymphocytes. It is more likely that the false signals were either the result of non-specific
fluorescent debris coinciding with a nucleus or the probe binding to an autosome. However, it
emphasises the necessity of confirming that the cells were indeed fetal. Using FISH alone,
the simplest method was to use X and Y-chromosome probes simultaneously and ever since
this was performed, no false positive results were incurred, despite the small numbers of
cells recovered.
Two women were followed throughout the first and early second trimesters to try and
establish any temporal relationship in the frequency of fetal cells in maternal blood.
Although fetal sex was correctly assigned in both cases, it was unfortunate that case 12
delivered a girl. From case 10, it is tempting to suggest that the number of (male) fetal cells
rises up to the early second trimester and then declines (table 7.6). This has been reported
previously and may have a physiological basis (chapter 3.6), but as this was only one case,
and the slides were searched in their entirety (unlike the other cases), any temporal
relationship is unproven and this issue remains unresolved.
Differentiating male from female cells using multicolour FISH is relatively straightforward
but it is a different matter if the cells (both fetal and maternal) have the same chromosomes
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but different copy numbers of a particular chromosome. If the aggregate probability of
detecting a single target chromosome is 0.9 (90%), then the chances of correctly detecting 3
chromosomes in a nucleus is 72.9% (0.9 x 0.9 x 0.9 = 0.729). Furthermore, even disomic
cells may occasionally appear trisomic using FISH (table 7.4). Therefore, analyses of cells
becomes a statistical exercise when counting the number of hybridisation signals within
individual nuclei and assignment of ploidy by FISH is based on a statistical pattern. Hence it
is necessary to define specific criteria for such assignment.
Compared with the control cells, there was a highly significant difference in the proportion
of cells showing three chromosome 21 signals, enriched from the blood of the woman about
to undergo termination of pregnancy for a Down's syndrome fetus. The confirmation of fetal
aneuploidy is an important verification of our negative enrichment technique and
demonstrates the need for in situ hybridisation. However, we cannot disregard the possibility
of an iatrogenic increase in the number of fetal cells in this case as substantially more
apparent fetal cells were found than in cases which had not undergone prenatal testing.
Little is known of the persistence of fetal erythroblasts in the maternal circulation but there is
some evidence that proportionately more cells enter the maternal circulation in aneuploid
pregnancies, possibly because of abnormal placentation (chapters 3.6 and 10.3), and our
findings are in keeping with other workers.
Ganshirt-Ahlert et al (1994) claimed that up to and including 16 weeks' gestation, they
could detect as many as 10,000 fetal erythroblasts in 91.3% of all pregnancies. However, in
this study a maximum of 70 male cells were identified at 14 weeks' gestation whilst in most
cases very few XY interphase cells were identified. There may be a number of explanations
for this difference.
Firstly, the obvious explanation is that positive selection using the MACS system is
considerably better than our negative enrichment approach. However, even using
multiparameter FACS, very few putative fetal cells have been recovered (chapter 3.6) and
we, like others, have found MACS inferior to Dynabeads (chapter 6.4.4). An alternative
explanation is that the analyses of Ganshirt-Ahlert et al were based solely on cell
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morphology using Romanowski stains with no other corroborating evidence such as
prospective fetal sexing or immunocytochemistry to confirm the identity of the cells. It is
plausible that the cells were polymorphs which had engulfed MACS beads and the nucleus
had then become pyknotic. From our own experience these cells can appear very similar to
normoblasts but the cytoplasm has a glassy appearance.
Another reason why there might have been so few apparent fetal cells is the decreased
hybridisation efficiency of erythroblasts (table 7.3). As cells degenerate, loss of cellular
target DNA results in poorer hybridisation efficiency (Ward et al, 1993). Certainly
normoblasts (whether fetal or adult) have pyknotic nuclei which are about to be extruded and
probe access to erythroblast DNA is poorer than for peripheral blood leukocytes. Therefore,
although there might be many more fetal erythroblasts in the final complement of cells,
efficient hybridisation is not occurring.
Despite the Dynabead enrichment process there were still hundreds of thousands of
nuclei. Examining every single 3-dimensional nucleus was extremely arduous and tiring,
taking several days to scan an enriched sample in fluorescence. We also had to be
pragmatic as the microscopes were required by many others. If we were sufficiently
confident about the quality of XY signals, scanning was stopped and fetal sex was predicted
on the basis of very few XY cells. Therefore there may have been more fetal cells present
but the ability to search for them manually was the limiting factor. This emphasises the need
for an automated slide search capability if the concept of analysing fetal cells from maternal
blood is to become reality (Piper et al, 1994; Tanke et al, 1996).
Of course, no data has determined just how many fetal erythroblasts are consistently
present in the maternal circulation and there may yet only be a handful in 20ml of blood.
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7.10.2 The potential of FISH in Prenatal Diagnosis
There are advantages to rapid karyotyping in antenatal diagnosis. Speedy results may
have a positive psychological effect and termination of pregnancy performed earlier in
pregnancy is physically and psychologically less traumatic. Furthermore, if there are time
constraints between the test and when management decisions must be made, rapid results
can be advantageous. FISH is less labour-intensive than traditional cytogenetics and is
applicable to tissues with a low mitotic index,
a) FISH and Amniocentesis
In 117 of a series of 556 uncultured amniocenteses, Klinger et al (1992) used five
contiguous cosmid probes to chromosomes 21, 13, 18, X and Y simultaneously and in less
than 2% was there any dubiety in fetal karyotype normality using their probe sets. However,
hybridisation efficiency was lower in trisomic samples principally, the authors claimed,
because pregnancy was more advanced at the time of sampling and these showed poorer
hybridisation. Although promising, the authors did not say why this was the case. Possibly a
fetal anomaly was detected on ultrasound scan, prompting the amniocentesis. This is a
reasonable supposition as, in almost 80% of cases, not all the probes were used. Their
choice of probes for a particular sample may have been guided by the suspected anomaly
and if so, it cannot be described as a truly blind study.
Seres-Santamaria et al (1993) compared standard amniocyte metaphase analysis with
interphase FISH, using an a-satellite probe which hybridised to both chromosomes 13 and
21 and only detected 12 of 16 Down's syndrome cases. However, this might have been
anticipated as there should be five hybridisation bodies (three chromosome 21 domains plus
two chromosome 13 domains) if hybridisation is 100% efficient. If the hybridisation efficiency
is only slightly reduced, a nucleus will show perhaps four domains and erroneously appear
diploid. Hence, a balance must be struck between obtaining a large, easily identified signal
or a smaller, but more specific, signal and demonstrates the importance of choosing probes
appropriately.
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More recently Eiben et al (1998 and 1999) reported their experience with FISH in over
3000 amniocenteses. There were no false-positive results and all cases of trisomy 13, 18
and 21 were detected apart from one case of trisomy 21 which was missed because of
hybridisation failure. This suggests that if a result is positive, further counselling may take
place immediately. However, when considering that all other trisomies were detected with
standard karyotyping, it confirms that cytogeneticists still cannot rely solely on the FISH
results and must wait until the final culture to ensure they have not missed any trisomies or
translocations.
b) FISH and chorionic villus sampling
The tissue obtained at chorionic villus sampling is metabolically active and hence FISH
results should be reliable and available very soon after the procedure. This should permit
CVS to be performed late in the first trimester (minimising the risks of limb reduction defects,
chapter 2.3) but sufficiently early to allow suction termination of pregnancy if requested.
Evans et al (1992) correctly identified the only case of trisomy 21 in a small study and
found that the hybridisation efficiency for uncultured chorionic villi was higher than for
uncultured amniocytes. Bryndorf et al (1996) reported a series of over 2700 CVS cases in
which they confidently assigned fetal karyotype. However, they were explicit in highlighting
the increased incidence of mosaicism in placental samples, which necessitated a further
invasive test, a problem that has dogged CVS from the start (chapter 2.3).
7.11 Summary
Our results suggest that it is possible to sex fetuses using FISH in early pregnancy from a
peripheral maternal blood sample and, possibly, more cells might be isolated before 16
weeks' gestation. Furthermore, it is possible that more fetal cells may be isolated from
aneuploid pregnancies. All these findings suggest that non-invasive prenatal diagnosis of
fetal aneuploidy in early pregnancy is feasible.
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However, this is a rather bold statement as so few cells were recovered in the
karyotypically normal cases, which will be the vast majority of pregnancies. Undoubtedly
more fetal cells must be recovered from maternal blood to improve diagnostic confidence.
FISH is now an established investigative modality but even with a pure sample of fetal
amniocytes there are false-negative results and, earlier in pregnancy, there are false-positive
results with CVS. Clearly prospective fetal sexing, to prove that such cells are fetal, is a step
in the right direction. However, half of all pregnancies involve a female fetus. Positive
identification of isolated cells would permit greater confidence in karyotype assignment and
until then they can only be described as "putative" fetal cells. The ideal way would be
simultaneous karyotyping and positive cell identification and the approaches to this will be
discussed in chapter 9.
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Chapter 8. Cell Deposition
At the end of enrichment the vast majority of cells remaining were non-nucleated
erythrocytes and maternal leukocytes (figure 6.8). Consequently, there were several aspects
to the deposition stage to be addressed.
Firstly, as many cells as possible must be deposited onto slides without incurring great
losses of rare fetal cells. Secondly, the total number of cells from each sample should be
deposited on three or four slides. If there are fewer slides and FISH failed, or a slide was
damaged, then the sample may be useless for diagnostic purposes. If more slides are used
then handling becomes a burden. And thirdly, cells should be deposited as a monolayer.
Mature erythrocytes do not show chromosome signals but if one covers a nucleated cell it
could interfere with hybridisation. Cells adequately separated might also allow FISH to be
combined with a method that has previously identified the fetal erythroblasts positively
(chapter 9). This would mean that only the positive cells need to be examined whilst FISH
signals in other nuclei could be disregarded.
Using model systems of fetal blood mixtures enriched in the way already described,




The enriched cells were washed, centrifuged and resuspended in 5ml of 2% (w/v) BSA in
PBS. 500pl aliquots were loaded into cytocentrifuge buckets and centrifuged at 100 x g for 5
minutes onto clean microscope slides using a Shandon II cytocentrifuge (Shandon). A non-
overlapping monolayer could be produced on 10 slides. The slides were fixed for
subsequent May-Grunwald-Giemsa staining, immunocytochemistry and/ or FISH.
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8.1.2 Settling technique
A wax ellipse, approximately 5cm2 (5 x 108 pm2) was drawn on the slide using a DAKO
wax pen (catalogue number, S2002) and allowed to dry. 2ml of the cell suspension were
then carefully loaded onto the slide within the ellipse. The cells were allowed to settle by unit
gravity in a 37°C incubator which encouraged evaporation of the suspension medium.
8.1.3 Methanol: acetic acid fixation
After the final centrifugation following enrichment (chapter 6.3.3), the 2% (w/v) BSA in
PBS was pipetted off to just above the tiny red cell pellet and the test tube was vortexed to
resuspend the nuclei Fresh Carnoy's methanol: acetic acid (3:1) was dropped, one drop at a
time, onto the cells using a Pasteur pipette whilst vortexing continued. Once the test tube
contained about 7ml of fixative it was left to stand at 4°C for fifteen minutes, centrifuged at
250 x g for 10 minutes and the fixative pipetted off to just above the cell pellet, which
removed the lysed red cell membranes. The pellet was vortexed again and three drops of
fixative was added. Using a fine-tipped Pasteur pipette a drop of the cell suspension was
dropped onto an ethanol-cleaned microscope slide from a few centimetres above the slide
and the fixative allowed to evaporate rapidly. The slide was inspected using a phase contrast
microscope to ensure that there were sufficient nuclei on the slide. This was repeated until
all the cell suspension was exhausted which usually required two or three slides. Slides were
then subjected to immunocytochemistry and/ or FISH.
Fixation, as above, was then investigated using varying ratios of methanol: acetic acid




In the latter stages of the project, a technique initially developed by Mrs. Patricia Eason
and subsequently modified and optimised by Mrs. Heather Finlayson and Dr. Alison Hill,
appeared to be very promising.
After enrichment, the remaining cells were resuspended in a small volume of fetal calf
serum with 1% dimethyl sulphoxide (DMSO). A smear was made in exactly the same way as
for whole blood i.e. depositing a drop of the cells on a microscope slide and drawing the
edge of another slide over the drop, along the length of the original slide. This allowed all the
remaining cells to be deposited onto six to eight slides with the majority of nucleated cells
concentrating at the feathered tail of the smear.
8.2 Results
Cytospin preparations gave excellent morphology and cells could be identified easily.
Fetal erythroblasts were also readily identified by y-globin immunocytochemistry (chapter 9).
However, there were frequent instances where no, or very few, cells could be found on the
slide and a pink halo was evident in the filter paper around the hole. These phenomena
imply that a significant proportion of cells irretrievably leach into the filter paper. The
cytospin is a 6mm diameter circle (radius, 3mm or 3000pm) so the deposition area is 2.83 x
10'pm2 (Ttr2). An erythrocyte has a diameter of 8pm and area of 50pm2. Therefore, if all the
cells were perfectly tessellated, there would be 5.6 x 105 cells on the slide. Clearly this is not
the case as there is always additional (wasted) space between cells. However, even if this
were the case, in ten cytospin preparations there would be 5.6 x 106 cells. At the end of the
two-stage enrichment process around 5 x 107 erythrocytes remained (figure 6.9). Therefore,
to deposit all the remaining cells would require around 100 slides and it is evident from these
simple calculations that cytocentrifuge slide preparations lost at least 90% of cells. This
degree of loss is supported by simply counting the total number of nucleated cells on the
slide and comparing this with the total number of nucleated cells known to be in the final,
enriched suspension.
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Assuming that this cell loss was non-selective, 90% of fetal erythroblasts would also be
lost. This was intolerable and cytospin preparations of enriched maternal blood samples
were abandoned.
The wax ring method provided an area of approximately 5 x 10s pm2. If we consider that
5 x 107 erythrocytes occupy 25 x 108 pm2, then all the remaining cells might be
accommodated on five slides if all the cells were reasonably approximated. Using this
approach cell loss should be minimal because the cells should have settled before any
significant evaporation took place. Unfortunately, because of the surface tension effect of
the ever-decreasing pool of fluid, the cells were pulled more centrally into the wax ellipse.
The resulting cell morphology was poor because all the cells heaped on each other and
investigations were pursued no further.
Fixation in suspension using 3:1 methanol: acetic acid fixed cells firmly onto slides and
lysed the remaining non-nucleated erythrocytes so that all the nuclei could be deposited onto
three slides. Having removed the cytoplasm and perinuclear proteins, probe access and
hybridisation was best. The disadvantage was that cell morphology was lost and positive
identification of cells was impossible. However, the results of the prospective study of fetal
sex prediction were obtained from cells treated in this manner (table 7.5).
More diluted acetic acid did not lyse all the erythrocytes but it retained the cytoplasm of
nucleated cells better. A 1:40 dilution resulted in reduced hybridisation efficiency but was the
best compromise between retaining cell cytoplasm for immunocytochemistry and later FISH
(chapter 9.3).
The reagents used with the smear technique were compatible with subsequent
immunocytochemistry but the problems of reduced hybridisation efficiency remained
because of the intact cytoplasm (chapter 9). This should not be an insurmountable problem
and, importantly, it should be possible to automate this technique using a robot arm which
would minimise inter- and intra-operator variation for monolayer cell preparation, a principle
which is fundamental to the whole approach.
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8.2 Discussion
The ideal deposition method should produce a monolayer of cells, covering a large area
of the slide so that many cells can be deposited onto a few slides, but without incurring
significant cell losses. The smear technique appeared to be most promising but it was
apparent that the major obstacle to depositing the remaining cells onto three slides is the
large number of remaining erythrocytes. This will be considered further in chapter 10.
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Chapter 9. Positive identification of fetal erythroblasts
Although we have successfully enriched for fetal cells from maternal blood and
prospectively sexed pregnancies, a number of issues are unresolved.
Fetal erythroblasts are end-stage nucleated cells, the nuclear material is tightly packed
and FISH is not as efficient as for other cell types (chapter 7). Our data suggest that very
few fetal cells were recovered. Alternatively, reasonable numbers of fetal erythroblasts
might have been recovered but, because of poor probe access, they were of no predictive
value. Furthermore, even among diploid cells, some cells show one or three FISH signals,
incorrectly suggesting aneuploidy. Male fetal cells are easily differentiated from maternal
cells by FISH, but 50% of pregnancies involve a female fetus. Finding no aneuploid cells, all
bearing two X chromosomes may indicate a normal female fetus but it may also mean that
no fetal cells were isolated in the first place. Finally, even after enrichment, the vast
majority of nucleated cells are maternal. However, as optimum FISH signals are obtained
when the cytoplasm has been removed, the actual cell type cannot be determined and every
nucleus must be examined.
To overcome these problems it is imperative that fetal cells are identified positively.
Using model systems of adult/ fetal blood mixtures, we attempted to identify fetal
erythroblasts in three ways and, thereafter, subject them to FISH. All the cells were
subjected to cytospin deposition to maintain optimal morphology but the limitations of this
deposition method have been highlighted in chapter 8.
9.1 May-Griinwald-Giemsa
Standard May-Grunwald-Giemsa staining (chapter 4) was combined with FISH, using the
Y-heterochromatin probe, pHY2.1 (table 9.1). In only one case involving maternal blood has
a definite erythroblast been observed (figure 3.4). Unfortunately, this slide had already been
mounted and when the coverslip was removed and the slide subjected to FISH, there was no
hybridisation. Furthermore, it was not known if this was a maternal or a fetal erythroblast
although its size suggested that it was probably fetal.
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9.2 Kleihauer-Betke Acid Elution
Fetal haemoglobin is more resistant to acid elution or alkali denaturation than adult
haemoglobin and is the basis of the Kleihauer-Betke-Braun reaction (1957).
Fetal blood samples were fixed on clean microscope slides for five minutes in 80%
ethanol. After air-drying the slides were dipped in the haemoglobin eluent (8.3mM
hydrochloric acid, 7.5g/l haematoxylin) for twenty seconds, washed for two minutes in tap
water and then air dried. Slides were then stained with erythrosin B (1 g/l) for three minutes,
washed in tap water and air-dried. Those cells retaining haemoglobin, i.e. fetal red cells,
were readily apparent against the ghosted adult erythrocytes and leukocytes (figure 9.1).
Their positions on the slide were manually recorded using a New England Finder and FISH
was performed using the protocol described in chapter 7 (Gaudoin et al, 1994; figure 9.2).
Using this identification method, despite exhaustive searching of enriched maternal
cytospin preparations, no cells were identified which were unequivocally fetal erythroblasts.
Of course cytospin preparations incur large losses (chapter 8) so any rare fetal cells which
might have been present could have been lost at the deposition stage.
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Figure 9.1 Fetal erythroblast following Kleihauer-Betke reaction
Note the erythroblast's large size (solid arrow) and the smaller, ghosted surrounding adult
erythrocytes (two collections of ghosted erythrocytes shown with dashed arrows)
Figure 9.2 FISH performed on fetal erythroblasts after Kleihauer-Betke reaction
Y chromosome probe visualised with FITC. Note the higher intensity cytoplasmic staining of
the Kleihauer-positive erythroblast compared to surrounding Kleihauer-negative cells.
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9.3 y-globin immunocytochemistry
The method for immunocytochemistry has been detailed in chapter 4.3. The monoclonal
antibody (mAb), UCHy, was an ascites preparation and the kind gift of Professor Peter
Beverley (Allen et al, 1987). It was a mouse IgG-i mAb against human y-globin and was
optimised to a 1 in 800 dilution for immunocytochemical work. Figure 9.3 (right hand
photomicrograph) shows clear differentiation between adult and fetal red cells with UCHy.
For optimal immunocytochemistry, cells were fixed in methanol: acetone (1:1).
Unfortunately, after y-globin detection, when FISH was performed there was extensive
background fluorescence rendering FISH signals uninterpretable.
FISH worked best after cells were fixed in methanol: acetic acid (3:1). However, this
lysed the cell cytoplasm, so combining immunocytochemistry with FISH was impossible.
Therefore, varying concentrations of methanol: acetic acid, ranging from 5:1 to 100:1 were
investigated to determine how this affected the degree of cell lysis and subsequent FISH
analysis (chapter 8.1.3). It was possible to fix the cells for one minute in methanol: acetic
acid, 40:1, and then drop them on to clean microscope slides. This did not lyse all the
erythrocytes but immunocytochemistry could be performed thereafter. In model experiments,
the position of positive cells was recorded and FISH was subsequently performed (figure 9.3,
left hand photomicrograph). Background fluorescence was greater than with fixation in 3:1
but it is promising for maternal blood samples.
To date we have not seen cells which were unequivocally fetal erythroblasts identified by
UCHy. Figure 9.4 shows a central cell in a cluster which has a perinuclear halo following
immunostaining and development with the New Fuchsin kit. It does not look like
erythroblasts recovered from termination samples but it is not known exactly what such cells
look like once they have spent some time in the maternal circulation. This cell had been
fixed and mounted and was not subjected to FISH analysis.
We have found y-globin-positive cells from an enriched maternal blood sample (case 14),
but which were undoubtedly polymorphs. When subjected to FISH, these cells showed two
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X-chromosome signals and the woman went on to deliver a male fetus (which was predicted
by FISH when other cells were fixed in 3:1 methanol: acetic acid).
Table 9.1 shows that prior positive identification reduces the hybridisation efficiency of
fetal erythroblasts using either a Y-chromosome probe or X and Y probes simultaneously.
Methanol: acetic acid (3:1), because it lysed the cell membrane and stripped the perinuclear
proteins, resulted in the best hybridisation efficiency but positive identification was
impossible. Kleihauer staining resulted in poorer hybridisation efficiency, which was reduced
further when two probes were used simultaneously. Methanol: acetic acid (40:1) allowed
positive identification of fetal erythroblasts prior to FISH although, in model experiments,
only 43% of erythroblasts from a male fetus showed simultaneous X and Y signals.
Hybridisation efficiency was similar to Kleihauer identification but the latter had the
disadvantage that it did not lyse any cells so many slides would be needed to deposit all the
cells after the enrichment process.
Table 9.1 Hybridisation efficiency of fetal erythroblasts using FISH combined with
prior cytoplasmic staining





Methanol: acetic acid (3:1) 61.6 ± 8.2% -
May-Griinwald-Giemsa* 32.0 ± 7.8% -
Kleihauer-Betket 45.9 ± 6.4% 37.5 + 9.2%
Methanol: acetic acid (40:1) + y-globin - 43.2 ± 30.0%
Cytoplasmic staining performed using protocols detailed in Chapters 4.1* and 9.2*.
FISH performed after cytoplasmic staining using protocol detailed in Chapter 7.4 and 7.6.
Note the superior hybridisation efficiency in the absence of cellular cytoplasm (fixation in
methanol: acetic acid, 3:1) compared to the staining techniques which leave the cytoplasm
intact.
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Figure 9.3 Combining UCHy immunocytochemistry with FISH
Right side: Immunocytochemistry using UCHy mAb on artificial admixture of cord and adult
blood. Top right cell is UCHy-positive, other two cells (bottom left) are UCHy-negative.
Left side: Same cells following FISH using an X-chromosome probe. Probe labelled with
digoxigenin and visualised with anti-digoxigenin-Texas Red.
Figure 9.4 y-globin-positive nucleated cell enriched from the blood of a pregnant
woman
The central lower cell (arrowed) shows some unconvincing immunostaining (developed with





Fetal erythroblasts do not hybridise as efficiently as leukocytes and attempting to
positively identify them prior to FISH, by leaving the cytoplasm intact, resulted in even
poorer hybridisation efficiency. Heavy metal salts interfere with FISH and these are present
in both the acid elution solutions and in Romanowski stains which explains why hybridisation
efficiency was compromised further using these modalities. Stripping the cytoplasm, even in
a limited fashion with more dilute preparations of methanol: acetic acid, improved the
hybridisation efficiency but positive identification was more difficult.
However, positive identification is a prerequisite because it would reduce the false-
positive and false-negative results associated with FISH and would enable pregnancies
involving female fetuses to be investigated. Hence, it would increase confidence in
karyotype assignment. Importantly, positive identification would also allow an automated
slide search capability to be developed. A scanning device could log the position of positive
cells whilst surrounding cells (contaminating maternal cells) could be disregarded. This
would obviate the arduous task of examining every nucleus for FISH signals, speed up
search times and permit large numbers of pregnancies to be evaluated (Piper et al, 1994;
Tanke et al, 1996). In turn, this would allow development of other methods of aneuploidy
detection (chapter 10) and more rapid optimisation of fetal cell enrichment techniques, so
maximising the recovery of fetal cells at the appropriate stages of pregnancy.
One of the major obstacles is that we still do not know what fetal erythroblasts look like,
particularly if they have been in the maternal circulation for a short while. There are no fetal
erythroblast-specific markers which limits the possibilities of positive selection (chapter 3.6)
and hence, there is no specific marker to identify fetal erythroblasts by immunostaining prior
to FISH analysis.
Fetal haemoglobin (HbF, 0C2Y2) is the predominant haemoglobin produced up to 30 weeks'
gestation. Adult haemoglobin (HbA, (X2P2) is produced from about 8 weeks' gestation
onwards, reaching a steady state of approximately 10% of total haemoglobin production until
164
30-34 weeks' gestation (figure 10.2). Allen et al (1987) reported that 1-3% of adult
erythrocytes were UCHy-positive but did not report if it had been tested against leukocytes.
Certainly our false-positive results are concerning as it may not be completely specific to the
haemoglobin y-chain.
Whether a Kleihauer-type reaction or monoclonal antibodies to y-globin is used, a
potential problem is that pregnancy is the only physiological condition in which fetal
haemoglobin production is switched on again. Seventeen percent of women show a rise
above normal levels in the first trimester, generally before the tenth week. These F-cells are
maternal as the amino acid sequence of the y-chain is of the adult variety, which is different
from the fetal y-chain sequence (Weatherall et al, 1974). HbF production can be reactivated
in pathological conditions (table 3.2) but these are rare in pregnant women and are likely to
be detected because of other clinical manifestations. A possible confounding variable is
hereditary persistence of fetal haemoglobin production, sickle cell disease and
thalassaemias. In these conditions there is also likely to be a substantial proportion of adult
erythroblasts in the peripheral circulation. In some parts of the United Kingdom (particularly
areas of London), and of course worldwide, this would become a sizeable problem.
Therefore, identification of fetal erythroblasts based on y-globin content may not be
applicable on a global scale.
Holcomb et al (1990) predicted that the 0.04% "background rate" of F-cells in pure adult
blood would render the Kleihauer-Betke test unreliable at cell counts below 0.1%.
Furthermore, there is growing evidence that many nucleated erythrocytes in maternal blood
are maternal (Slunga-Tallberg et al, 1995; de Graaf et al, 1999). This suggests that
alternative markers are necessary to confirm the fetal origin of the erythroblasts.
Monoclonal antibodies to the early embryonic haemoglobins (Hb-Gower: s4; Hb-Portland:
C2Y2; and Fib-Bart's: y4,) may be more fetal-specific than UCHy and if these can be produced
reliably they may avoid the problems associated with y-globin (chapter 10).
An exciting development has been the positive identification of fetal erythroblasts on slide
using mAbs to FlbF or other embryonic haemoglobins, dissecting only the positive cells off
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the slide and then subjecting them to PCR. Cheung et al (1996) identified between 7 and 22
cells from 16-18ml of maternal blood in a series of 10 cases and correctly (albeit
retrospectively) predicted a normal fetal karyotype in two cases at risk of
haemoglobinopathies. They stated a preference for^-globin as they felt it should be more
fetal-specific. They would also have preferred to recover more cells as they often saw
extraneous DNA bands because of the multiple amplification steps required. If there was the
slightest contamination, this would also be amplified and reduce the predictive value of the
results. Moreover, multiple cells would minimise the problems of DNA-degradation of one of
the primer alleles which would minimise the false-negative rate, particularly as fetal
erythroblasts are end-stage cells. Zheng et al (1993, chapter 3.6) and Cheung et al (1996)
deposited the enriched cells using cytospins. This deposition method is unreliable (chapter 8)
but if a better method can be developed then more cells might be recovered which would
open up the whole field as any chromosome or gene disorder might be diagnosed in this
way.
Positive identification is one of the prerequisites if fetal cell analysis from maternal blood
is to become a reality. To date there have been very few publications of positively identified
fetal erythroblasts in maternal blood which have subsequently undergone cytogenetic
analysis. Unfortunately the data presented in this and preceding chapters emphasises again
the complex inter-dependence between enrichment, deposition, identification and
cytogenetic analysis.
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Chapter 10. Future Developments
Although we have successfully sexed fetuses in early pregnancy it is apparent that there
remain a number of problems. Firstly, at the end of enrichment there are too many
erythrocytes. Secondly, the deposition process is far from optimised. Thirdly, the method of
positive identification is not yet established and the hybridisation efficiency, already poor with
fetal erythroblasts, is reduced further if performed after positive identification. Finally, it is
imperative that the whole process is automated if such an approach is to be used on a large
scale.
10.1 Differential lysis of adult erythrocytes
At the end of enrichment there were too many erythrocytes to be deposited on to three or
four slides (chapter 8) and a simple preliminary step is necessary to remove these excess
cells.
Boyer et al (1976) developed a technique to aid the antenatal diagnosis of fetal
haemoglobinopathies in amniotic fluid samples contaminated with maternal blood by
modifying the standard ammonium chloride red cell lysis buffer (the 0rskov-Jacobs-Stewart
reaction) to exploit the biochemical differences between adult and fetal erythrocytes. Carbon
dioxide carriage in blood is largely dependent on diffusion into erythrocytes and binding with
water to form carbonic acid (H2C03). This dissociates into hydrogen (H+) and bicarbonate
(HC03 ) ions. Red cell lysis is achieved by the addition of ammonium chloride. Bicarbonate
exchanges with chloride which is matched by an inward diffusion of ammonia to form
ammonium (NH4+) ions. The intracellular increase in ion pairs osmotically draws in water, the
cell swells and eventually bursts. The rate-limiting step of haemolysis is carbonic anhydrase-
dependent and can be reduced by the addition of carbonic anhydrase inhibitors such as
acetazolamide (figure 10.1). Fetal erythrocytes have 100-fold less carbonic anhydrase I than
adult red cells whilst acetazolamide penetration times are similar. F-cells (adult erythrocytes
containing large amounts of fetal haemoglobin) do not preferentially survive haemolysis so
they should not confuse the situation. Furthermore, the differences may be more pronounced
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less than 20 weeks' gestation because of the marked difference in fetal red cell physiology in
early pregnancy (Boyer et al, 1983). Clearly these observations would be advantageous with
respect to fetal erythroblasts enriched from maternal blood for prenatal diagnostic purposes.
Importantly, nucleated erythrocytes are more resistant to haemolysis than their non-
nucleated counterparts which would facilitate further enrichment (Takeda and Nagai, 1981).
Differential lysis appears to be a simple but extremely promising avenue to improve the
enrichment process and work was beginning on this, under the supervision of Dr. Alison Hill,
at the end of my work in the Human Genetics Unit. Clearly the optimum concentration of
acetazolamide, the effects these chemicals have on methods to identify fetal erythroblasts
positively and the effects on subsequent FISH analysis will need to be determined.
10.2 Novel enrichment techniques: Charge flow separation
Wachtel et al (1996 and 1998) reported a novel technique, charge flow separation, which
subjected cells to a cross flow electric field. The cells were channelled into different
compartments, depending on their surface charge densities, and erythroblasts focussed like
erythrocytes and some lymphocytes. FISH was performed on the several thousand cells
collected from each maternal sample but gender prediction only tended towards significance
(p = 0.07). Y-DNA PCR on the recovered cells achieved similar predictive results (p = 0.09).
The data suggest that the large number of putative erythroblasts was unlikely, especially as
it is considerably more than any other group have claimed. However, the authors suggested
that because charge flow separation was inexpensive, rapid and reproducible and did not
require monoclonal antibodies, it could provide a helpful modality, even if an additional











Figure 10.1 Differential Erythrocyte Lysis
(0rskov-Jacobs-Stewart reaction)
Note that the rate-limiting step is carbonic anhydrase-dependent
and is influenced by the addition of acetazolamide
169
10.3 Fetal cell culturing
Lo et al (1994) reported that fetal blood cell progenitors were more sensitive to
erythropoietin than adult progenitors. They cultured whole blood from five pregnant women
and subjected the proliferating cells to Y-chromosome FISH. Prior to culturing there were no
Y-positive cells but after culturing there was 1 Y-positive cell to 400-9500 Y-negative cells.
Hence, it appeared that culturing increased the relative and absolute number of fetal cells.
Valerio et al (1996) enriched for erythropoietin-positive cells, cultured the recovered colony-
forming unit-erythroid (CFU-E) and burst-forming unit-erythroid (BFU-E) cells and subjected
these cells to PCR. Although fetal sex was already known in 5 of the 8 cases, gender
prediction was 100% accurate (p < 0.004). They also reported that fetal erythroid progenitors
were preferentially cultured. Some of the samples were subjected to interphase FISH
analysis including two cases involving fetal trisomies. In these two cases there were more
CFU-E and BFU-E cells with a higher proportion of trisomic cells. This supports the growing
impression of greater fetal cell deportation into maternal blood in aneuploid pregnancies
(chapter 7.9.3) and improves the prospects of definitive non-invasive prenatal diagnosis of
aneuploidies. Little et al (1997) also cultured flow-sorted haematopoietic progenitor cells and
similarly found a slight preferential expansion in detectable fetal cells. Perhaps of greater
significance, however, was their observation that culturing improved the quality of the FISH
preparations which, given the poor hybridisation of fetal erythroblasts (chapter 7), may be an
important consideration.
Cell culturing has the disadvantage that it takes time and the speed of sample-processing
is fundamental to the ethos of mass screening. Of course, if only a handful of cells can be
recovered but successfully replicated, then it may be necessary and it may also result in
good metaphase preparations which would allow structural chromosome abnormalities to be
diagnosed as well.
However, even in enriched and cultured samples, maternal cells will probably outnumber
fetal cells and positive identification prior to cytogenetic analysis remains necessary to
minimise false results. It would be ideal to avoid cell culturing if possible but given the few
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fetal cells recovered it may become necessary and further investigation of differential
culturing is still required.
10.4 Positive identification
UCHy monoclonal antibody did not appear to be sufficiently specific for fetal haemoglobin
for our purposes (chapter 9.4). Figure 10.2 shows the temporal relationship of the synthesis
of the various fetal haemoglobins during gestation (Grosveld et al, 1993). Fetal red cells
contain embryonic haemoglobins until at least 18 weeks' gestation and there is no known
reactivation of these haemoglobins during normal pregnancy. Therefore, if monoclonal
antibodies can be raised to Q- or e-chains, they might be more specific than UCHy (Cheung
et al, 1996; Mesker et al, 1998).
In a slightly different approach, Hengstschlager and Bernaschek (1996) reported that fetal
cells appeared to express considerably higher intracellular thymidine kinase activity than
adult blood cells which could provide an additional marker to sort for, or positively identify,
target cells and further investigation into both these areas is necessary.
10.5 Other molecular techniques
The explosion in molecular biological techniques in the past twenty years has allowed
much of the work contained in this thesis to be performed. Ideally a diagnostic test should be
applicable to one cell but several cells would be preferable to minimise inconclusive results
and techniques continue to develop which might be applied to the handful of recovered fetal
cells.
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10.5.1 Primed in situ DNA synthesis
Primed in situ DNA synthesis (PRINS) combines the sensitivity of PCR with the visual
appeal of FISH such that small, chromosome-specific DNA sequences can be amplified and
visualised within a nucleus. Although in its infancy, in time it may allow disorders at the gene
level to be diagnosed rapidly from enriched fetal cells rather than simply the common
aneuploidies which are, relatively, gross genetic abnormalities (Gosden and Scopes, 1996;
Orsetti et al, 1998).
10.5.2 Quantitative PCR
If fetal cells can be identified positively on a slide they could be micro-dissected off the
slide and subjected to quantitative PCR which could overcome the problems of reduced
hybridisation efficiency associated with erythroblasts (Cheung et al, 1996, chapter 9.4). Toth
et al (1998) reported fluorescent PCR amplification of polymorphic small tandem repeat
sequences on very few cells for chromosomes 21 and 18 and believe that it could be applied
to fetal cells isolated from maternal blood, provided these can be positively identified on-
slide prior to cytogenetic analysis.
Mosaic cells may give false-negative or ambiguous results and structural aberrations may
go undetected but this is a promising avenue. Even more exciting is that it should be
possible to diagnose genetic disorders which potentially takes the whole field to another
developmental level.
10.6 Slide searching and Automation
Even after enrichment, there are too many cells to search the slide manually (chapter 7)
and this must be taken in the context of a mass screening programme involving what is
likely to be the majority of pregnant women. It may be that fetal cells are present but they
have not been seen because of the inability to search the slides in their entirety.
For the reasons outlined in chapter 9, an automated approach is fundamental to the
whole concept of fetal cells enriched from maternal blood. An automated slide-search
capability should preferably incorporate a confocal microscope as this takes slices through a
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3-dimensional structure (such as a nucleus). To achieve this would require considerable
expertise but is not beyond the present capabilities of pattern recognition scientists (Piper et
al, 1994). Figure 10.3 shows such a device, developed at the MRC Human Genetics Unit,
Edinburgh. It is part of a robotic system which automatically prepares a monolayer of cells
on microscope slides from a suspension of cervical cells, stains the slides and scans them.
The robot records the position of potential dyskaryotic cells for later review by a cytologist.
Using high numerical aperture lenses to gather the maximum amount of light from
fluorescent signals we have calculated that it would take about 16-20 hours to scan three
slides for intranuclear FISH signals and log the position of possible karyotypically abnormal
cells for later manual review. This is too slow for practical purposes but it would be
accelerated dramatically if a machine could search simply for a positive marker and
thereafter return to those particular cells to analyse the FISH signals (Tanke et al, 1996).
Scientists at the MRC-Human Genetics Unit, where all the work contained in this thesis
was carried out, were beginning to work on this aspect of the project. Rather shortsightedly,
in my view, the Pattern Recognition Department of the Unit was disbanded with the
retirement of its section head, Dr. Denis Rutovitz. Denis Rutovitz was instrumental in setting
up this project and until the absolute necessity for this stage is appreciated it is unlikely that
this will ever be carried out.
10.7 Ethical considerations
Fetal cell isolation and cytogenetic analysis also raises ethical and moral issues that have
yet to be debated. Prenatal screening is concerned with increasing choice and, in this case, it
is the choice between having and not having a test. First trimester termination of pregnancy
is considerably less distressing than a second trimester procedure but first trimester
diagnosis may not always be necessary as many of these pregnancies would, in any case,
go on to abort spontaneously. Therefore, offering women termination of an affected
pregnancy may place them in a moral dilemma. Furthermore, in some areas of the world
fetal sexing may be of primary importance and such a capability is open to abuse.
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Particularly in the Western World, expectations are undoubtedly changing and "the
perfect baby" is often anticipated. Non-invasive prenatal diagnosis will alter these
expectations further and defensive medicine then becomes an issue. If a particular test is not
offered and the baby has Down's syndrome it exposes the obstetrician to a possible lawsuit.
With current technologies fetal cell isolation and cytogenetic analysis could be applied
only to a handful of common aneuploidies and will not detect non-genetic structural
anomalies or gene defects. However, the recent, highly publicised completion of the Human
Genome Project opens the field up even further as, in time, any genetic problem may be
detected from a simple maternal blood test. Therefore, a credible body is needed to
determine the conditions for which screening is worthwhile and doctors must be able to
follow these standards without fear of litigation.
10.8 An International Programme
If fetal cell recovery is to become routine, large numbers of pregnancies require
evaluation. Studying pregnancies by matching cell type with Y-chromosome FISH analysis
would determine the proportion of pregnancies in which erythroblasts might be found. The
method could then be extended to aneuploidy detection using previously known aneuploid
pregnancies from, perhaps, chorionic villus sampling.
A number of groups worldwide (notably Diana Bianchi, Sherman Elias, Joe Leigh
Simpson, Wolfgang Holzgreve and Dorothy Ganshirt-Ahlert) have now set up such a venture
to try and address many of the issues highlighted in the previous chapters (Holzgreve et al,
1998). To date there have been no firm conclusions reported but international collaboration
is essential if the field is to progress.
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Figure 10.3 Automated slide preparation robot ...




A significant proportion of pregnancies warrants some form of prenatal investigation and
currently there are over two thousand conditions which can be diagnosed antenatally.
For a diagnostic procedure to be acceptable, it should be of no or low risk and preferably
be offered early in pregnancy so that if a termination is requested it can be performed less
traumatically. It should have a high specificity and accuracy, should not require a high rate of
resampling, should be easy to administer and easy to understand. The cost: benefit ratio
should be low and the technique should be applicable to many conditions with only a
variation in the end point testing required for changing the object of the test.
Many of these criteria are fulfilled by current invasive diagnostic tests. The "risk" of the
test to the pregnancy must be weighed against the risks of the fetus having a particular
condition and a couple's perception of that condition. Ultrasound is the only non-invasive test
but it cannot definitively diagnose most aneuploidies and, therefore, invasive testing can
only be offered to certain women.
Down's syndrome is the most common clinically serious aneuploidy at term and rates
increase with increasing maternal age. Age, however, can no longer be the sole screening
criterion as maternal serum biochemical screening has improved detection rates.
Nevertheless, an invasive procedure is still required and most often the suspicion is
unconfirmed. These qualifications make isolating and cytogenetically analysing fetal cells
from maternal blood a very attractive concept.
Of all potential fetal cell types, trophoblast cells and erythroblasts are the most promising
because they are most readily distinguished from maternal cells. Unfortunately fetal cells
probably occur in ratios of 1 in 106-108 maternal leukocytes and enormous enrichment is
necessary to permit meaningful genetic analysis. Polymerase chain reaction cannot be used
to diagnose fetal aneuploidies because, even in enriched samples, maternal cells, and
therefore maternal chromosomes, will always outnumber the abnormal copy number of the
fetal chromosomes. Hence, fluorescence in situ hybridisation is required.
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There is always a tendency to publish only positive findings but even amongst the
published data, different groups using similar enrichment techniques have obtained different
results ranging from very optimistic to very discouraging. Furthermore, some studies suggest
that fetal cells persist for a considerable time in the maternal circulation after delivery whilst
others report they do not. This probably suggests that there is substantial inter-pregnancy
variation in the incidence of fetal cells and/ or there is considerable variation in similar
enrichment and analytical techniques in the hands of different groups. Clearly these
techniques must become more reproducible and robust.
If the test is to be diagnostic, it must be at least as good as the invasive tests it replaces.
As a screening test, it must be as good as maternal serum screening and ultrasound
screening for nuchal thickness. Furthermore, any procedure must be amenable to
automation if it is to be used on a large scale for screening and it must also be inexpensive.
Fluorescence activated cell sorting is too expensive and, at present, the most hopeful
avenue is density gradient centrifugation followed by immunomagnetic enrichment and
thereafter FISH.
Positive selection using immunomagnetic beads probably has limited potential as raising
specific anti-trophoblast monoclonal antibodies is difficult whilst there are no specific cell
surface markers for fetal erythroblasts. Using Dynabeads we were able to select 93.2 ±
10.7% of CD71-positive fetal erythroblasts but this lacked specificity as it also removed 62.5
± 24.4% of leukocytes. Overall, this represented enrichment by only one order of magnitude.
Therefore, we based our investigations on negative enrichment i.e. removing unwanted
cells. We specifically attempted to enrich for fetal erythroblasts but this approach might,
simultaneously, also enrich for trophoblast cells. The techniques were developed on model
systems and thereafter applied to maternal blood samples.
In model systems using Histopaque 1119, we removed 99.95 ± 0.07% of erythrocytes and
recovered 53.1 ± 26.9% and 43.2 ± 34.4% of leukocytes and fetal erythroblasts respectively.
Ficoll-containing media, such as Histopaque, resulted in excellent removal of erythrocytes
but inevitably erythroblast recovery was less than leukocyte recovery because of additional
177
red cell aggregation. In a direct comparison of Histopaque 1119 with Nycodenz 1.085 (which
does not contain any aggregating agent), the latter medium resulted in better erythroblast
recovery and is a promising avenue for future research.
Once the majority of the erythrocytes were removed by Histopaque 1119, a simple
cocktail of monoclonal antibodies conjugated to immunomagnetic Dynabeads, removed 99.1
± 0.4% of leukocytes and recovered 82.0 ± 20.5% of erythroblasts i.e. an overall recovery of
approximately 32% of all starting fetal erythroblasts. This represented enrichment by three
orders of magnitude. Leukocyte removal could be increased further by targeting B-cells but
the anti-HLA.DR monoclonal antibody we used also bound to receptors on the erythroblasts
which resulted in unacceptably low fetal erythroblast recovery.
Once the two-stage enrichment was completed, cells were fixed in suspension in
methanol: acetic acid to lyse the cytoplasm. This allowed all the remaining nuclei to be
deposited on to three slides and improved nuclear access for the chromosome probes, so
improving the quality of the FISH signals. Using a Y-chromosome probe singly, or later X
and Y probes simultaneously, the cells were subjected to FISH and we successfully
predicted fetal sex by the middle of the second trimester in 13 of 15 pregnancies (p <
0.004). However, this was achieved on the basis of very few cells in most samples.
Furthermore, the two false-positive results demonstrate that other markers are necessary to
confirm the fetal origin of the cells.
We also obtained blood from a woman who was carrying a Down's syndrome fetus,
diagnosed by CVS, prior to first trimester termination of pregnancy. The blood was enriched
using the two-stage method and the recovered cells subjected to FISH with a chromosome
21 contiguous cosmid probe. There were proportionately more trisomy 21 cells in this
enriched blood sample than in the control sample so not only was it possible to confirm the
abnormal fetal karyotype but it possibly suggests that more fetal cells escape into the
maternal circulation in aneuploid pregnancies. These are encouraging findings and similar to
results reported by others.
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However, there is still much to be done. Amongst the issues to be resolved is the optimal
cell type for enrichment, the ideal enrichment method, what level of enrichment can be
achieved and indeed what level of enrichment is necessary. We did not identify as many
cells as we had hoped. This may have been because there were so few fetal cells in the
original sample, the technique incurred large losses of fetal cells or, because of the arduous
nature of searching slides manually, we could not analyse sufficient numbers of nuclei.
Whether sufficient numbers of fetal cells can be recovered in all early pregnancies is not
known. Ideally blood should be taken within the first half of pregnancy but the optimal time
has not been determined. It might be necessary to sample women repeatedly to recover
sufficient cells for cytogenetic analysis which may be unacceptable and, in addition,
processing large numbers would present logistical problems.
Depositing all the cells onto three slides was ideal for slide handling purposes but was
only possible because we lysed the cytoplasm of the remaining cells. These were mostly
erythrocytes which occupy valuable space on the slide and ideally we require enrichment by
another order of magnitude whilst maintaining cellular cytoplasm. Differential red cell lysis
could be a way forward, particularly as the majority of erythroblasts were lost at the density
gradient centrifugation stage, and if an alternative enrichment modality were employed,
erythroblast recovery might be improved.
Maximising the number of cells which are deposited onto a slide, whilst maintaining
cellular cytoplasm, should allow positive identification of fetal erythroblasts by fetal
(embryonic) haemoglobin content and facilitate the development of an on-slide search
capability. We have attempted to do this with a novel deposition technique similar to making
a blood smear that concentrated the majority of the nucleated cells at the feathered end of
the smear. Thereafter, immunocytochemistry could be performed using an anti-y-globin
mAb and the positive cells subjected to FISH.
The problems associated with in situ hybridisation must be overcome. Background
fluorescence following positive identification was unacceptably high but all groups (whether
commercial or governmental) must appreciate the necessity for better deposition techniques
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and positive identification prior to FISH. This will establish the number of cells that can be
recovered and analysed and will determine the level of sensitivity and specificity that would
permit established tests to be obviated. However, this will require evaluation of hundreds of
thousands of pregnancies.
The small number of cells recovered in the majority of studies raises questions about the
accuracy of fetal cell analysis at the clinical level. If no, or very few, cells can be recovered
following repeated maternal blood sampling by the end of the first trimester, CVS might still
be an (undesirable) option. The question of confounding factors (particularly previous
pregnancies, multiple pregnancy, reactivation of fetal haemoglobin production, incompatible
blood groups and other antigen incompatibilities) must be addressed and, importantly, the
ethical issues raised by this whole concept must also be debated fully.
We envisage that diagnoses of fetal abnormality made from maternal blood samples
would initially require confirmation by established invasive prenatal tests but this can only be
achieved once the above issues have been resolved.
Despite suggesting that a small number of fetal cells can be recovered and
cytogenetically analysed from maternal blood in early pregnancy, the work encompassed in
this thesis has been too limited to address these issues. Many groups around the world are
working in this area, but after the enthusiasm in the early and mid-1990's it is disappointing
that there have been relatively few new studies published in the last two or three years. What
series have been published, have been small which suggests that much is still required
despite claims in the media that a non-invasive test "is just around the corner". Unless
thorough scientific investigation continues, unhampered by commercial interests, we risk
jeopardising an extremely promising development in prenatal diagnosis. It must be
remembered that it was over fifteen years between the first reports of chorionic villus
sampling and its incorporation into common practice.
Fetal cells isolated from maternal blood have considerable potential. Whether the above
problems can be overcome remains to be seen but in time it is hoped that definitive, non¬





BSA Bovine serum albumin
CD Cluster of differentiation
CVS Chorionic villus sampling
DNA Deoxyribonucleic acid
EDTA Ethylenediaminetetraacetic acid
FACS Fluorescence activated cell sorting
FISH Fluorescence in situ hybridisation
FITC Fluorescein isothiocyanate
GPA Glycophorin-A
HLA Human leukocyte antigen
kbp kilobase pair
mAb Monoclonal antibody
MACS Magnetic activated cell sorting
MHC Major histocompatibility complex
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TAE Tris-Sodium acetate-EDTA
TBS Tris buffered saline
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BDH, product number, 35025
BDH, product number, 35086
Sigma, catalogue number, M 9140
1 volume sodium citrate (30g/l) +
4 volumes sodium chloride (9g/l)
Immunocytochemistry materials
Bovine serum albumin (BSA)
New Fuchsin Kit














Product No. A-7030 (Sigma)
DAKO, K698
= 1 part normal rabbit serum + 4 parts TBS
(Scottish Antibody Production Unit)
DAKO, D396
Diluted 1: 300 in TBS
2-amino-2-(hydroxymethyl)-1,3-propandiol, C4H11N03
250ml distilled water + 6.05g Tris = Solution A
192ml distilled water + 3.4ml concentrated Hydrochloric acid
(7N)
= Solution B
Add Solution A to Solution B.
This is the working solution of TBS.
IgG (SAPU)
IgG (Sigma)
Biotinylated rabbit anti-mouse IgG (DAKO, Denmark, Code
E354) diluted 1:200 with NRS
Sigma, catalogue number, 1077-1
Sodium diatrizoate and ficoll 400
Sigma, catalogue number, 1119-1
Sodium diatrizoate and ficoll 400
Tris 5mmol/l, Potassium chloride 3mmol/l, Disodium calcium
EDTA 0.3mmol/l, Sodium Chloride 7.5%, dissolved in 1 litre
of distilled water and made up to pH 7.5 with concentrated
HCI.
Nycomed Pharma AS,Prod. No. 1002417
5 - (N-2, 3-dihydroxypropylacetamido)-2, 4, 6-tri-iodo-N, N'-















Product Number 11011 (Dynal, UK)
2ml, 4 x 108 beads/ml
Product Number 11013 (Dynal, UK)
2ml, 4 x 10s beads/ml
Phosphate Buffered Saline/ 2% BSA/ 0.02% Sodium azide
IgG-i, anti-HLA.DR mAb (Guy et al, 1982)
Tissue culture supernatant, 90pg/ml.
lgG2a, anti-CD18 mAb (van Heyningen and Guy,
unpublished). Tissue culture supernatant, 60pg/ml.
IgG-i, anti-CD3 mAb (Beverley and Callard, 1981)
Tissue culture supernatant, 4pg/ml.
IgG^ anti-CD2 mAb (Verbi et al, 1982)
Ascites, 0.1mg/ml.
IgG-,, anti-y-globin mAb (Allen et al, 1987).
Ascites, IgG concentration undetermined (P. Beverley,
personal communication).
lgG2a, anti-CD45 mAb (Smith et al, 1985)
Tissue culture supernatant, IgG concentration 4pg/ml.
IgG-i, anti-CD71 (DAKO, catalogue number M734)
Tissue culture supernatant, IgG concentration 175pg/ml.
Mouse IgG! Irrelevant mAb (Sigma)
Fluorescence in situ hybridisation materials
DNA purification
TELT Buffer Tris 50.0mM, 6.05g
EDTA 62.5mM (23.27g)
Lithium Chloride 2.5M (106.00g)
Triton X 0.4%, pH 7.5
TAE Buffer Tris 40mM (pH8.2)
Sodium acetate 20mM
EDTA 1mM
Ethidium bromide, 5pl/50ml of gel
PromegaWizard Maxiprep
Promega Maxipreps DNA Purification Systems
Catalogue number, A7100









Sodium dodecylsulphate (SDS), 1%


















100mM, diluted 1:200 with distilled water (Pharmacia)
1nmol/pl (Boehringer Mannheim GmbH)
1nmol/pl (Boehringer Mannheim GmbH)
1nmol/pl (Boehringer Mannheim GmbH)
1mg/ml in 0.15M sodium chloride; 50% glycerol. Made up




0.5M Tris, pH7.5; 0.1 M MgS04; 1mM dithiothreitol;
500pg/ml (BSA fraction V Sigma)
Ethylenediaminetetraacetic acid, C10H16N2O8, mw 292.2,
(Sigma)
Sodium dodecylsulphate, C2H2504SNa, mw 288.5, 5%
solution (Sigma)
Tris EDTA (10mM Tris, pH 7.5 and 1mM EDTA, pH8.0)











200pg/pl, Blugene Kit (Gibco-BRL)
SK 5400 (Vector)
0.1M Tris, 0.15M NaCI, pH 7.5
0.1 M Tris, 0.15M NaCI, 3% BSA Fraction V, pH 7.5





















SSC (Sodium saline citrate)
Vectashield
1:100 dilution of stock (Vector)
10pl of avidin-FITC in 1ml of blocking buffer
1:500 dilution of stock (Vector)
2pl of avidin-Texas red in 1ml of blocking buffer
1:500 dilution of stock (Vector):
Goat monoclonal antibody, 1:100 dilution of stock (Vector)
4xSSC/ 5% skimmed milk (Marvel):
2ml of 20xSSC + 8ml of distilled water + 0.5g of skimmed
milk
Centrifuged at 4°C for 15 minutes to remove conjugates
1mg/ml, sonicated to 500 base pair lengths (Gibco-BRL)
50pg/ml diluted to a final concentration of 500ng/ml (Sigma)
For hybridisation mixtures: 50% in distilled water, Pharmacia
For hybridisation mixtures:
AnalaR grade, BDH, deionised with Amberlite monobed NB-
1 resin, BDH
1:500 dilution of stock (Vector)
8ml stock 0.1 M calcium chloride, 8ml of stock 1M Tris and
384 ml distilled water
0.5pl: 1mg/ml (Sigma) diluted in 0.5ml Vectashield to a final




Sodium saline citrate, 20 times concentration:
sodium chloride, 170.53g; trisodium citrate, 80.82g and
made up to one litre with distilled water
Vector Laboratories Inc.
0.5ml of Vectashield + 5pl of 50pg/ml stock DAPI ± 0.5pl of
1mg/ml stock propidium iodide
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each year over 400 000 Finnish citizens travel each year to
Russia and about 200 000 Russians visit Finland. The patient
described here and the fellow traveller with a positive throat
culture both had a contactwith a local inhabitant, during which
exchange of saliva occurred. Although diphtheria is endemic in
Russia, the risk for an average traveller is not very big.
However, a booster of diphtheria vaccine is recommended,
even for a short trip to Russia, if the traveller is not vaccinated
or has not had a booster dose within 10 years.
The risk of spread of diphtheria in Finland, where the
coverage of childhood vaccination is good, is improbable.
However, in several countries ofwestern Europe, surveys have
shown that immunity to diphtheria is poor, especially among
women over 40.3 Male individuals are better protected because
they are given an additional booster dose during military
service. There have been small outbreaks of diphtheria in
Sweden and Denmark recently.4 With increasing travel to and
from countries endemic for diphtheria, booster vaccinations of
the adult population in western European countries may have
to be reconsidered; and health care workers, who are at greatest
risk of exposure to the saliva of diphtheria patients, should be
adequately immunised.
Jukka Lumio, Matti Jahkola, R/'sto Vuento, Olli Haikala,
Juhani Eskola
Departments of Internal Medicine and Clinical Microbiology, Tampere University
Hospital, 33521 Tampere, Finland; and Department of Infectious Disease
Epidemiology, National Public Health Institute, Helsinki, Finland
1 The Official Statistics of Finland XI:72,73. Helsinki: Public Health
and Medical Care, 1974: 125.
2 WHO. Expanded program of immunization: outbreak of diphtheria,
update. Wkly Epidemiol Rec 1993; 68: 134-38.
3 Christensson B, Bottiger M. Serological immunity to diphtheria in
Sweden in 1978 and 1984. ScandJ Infect Dis 1986; 18: 227-33.
4 Karzon DT, Edwards KM. Editorial: diphtheria outbreaks in
immunized population. N EnglJ Med 1988; 318: 41-43.
Falloposcopic instillation of prostaglandin in
tubal pregnancy
Sir—Falloposcopy, the transcervical endoscopic examination
of the fallopian tube by a linear everting catheter (LEC), was
reported in 1990.' It has been used diagnostically in infertile
patients. Visualisation of the tubal lumen may assist in
planning rational treatment of infertility, permitting surgery or
tubal transfer of embryos or gametes if themucosa is normal. A
further possible application is the diagnosis of tubal pregnancy.
The LEC may also be useful in the non-surgical treatment of
unruptured tubal pregnancies. We tried to manage an un¬
ruptured tubal pregnancy with high initial beta-human chorio¬
nic gonadotropin ((J-hCG) levels by prolonged prostaglandin
(PG) F2a application via LEC. Previously, non-surgical
treatment of tubal pregnancy by local PGF2(X instillation had
been limited to cases with initial P-hCG under 2500 mlU/mL
serum; higher concentrations were correlated with unfavou¬
rable outcome.23
In a 25-year-old patient with a 3-year history of infertility,
tubal pregnancy was diagnosed by vaginal ultrasound. P-hCG
was 4506 mlU/mL. Under general anaesthesia and laparosco¬
pic control, the LEC was introduced into the relevant tube.
The tip of the catheter was positioned directly on the
gestational sac. After visualising the lumen of the fallopian tube
and the tubal gestation, 10 mg PGF2a was injected. Laparo-
scopy was ended with the LEC left in place. 3 hours later, a
second dose of 5 mg was injected with no adverse effects and the
catheter was removed. The patient was discharged the next
day. Serial P-hCG rapidly fell, and was undetctable after 4
weeks (figure). Vaginal ultrasound revealed that the tubal
pregnancy had disappeared.
days 0-30
Figure: P-hCG after falloposcopic prostaglandin
Falloposcopy by means of LEC may lead to a new approach
in the non-surgical management ofunruptured tubal pregnan¬
cies. Repeated injections of PGF2a via LEC may allow
adequate doses, depending on initial P-hCG. However, PGF2a
is not necessarily the only drug to be used in this indication;
methotrexate4 or even hypertonic glucose solution5 could also
be used.
H Kiss, Ch Egarter, R Wenzl, P Husslein
Department of Gynecology and Obstetrics I, University of Vienna,
A-1090 Vienna, Austria
1 Kerin J, Daykhovsky L, Grundfest W, Surrey E. Falloposcopy, a
miciocndoscopic, transvaginal technique for diagnosis and treating
endotubal disease incorporating guide wire cannulation and direct
balloon tuboblasty. J Reprod Med 1990; 35: 606-12.
2 Egarter Ch, Fitz R, Spona J, Vavra N, Husslein P. Treatment of tubal
pregnancy with prostaglandins: correlation between hormone profile
and success. J Obstet Gynecol 1991; 11: 119-22.
3 Egarter Ch, Husslein P. Treatment of tubal pregnancy by
prostaglandins. Lancet 1988; i: 1104-05.
4 Pansky M, Bukovsky I, Golan A, et al. Tubal patency after local
methotrexate injection for tubal pregnancy. Lancet 1989; ii: 967-68.
5 Lang PF, Tamussino K, Honigl W, Ralph G. Treatment of
unruptured tubal pregnancy by laparoscopic instillation of
hyperosmolar glucose solution. Am J Obstet Gynecol 1992; 166:
1378-81.
Non-invasive antenatal diagnosis
Sir—Lo and colleagues (May l,p 1147) attempt to determine
the rhesus status of fetuses in utero by non-invasive means.
They admit that this method has not reached the precision
required for routine application (because a 20% false negative
and almost 20% false positive rate is too high), but it shows
great promise. Furthermore, it will contribute to a better
understanding of normal fetomaternal physiology and to the
quest for a non-invasive but definitive antenatal diagnostic
procedure that would carry no risk to the fetus. Research into
the isolation and genetic analysis of fetal nucleated cells in the
maternal circulation is gaining momentum, and three types of
cell—trophoblast,1 lymphocytes,2 and nucleated fetal erythro¬
cytes (NFEs)3—are the main focus of attention. For several
reasons the first and last of these are the most likely candidates
and each has its proponents. Trophoblast is physiologically
shed into the maternal circulation, whereas, in early pregnancy,
NFEs are the most common type of nucleated fetal cell in the
fetal circulation.4 However, there is a growing opinion
favouring NFEs.5
Because Lo et al did not use any relative enrichment
techniques, it is not known if they analysed one particular type
of cell or a combination of types. However, from their
polymerase chain reaction results, it seems that in most cases
there is 1 fetal cell for every 105-106 maternal cells. These
workers clearly demonstrate the ability to detect signals in
patients with substantial antibody concentrations, but do not
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state whether in these cases there was a rising titre of anti-D;
this, however, can be construed because they went on to do
cordocentesis in the patients with high values. If the analysed
cells were NFEs, then at 22 weeks' gestation (case 8) this should
represent a transplacental haemorrhage of about 0-5 mL,4
which would certainly be sufficient to stimulate a secondary
immune response in an isoimmunised mother. If so, maternal
antibodies would probably have mopped up the NFEs before
their analysis, suggesting that the analysed cells are of a
different type.
Little is known of fetomaternal cell transfer at much earlier
stages of pregnancy, though there is growing evidence that
NFEs occur in proportionately greater numbers in the mater¬
nal circulation at earlier gestations.3 The question of which
type of cell is most likely to give the desired result remains
unanswered, but work such as theirs will help to elucidate this
matter. In combination with methods of selective cell enrich¬
ment and prospects such as fluorescence in-situ hybridisation,
it may ultimately lead to routine definitive diagnoses of fetal
genetic abnormalities from simple maternal blood tests.
M R Gaudoin
Medical Research Council, Human Genetics Unit, Western General Hospital, Edinburgh
EH4 2XU, UK
1 Mueller UW, Hawes CS, Wright AE, et al. Isolation of fetal
trophoblast cell from the peripheral blood of pregnant women. Lancet
1990; 336: 197-200.
2 Herzenberg LA, Bianchi DW, Schroder J, Cann HM, Iverson GM.
Fetal cells in the blood of pregnant women: detection and enrichment
by fluoroscence-activated cell sorting. Proc Natl Acad Sci USA 1979;
76:1453-55.
3 Bianchi DW, Stewart JE, Garber MF, Lucotte G, Flint AF. Possible
effect of gestational age on the detection of fetal nucleated erythrocytes
in maternal blood. Prenat Diag 1991; 11: 523-28.
4 Millar DS, Davis LR, Rodeck CH, Nicolaides KH, Mibashan RS.
Normal blood values in the early mid-trimester fetus. Prenat Diag
1985; 5: 367-73.
5 Adinolfi M. Breaking the blood barrier. Nature Genet 1992; 1: 316-18.
Local treatment of thrombocytopenic
mucosal haemorrhage
Sir—The management of patients with epistaxis or diffuse gut
bleeding due to thrombocytopenia is difficult since platelet
transfusion is often ineffective because of platelet antibodies.
We tried local application of platelet concentrates in 12
consecutive patients with leukaemia (9) or lymphoma (3) who
had severe mucosal haemorrhages due to thrombocytopenia. 9
had epistaxis, 2 had a haemorrhagic gastritis, and 1 had diffuse
colonic bleeding.
The local applications were random-donor concentrates
which contained about 10" platelets in 50 mL plasma. For
patients with epistaxis, 10 mL of concentrate was applied to
both nostrils in 1 mL doses with a syringe. In the patient with
diffuse gut bleeding, 50 mL of platelet concentrate was diluted
in 500 mL 0-9% NaCl and administered as an enema. The
gastritis patients were given 50 mL of platelet concentrate at
gastroscopy. The haemorrhage was successfully treated and
prolonged freedom from bleeding achieved in all patients
except 1 whose haemorrhage was caused by diffuse gastric
infiltration with chronic lymphocytic leukaemia and who had
only short-term relief.
Local application of platelet concentrates shows potential in
treating diffuse mucosal haemorrhage due to thrombo¬
cytopenia.
J Hastka, R Hehlmann
III Medizinische Klinik Mannheim, University of Heidelberg. 6800 Mannheim 31.
Germany.
Halofantrine sensitivity
Sir—Brasseur and colleagues (April 3, p 901) investigated
the in-vitro and in-vivo sensitivity of Plasmodium falci¬
parum to halofantrine in the Congo and in Cameroon in
1992, and in the Congo recorded a high frequency of
resistance. In Gabon halofantrine came on the market three
years ago and has since been widely used. In 1992 we
studied the response of P falciparum according to WHO
criteria. For the in-vitro studies halofantrine was precoated
on microtitre plates, resulting in final concentrations of 0-3,
1, 3, and 10 nmol/L blood/medium mixture. Isolates were
obtained and successfully grown in vitro from 40 patients.
The EC50, EC90, and EC99 were 0-4091, 0-9400, and 1-8523
nmol/L, respectively, indicating very good sensitivity of
Pfalciparum to halofantrine in vitro.
In a clinical trial 30 children with uncomplicated
falciparum malaria were included, distinct from those of the
in-vitro study. They had not received antimalarial
treatment within the preceding 7 days and were 4—14 years
old. Their parents gave informed consent. A micronised
formulation of halofantrine with a two-fold increase in
absorption was used. The patients received three 8 mg/kg
doses of halofantrine 6 hourly. Parasitaemia on thick blood
films and symptoms were recorded daily for the first week
and subsequently every week until 28 days after therapy.
The median parasitaemia on admission was 21 000 asexual
parasites per (tL (range 200-140 000). The parasitaemia was
cleared within 48 h in 4 patients and within 72 h in 26. The
patients were free of symptoms in 24-72 h. Thick blood
films of28 patients remained free of parasites until day 28 of
follow-up; in the other 2 patients symptomless parasitaemia
of 15 and 50/jiL was detected on day 28.
Our findings indicate pronounced sensitivity of P falci¬
parum to halofantrine in Gabon in 1992 despite its
widespread use there over the 3 previous years.1 This
experience is very different from that of Brasseur and
colleagues in neighbouring Congo. The ECS0 in the Congo
was 30 times higher. This could be due to the notorious
solubility problems with halofantrine which will be especi¬
ally prominent in in-vitro systems with drug in solution.
Almost half the Congo patients still had detectable para¬
sitaemia on day 4; in Gabon all patients had a negative thick
blood film on day 3, and this may be explained by the use of
a new formulation of halofantrine.
£ Wild ling, S Winkler, C Brandts, LJenne, W Graninger,
IV H Wernsdorfer, U Bienzle, P G Kremsner
International Research Laboratory, Albert Schweitzer Hospital, BP 118, Lambar6n6,
Gabon; Department of Infectious Diseases, University of Vienna, Vienna, Austria;
Institute of Specific Prophylaxis and Tropical Medicine, University of Vienna; and
Landesinstitut furTropenmedizin, Berlin, Germany
1 Richard-Lenoble D, Kombila M, Martz M, et al. Efficacy, safety and
acceptability of halofantrine in the treatment of acute Plasmodium
falciparum malaria in African children (Gabon). Parasitol Today 1989;
suppl: 59-63.
Authors' reply
Sir—The history of resistance to antimalarial drugs has been
accompanied by a parallel move of resistance of some resear¬
chers to admit that it may be so. This happened with early
reports of resistance to chloroquine, quinine, and meflo¬
quine,1-2 and it now seems to be happening with halofantrine
(May 15, p 1282, and the above letter).
Vol 342 • July 3, 1993 55
THE LANCET
persisted despite treatmentwith steroids. InOctober, 1986, she
developed raised DNA binding and low complement C3 and
C4 concentrations. In 1991 she presented with migraine, and
four months later a vasculitic rash in a butterfly distribution
typical of lupus; biopsy showed non-specific inflammatory
changes. In May, 1993, she developed flitting polyarthralgia
affecting her knees, hips, ankles, and wrists, leucopenia,
thrombocytopenia, and renal impairment (1-5 g per day
proteinuria, glomerular filtration rate 55 mL/min per 1 -73 m2).
Renal biopsy showed mild mesangial proliferative
glomerulonephritis with granular localisation of IgG, IgM,
IgA, Clq, C3, and C4, consistent with lupus nephritis. She is
now well and off medication, but has DNA binding of 10-1
mg/L (normal range 0-4) and depressed complement
concentrations.
A 26-year-oldman was referred in 1981 with a 5-year history
ofarterial and venous thromboembolism leading to amputation
of part of one foot. ESR was 34 mm in the first hour and ANF
diffusely weak positive. Anticardiolipin antibody (aCL) was
detected, but complement concentrations, autoantibody
screen, and DNA binding were repeatedly normal. In 1985 he
had raised DNA binding and persistently low complement
concentrations, but remained symptom-free. In 1991,
however, he developed symmetrical polyarthropathy affecting
the metacarpophalangeal joints, wrists, elbows, shoulders, and
knees, with ANF strongly positive and raised DNA binding.
He also had persistent leucopenia and thrombocytopenia. His
arthralgias responded to oral prednisolone but returned when
the dose was reduced to below 7-5 mg per day; indices of lupus
activity have remained high.
At presentation, neither of these cases had raised DNA
binding, satisfied standard criteria for the diagnosis of SLE,3 or
for the loosely-defined "lupus-like" syndrome.4 Both were
diagnosed as APS on the basis of the clinical history together
with an equivocal ANF and raised aCL/aPL antibody.
However, each developed lupus after an interval of 8 and 10
years, respectively, with both clinical and serological markers
of disease activity. We suggest that primary APS may be a
feature of early lupus in some patients and that regular
serological and clinical review is indicated.
Peter A Andrews, Geoffrey Frampton, J Stewart Cameron
Renal Unit, Guy's Hospital, London SE1 9RT, UK
1 Mackworth-Young CG, Loizou S, Walport MJ. Primary
antiphospholipid syndrome: features of patients with raised
anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989;
48: 362-67.
2 Frampton G, Cameron JS, Thorn M, et al. Successful removal of
antiphospholipid antibody during pregnancy using plasma exchange
and low-dose prednisolone. Lancet 1987; ii: 1023-24.
3 Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the
classification of systemic lupus erythematosus. Arthritis Rheum 1982;
25: 1271-77.
4 Asherson RA, Baguley E, Pal C, Hughes GRV. Antiphospholipid
syndrome: five year follow up. Ann Rheum Dis 1991; 50: 805-10.
Anticardiolipin antibodies in ischaemic heart
disease
Sir—In their commentary (July 24, p 192) Cortellano and
colleagues conclude that antiphospholipid antibodies (aPL) are
not important prognostic indicators of further events in
survivors ofmyocardial infarction. Anticardiolipin antibodies
(aCL) aremembers of a group ofaPL. We measured aCL in 249
consecutive admissions to the coronary care unit of a district
general hospital. 159 patients (139 male, 20 female, mean age
58-2 [SD 9-9]) had an acute myocardial infarction, confirmed by
a significant rise in cardiac enzymes, and 90 (64 male, 16 female;
mean age 56-4 [9-8]) had unstable angina. 38 patients were aged
less than 45 years (mean 421 [2-4]), of whom 21 had an acute
myocardial infarction and 17 unstable angina. The controls
were 299 consecutive patients (149 male, 150 female; mean age
47-3 [11-2]) attending a health screening clinic. Measurement
of aCL was done with an enzyme-linked immunosorbent assay
ELISA validated against international workshop standards.1,2
Results above 25 gPL (proposed unit2 for IgG aCL) or 25 mPL
(for IgM aCL) were regarded as abnormal. The frequency of
aCL in patients with ischaemic heart disease was not higher
than that in controls. Raised aCL values (either IgG or IgM)
were shown in 5 patients with acute myocardial infarction, 4
patients with unstable angina, and 8 controls. In patients aged
less than 45, none had raised aCL values.
What are the prevalence and importance of aCL in patients
with coronary artery disease? Hamsten1 reported aCL in 21%
of 62 survivors of acute myocardial infarction who were aged
less than 45;3 during follow-up there was a significantly higher
incidence of further thrombotic events in the group with raised
aCL. In patients after coronary artery bypass grafting who had
raised preoperative aCL titres, the rate of late graft occlusion
was higher than in those who had no aCL,4 whereas others
showed that an increased frequency of aCL in patients
following myocardial infarction was not an independent risk
factor for further thrombotic events. By contrast, other
studies5,6 showed no significant difference in aCL between
patients and healthy controls; and no rise in aCL in young
patients with previous myocardial infarction.
Our results suggest that aCL do not have a part in acute
myocardial infarction, or unstable angina, in most patients with
ischaemic heart disease in the absence of connective tissue
disease.
T Edwards, R D Thomas, N J McHugh
Cardiology Unit, Royal United Hospital, Bath; and Royal National Hospital for
Rheumatic Diseases, Bath BA1 1RL, UK
1 McHugh NJ, Maymo J, Skinner RP, James I, Maddison PJ.
Anticardiolipin antibodies, livedo reticularis and major cerebrovascular
and renal disease in systemic lupus erythematosus. Ann Rheum Dis
1988; 42: 110-15.
2 Harris EN. The Second International Anti-Cardiolipin
Standardization Workshop/The Kingston Anti-Phospholipid
Antibody Study (KAPS) Group. Am J Clin Pathol 1990; 94: 476-84.
3 Hamsten A, Norberg R, Bjorkholm M, De Faire U, Holm, G.
Antibodies to cardiolipin in young survivors of myocardial infarction:
an association with recurrent cardiovascular events. Lancet 1986; ii:
113-15.
4 Morton KE, Gavaghan TP, Krilis SA, et al. Coronary artery bypass
graft failure—an autoimmune phenomenon. Lancet 1986; ii: 1353-57.
5 de Caterina R, d'Arcanio A, Marzone A, et al. Prevalence of
anticardiolipin antibodies in coronary artery disease. Am J Cardiol
1990; 65: 922-24.
6 Phadke KV, Phillips RA, Clarke DTR, Jones M, Naish P, Carson P.
Anticardiolipin antibodies in ischaemic heart disease: marker or myth
Br Heart J 1993; 69: 391-94.
Transcervical flushing and antenatal
diagnosis
SIR—The advantages of interphase cytogenetics with earlier
and less invasive antenatal diagnostic tests are indisputable, but
in their analysis Adinolfi and colleagues (Aug 14, p 403) do not
estimate the total number of fetally-derived cells that might be
obtained by this method or say how many cells they analysed
from each sample. From their data the proportion of fetal-
specific cells is very small, the range is very large, and there is
considerable overlap between the percentage of cells bearing a
Y-signal in male and female pregnancies.
Calculations on such small numbers is far from satisfactory.
However, the mean (1SD) is 20-7",, (121), which gives, as they
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propose, a louver cut-off limit for a positive diagnosis of 9% of
cells. This fynding suggests a sensitivity of 85-7%, a rather high
false negat ive rate of 14-3%, a 0% false positive rate, and a
positive predictive value of 100%. Alternatively, if 2 SD is
considered then the respective figures become 100%, 0%, and
a very poor 75% and 70% respectively.
Trisomy 18 was diagnosed by transcervical chorionic villus
sampling before their test, so many of the apparent fetal cells
might have been introduced iatrogenically in the lower uterine
pole. Adinolfi and colleagues do not mention the hybridisation
efficiency of their probe sets, though with pure fetal tissue and
the chromosome 18 probe it is only 65%. In a recent large study
by Ward et al,1 such a low hybridisation rate would have been
classed as uninformative and no definitive result achievable.
One view of the future of antenatal diagnosis might include a
panel of chromosome-specific probes to diagnose rapidly the
more common aneuploidies1 in interphase nuclei. With any
screening test there is a trade-off between what is absolutely
achievable and what is achievable (and acceptable) within
available resources. The method clearly needs further
evaluation. However, extrapolating from these data, it follows
that if the total number of fetal cells is very small or the
hybridisations unreliable, or both, there will be many false-
positive diagnoses resulting in an overwhelming number of
pregnancies undergoing definitive antenatal diagnostic testing.
Alternatively, many chromosomally abnormal pregnancies will
be missed—in a test which is far from non-invasive.
M R Gaudoin
Medical Research Council, Human Genetics Unit, Western General Hospital,
Edinburgh EH4 2XU, UK
1 Ward BE, Gersen SL, Carclli MP, et al. Rapid prenatal diagnosis of
chromosomal abnormalities by fluorescence in situ hybridisation:
Clinical experience with 4500 specimens. Am J Hum Genet 1993; 52:
854-65.
Authors' reply
Sir—Gaudoin's comments offer us the opportunity to clarify
our findings. Our pilot study was planned to solve the
controversy raised by the demonstration that Y-derived
sequences could be detected by the polymerase chain reaction
(PCR) in transcervical cells (TCC)1 and the denial published in
the accompanying editorial.2 The detection by fluorescence
in-situ hybridisation (FISH) of the Y chromosome in some
TCC samples when the conceptus was male; the presence of
cells with trisomy 18 derived from an affected fetus; and the
morphological and immunological demonstration of
syncytioblastic and trophoblastic cellular elements in these
samples seem to us clear evidence that placental cells are shed
into the endocervical canal between 8 and 13 weeks ofgestation.
Because of their great heterogeneity, the total number ofcells
present in each sample does not bear any relation to the number
of fetal cells. We are now investigating the proportion of the
various types of cells present in TCC samples with several
monoclonal antibodies (MAbs). Between 50 and 100 nuclei
were analysed in each slide tested by FISH. The hybridisation
efficiency of the chromosome 18 probe is over 90%, but we
suspect that maternal cells contaminate the placental samples
from the aborted fetus, thus reducing the percentage of
trisomic cells, since conventional cytogenetic tests showed that
the fetus was not a mosaic.
The diagnostic value of the use of TCC samples for prenatal
diagnosis can only be established by appropriate trials. Before
starting one, we are investigating the possibility of obtaining
the cells by aspiration, thus avoiding flushing, which could
potentially spread infection. Swabs and flushed and aspirated
samples are obtained and the results compared. We are also
testing different procedures for the isolation of the fetal cells
and extending the range of MAbs used to analyse the
proportion of the various subpopulations of cells. Once this
information is available we plan to start a trial in which TCC
and chorionic samples will be tested simultaneously.
Matteo Adinolfi, Angela F Davies, Peter Soothill, Charles Rodeck
Division of Medical and Molecular Genetics, UMDS of Guy's and St Thomas's
Hospitals, London SE1 9RT, UK; Department of Obstetrics and Gynaecology, University
College and Middlesex School of Medicine, London WC1; and Institute of Child Health,
London WC1
1 Griffith-Jones MD, Miller D, Lilford RJ, Scott J. Detection of fetal
DNA in transcervical swabs from first trimester pregnancies by gene
amplification; a new route to prenatal diagnosis? Br J Obstet Gynaecol
1992; 99: 508-11.
2 Morris N, Williamson R. Non-invasive first trimester antenatal
diagnosis. BrJ Obstet Gynaecol 1992; 99: 446-48.
Diaphragmatic paralysis preceding
amyotrophic lateral sclerosis
Sir—Diaphragmatic paralysis is uncommon because
appropriate tests to detect it are not done. Usually the
diaphragm is only one of several weak muscles, directing the
clinician to the diagnosis of diaphragmatic paralysis.1 Its most
serious consequence is respiratory failure.2 We report a case of
isolated bilateral diaphragmatic paralysis with severe acute
respiratory failure that revealed lateral amyotrophic sclerosis.
A 46-year-old, previously healthy man was admitted in June,
1989, to intensive care for acute respiratory failure. Heart rate
110/min, systolic blood pressure 160 mm Hg, respiratory rate
40/min, and temperature 38'5°C. The patient was unconscious
and had cyanotic extremities. Blood gases revealed severe
respiratory acidosis (pH 7-10 and PaC02 105 mm Hg) and
hypoxaemia (Pa02 20mm Hg)). He was urgently intubated and
underwent mechanical ventilatory support. An hour later, he
fully recovered consciousness and clinical examination was
normal. The chest radiograph indicated bilateral atelectasis
lines. Other tests were normal and alcohol and narcotics were
not detected. The electrocardiogram, 2D-echocardiogram, and
pulmonary angiogram were normal. Over the following days,
despite normal clinical examination and arterial blood gases,
every attempt to wean the patient from the ventilator failed.
During weaning, he had paradoxical abdominal respiration
that drew our attention to a possible diaphragmatic weakness.
Electromyography of the limbs and of the diaphragm revealed
(in both) fasciculation potentials in muscles, reduced number
and increased size of motor-unit action potentials, and normal
excitability and conduction velocity of the remaining fibres of
motor nerves. The respiratory distress was considered to be
due to bilateral diaphragmatic paralysis from motorneurone
disease. Cerebrospinal fluid examination revealed normal
protein levels and no cells. Serum creatine kinase was normal.
The patient underwent tracheostomy and was discharged from
hospital under continuous mechanical ventilation, 7 weeks
after admission.
3 months later, he was admitted to intensive care for general
fatigue and difficulty swallowing. At that time he had
amyotrophic extremities, decreased peripheral and axial
muscle strength, evidence of muscle fasciculation and
fibrillation, and hyperactive reflexes without clonus and
without Babinsky's sign. He was bed-bound, and unable to talk
and swallow. He went home onmechanical ventilation and with
a nasogastric tube, and died in March, 1991, from severe
bronchopneumonia.
Diaphragmatic paralysis should not be overlooked in acute
respiratory failure. Its diagnosis may be difficult in the absence
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aims in our new curriculum. Firstly, in relation to
communication skills it addresses the develop¬
ment of students' skills in self awareness and
reflective learning. Secondly, the workbook en¬
courages the students to understand their patient
is a complex person whose health and wellbeing
depend on more than biomedical considerations.
The depth and extent of this understanding have
been shown in some work of exceptional quality
and insight.
We believe that the integrated workbook assign¬
ment embodies the ideals of our curriculum and, in
particular, has considerable potential for continu¬
ing the General Medical Council's recommended
strands of ethics, law, behavioural science, and
communication skills throughout the clinical
course.
annie cushing peter hajek
lendoyal sheila iiillier
Confederation of East London Colleges,
London Hospital Medical College,
London El 2AD
I Lowry S. Assessment of students. BMJ 1993;306:51-4. (2
January.)
Harvard's "new pathway"
Editor,—As one who taught on Harvard's "new
pathway" during the two pilot years,' as well as on
its traditional courses, I would like to make some
comments.
The success of any programme rests on the
faculty's enthusiasm and support. Teaching well
takes time and often yields little tangible reward.
Harvard's new pathway got through its pilot years
relying on the motivated staff and fellows. This
staffmay not be available at many medical schools.
The greatest change in the curriculum produced
by courses based on the new pathway is seen in the
preclinical faculty. Preclinical staff usually have
busy schedules and may not be particularly well
oriented to clinical matters. For example, teaching,
say, the pharmacology of tetracycline in the
traditional way is usually fairly easy for a preclinical
pharmacologist with a related scientific interest.
Less easy for (and possibly of less interest to)
preclinical staff is dealing with a case study for the
new pathway; such a case might start with the
pharmacology of tetracyclines, pass through their
therapeutic use in general, and end on a debate
about whether oxytetracycline should be used as
prophylaxis for traveller's diarrhoea in Mexico.
Team teaching, with both preclinical and clinical
staff present at each session, may be a feasible
alternative, given the staff available at most medical
schools.
It is true that the, new pathway was oversub¬
scribed in both pilot1 years. During the first pilot
year, however, there was a sense among the
"traditional" class that their colleagues in the new
pathway were taking an extraordinary gamble with
their medical education. During the second year
this feeling persisted, but less strongly. I do not
agree with Stella Lowry that "special arrangements
that had been made for the new pathway students
had caused resentment among other students, who
felt that they were being treated like second class
citizens."
Lastly, the success rate at Harvard in the
national board examinations has always been
extremely high (as it is at most American medical
schools). These examinations are probably a poor
instrument for measuring the quality of medical
education because they concentrate on factual
retention.
' a w fox
Raleigh 27608,
NC, USA




Editor,—Dr Nigel Oswald, cited by Stella
Lowry,' is correct in implying that learning skills
in clinical decision making requires seeing large
numbers of patients in a short space of time. This,
however, is an argument against rather than for
community based learning.
This is illustrated by an example from our
practice. An average general practice of 10000
patients refers 34 patients a year for assessment of
breast lumps. A student attending a well directed
breast clinic may personally see this number of
patients in less than a month and be taught to make
an accurate clinical assessment. She or he would
have to spend a year in general practice to have the
opportunity to acquire similar skills. To paraphrase
Oswald, "It is more important to see 30 patients
who might have breast cancer than five who do (but







1 Lowry S. Trends in health care and their effects on medical
education. BMJ 1993;306:255-8. (23 January.)
Teaching how to elicit and
interpret physical signs
Editor,—John R Hampton may be right to
lament the decline in doctors' abilities to elicit and
interpret physical signs, but I believe that he is
wrong to conclude that training in the setting of
general practice will sound the death knell of these
skills.'
My memories of cardiac teaching rounds are of a
dozen students queueing to listen to a murmur
while the registrar stood at the end of the bed
swinging a stethoscope and staring out of the
window. Aware of restive colleagues, one listened
hurriedly and joined the whisper going round the
group: "What did you hear?" Coming back later on
one's own was rarely useful: even if the relatives
weren't round the bed there was rarely a doctor
prepared to give guidance. "We don't spoonfeed
you here" was one of the less excusable reasons
given for declining to help floundering students.
Traditionally, doctors were trained by being
apprenticed to established physicians. In hospitals
the system has broken down under the pressure of
numbers and new teaching methods are only
slowly being found, but teaching in general
practice has remained close to the tradition in







1 Hampton JR. Path to clinical confidence. BMJ 1993;306:595.
(27 February.)
Move amedical school to
Milton Keynes
Editor,—Why not move one of London's medical
schools to Milton Keynes? Designated to receive
most of its population from London, the city could
now adopt one of its medical schools as well. There
are precedents for such a move: during the second
world war some students and staff from University
College Hospital, London, relocated to Cardiff.
Milton Keynes has its own hospital; consultants
and senior staff could move there with the medical
school. Even the name of the medical school could
be retained with just the postcode changed.





Editor,—The increase in antenatal diagnoses of
Down's syndrome suggests a more widespread use
of biochemical screening. This, and analysis of the
results by David E Mutton and colleagues,' is to be
encouraged but raises some interesting points
which have potential implications for resource
allocation. The two main reasons for antenatal
screening are (a) to plan the most appropriate place
and mode of delivery to minimise the hazard to
neonatal life and (b) to offer termination of preg¬
nancy if the diagnosis is made before 24 weeks'
gestation (previously 28 weeks').
From Mutton and colleagues' raw data, assay of
serum a fetoprotein concentration detected 21% of
the detected cases in women under 35 while triple
testing detected only 17%. This might suggest that
assay of a fetoprotein concentration alone is better
at detecting Down's syndrome than triple testing.
The converse, however, is the case, and the
difference can probably be explained simply by the
more widespread use of assay of a fetoprotein
concentration during the period studied.
Although the total proportion of diagnoses
seems to be rising, the rise is steepest in those who
historically have fallen into a high risk group—that
is, woman aged 35 and older. This is not surprising
as the algorithm to assign risk is weighted in favour
of such cases. Unfortunately, around three quarters
of cases of Down's syndrome occur in fetuses of
women under this age, and in 1991 biochemical
testing detected only 6-5% of all cases of the
syndrome. From the analysis we do not know the
proportion of pregnant women who participated in
this form of screening, but it seems that around
48% of cases might be detected if triple screening
was universal.2
Detailed ultrasound scanning detected 7-2% of
all cases of the syndrome, though, again, the same
rules apply—that is, what proportion of all ante¬
natal patients underwent detailed scanning?
Recently, however, Luck reported that in an
unselected population detailed ultrasound scan¬
ning detected all of the cases of Down's syndrome
when a physical abnormality was present.' At least
half of all fetuses with the syndrome have a
congenital heart defect, and many others have
bowel atresias. .Perhaps of greater importance,
however, is that .only half of liveborn infants with
aneuploidies have Down's syndrome. Many of the
other common arieuploidies (such as trisomy 13,
trisomy 18, and Turner's syndrome-XO) are
associated with physical abnormalities that are
more readily appreciated on ultrasound scanning
than the subtle ones associated with Down's
syndrome.' Furthermore, ultrasound scanning
detects other physical anomalies, of which some
are associated with genetic abnormality. Many
represent a hazard to neonatal life. If these anoma¬
lies are detected in good time the parents can
receive counselling and the subsequent manage¬
ment of the pregnancy can be planned, so reducing
the national perinatal mortality rate.'
Detailed ultrasound scanning has been shown to
be cost effective as it detects most cases of Down's
syndrome as well as other life threatening condi¬
tions.' Perhaps its wider implementation in early
pregnancy should be an aim of all obstetric depart¬
ments.
m rgaudoin
MRC Human Genetics Unit,
Western General Hospital,
Edinburgh EH4 2XU
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wntkow less lister than it fa Hm Ljonrodlom.. This is
omaiehf mnnmiue of Brighton, wincre the higjt
pnerafanoe off HIY-l Mcctinn in himmtosieraial men
is similar to that in London. Indeed, the rate of
irftccmjn in Brighton is probably the highest in
Britain ("90 new infections im houmascxaial men
reported in 1992 (23% of those tested)). By any
stiristfca! configuration, the concentration of HIV
infected homosexual nnen in Brighton is higher
than that in London or elsewhere im Britain. The
chance of infection through unsafe sex in Brighton
is therefore relatively higher.
Monnation on safe sex aimed at homosexual
men in Brighton is needed. Statutory and voluntary
organisations have recently intensified education
tnd tnforaiation programmes and increased the
educational involvement of outreach groups with





II Evans BG, Gatdtpdle M» Hepeemitallli J„ Monimer J, Mc-
Carngk C„ NknU A. est of. Sexually Dansmitted diseases and
HIV-1 infeoioin among homosexual men in England and
Wales. «MJlW3;30fc426-S. (13 February.)
Editor,—We have conducted a similar study to
that of B G Evans and colleagues of sexually
transmitted diseases and HIV-1 infection among
homosexual men in England and Wales.1 Our
results reinforce their findings to a certain extent,
but our experience in 1992 shows a further reduc¬
tion in new cases of gonorrhoea in men and in the
diagnosis ofHIV positivity in male homosexuals.
We looked at the total incidence of gonorrhoea;
the number of cases of gonorrhoea found in men
overall and in homosexual men; the male to female
ratio of cases of gonorrhoea; and the number of
new cases of HIV infection diagnosed in homo-
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Editor,'—B G Evans and eolleagues present
twnip'eiiiing evidence that unsafe sexual behaviour
and transmissjon ofHIV have increased among gay
and bisexual mem in England and Wales after a
decline in the 1980s." They suggest that this may
partly be due to a failure to sustain the successful
comniunity based health education activities of the
early andmid-1980s.M
To ascertain the level of HIV prevention activity
specifically targeting gay or bisexual men in
Britain, staff and volunteers at the National AIDS
Manual, North West Thames Regional Health
AuthoriGy HIV project, the Terrenes Higgins
Trust, and Gay Men Fighting AIDS undertook a
survey between November 1991 and April 19922
Two hundred and forty organisations with a remit
for HIV prevention work were identified. Answers
to a standard telephone questionnaire were ob¬
tained from 226 (94%); 202 respondents were
statutory organisations and 24 were voluntary
agencies.
Altogether 149 respondents reported that
they had never undertaken or funded any HIV
prevention work specifically aimed at gay or
bisexual men. Of the remaining 77, only eight had
ever offered a "substantial" programme of such
work; this was a relatively unexacting definition,
requiring only a written needs assessment and the
employment of a whole time or part time worker
with a specific remit for this work. Only three
agencies had ever offered a "comprehensive"
package of HIV prevention work for gay and
bisexual men, defined as needs assessment, the
production of local health education resources, one
or more public education events, staff training,
and the employment of a worker.
At a time when it is increasingly popular to
search for complex explanations for continuing or
increasing levels of unsafe sexual behaviour among
gay and bisexual men the most obvious explanation
—Ut fflf ©»wtii«wi»i8 edtacaiMffi atoat safer sex™-
mast wat fee ©wsttoatei. Evarns ®wi
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feeea abe swast to yeats, HtV
pwwiriwswate must easwe tte they prioritise
their writ aceaUiiing t® epdes»d®®tea% de»®n-
siuafele wwed if the alawaing wands » stwveillattee
data ®ts smtaiy ot®as«ttitted diseases and HIV
Mean®® ate t® fee attested ®r reverse,'..
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EorroR,—We recently highlighted an increase in
unsafe sexual behaviour and transmission of HIV
among homosexual men in England and Wales
after a period of decline.' Our data included
documented seroconversions to the end of 1991—
that is, newly diagnosed HIV-1 infection in men
for whom the year and month of a previous
negative result of an HIV-1 test were available.
The table summarises revised data, including
tlte seroconversions reported during 1992, The
number of reported seroconversions has risen
steadily since 1986; tlte number of cases in which
transmission ofHIV-1 was known to have occurred
during 1990-2 (157) was more than double the
number recorded during 1987-9 (74),
Tear of HIV-1 seroconversion in 503 homosexual men
who had had negative test results, England and IFuto
Year
oflast Year of first positive result
negative
result 1985 1986 1987 1988 1989 1990 1991 1992
1985 16 22 11 5 4 2 3 7
1986 16 20 2 5 7 9 6
1987 15 7 13 17 10 9
1988 11 21 14 16 10
1989 7 27 15 19
1990 15 33 22
1991 21 42
1992 24
Total 16 38 46 25 50 82 107 139
Despite widespread recognition in 1991 of the
unfavourable trends in sexually transmitted
diseases among homosexual men" transmission of
HIV during 1992 seems not to have declined but






PHLS Communicable Disease Surveillance Centre,
London NW9 5EQCases ofnewly diagnosed gonorrhoea andHIV infection, 1985-92
1985 1986 1987 1988 1989 1990 1991 1992
Cases ofgonorrhoea:
Total 424 355 138 160 162 122 82 72
In men 268 203 76
. 98 96 82 52 47
In homosexual men
(%) 49(18) 13(6) 4(5) 8(8) 11(11) 24 (29) 13(25) 6(13)
Male:female ratio 1-7 1-3 1-2 1-6 1-5 21 1-7 1-9
Cases ofHIV
infection in
homosexual men 27 24 16 17 18 18 21 14
1 Evans BG, Catchpolc MA, Heptonstall J, Mortimer JY,
McGarrigle CA, Nicoll AG, ei al. Sexually transmitted diseases
and HIV-1 infection among homosexual men in England and
Wales. BMJ 1993;306:426-8. (13 February.)
2 Riley VC. Resurgent gonorrhoea in homosexual men. Lancet
1991 ;337:183.
3 Waugh MA. Resurgent gonorrhoea in homosexual men. Lancet
1991 ;337:375.
4 Young H, Moyes A, McKenna JG, McMillan A. Rectal gonor¬
rhoea and unsafe sex. Lancet 1991 ;337:853.
5 Tomlinson DR, French PD, Harris JRW, Mercey -DE. Does
rectal gonorrhoea reflect unsafe sex? Lancet 1991;337:501-2.
























































































































































































































































































































































































































I Marco Gaudoin, MB, ChB, Academic Registrar,
H Department ofObstetrics and Gynaecology, Queen Mother's
| Hospital, Yorkhill, Glasgow G3 8SJ, UK.
INTRODUCTION
Down's syndrome affects one in 800 live births and is
the most common clinically significant trisomy.
The introduction of amniocentesis and subsequently
chorionic villus sampling allowed a select group of
women, usually over 35 years old, to be offered definitive
testing. However, these invasive tests carry a
small but definite risk to the pregnancy and many
procedures are performed to detect one Down's syndrome
fetus. Significantly, 66% of cases are actually born to
women who are younger than the traditional 35-year cut¬
off (Figure 1) and so the majority of cases go undetected.
Maternal age (years)
Figure 1 Maternal age distribution for the incidence of Down's syndrome in
live births. {Adapted from Staples at af. 1991 Wfth permission from "University
of Chicago Press.)
Maternal serum biochemical screening has improved
detection rates of Down's syndrome to around 60%,
but invasive testing must be performed to confirm the
suspicion and still around 40 amniocenteses are
performed to detect a single case.
Due to these inherent drawbacks of currently
available screening techniques, the possibility of
isolating and analysing fetal cells from maternal blood is
intriguing. It offers the opportunity to screen all women
with no risk to the pregnancy and has the capability of
detecting most cases of Down's syndrome. As
technologies develop this could be extended to the
detection of other genetic abnormalities and ultimately
the need for invasive tests may be obviated, as such
diagnoses will be made from a simple maternal blood
sample alone.
FETAL CELLS IN MATERNAL BLOOD
In 1893 a German pathologist, Schmorl, identified
fetal (trophoblast) cells in the pulmonary vessels of
women who had died of eclampsia, proving that fetal
cells escape into maternal blood. Of course rhesus
isoimmunisation in the absence of vaginal bleeding is
further, and less dramatic, evidence of transplacental
passage of fetal cells.
Evidence suggests that transplacental passage of cells
occurs as a series of minor events and is a physiological
and normal part of pregnancy. A steady state is
eventually reached where fetal cells are removed at the
same rate as they are added (Parks & Herzenberg 1982).
If these cells can be isolated from maternal blood they
might be used for antenatal diagnostic purposes.
Unfortunately, they are thought to occur in the
maternal circulation in numbers approximating to 1 in
100 million maternal cells or less (Bianchi et al. 1990) and
20 The Diplomate
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figure 2 A single fetal erythroblast in maternal blood surrounded by non-
odeated erythrocytes. Note the large size and characteristic round, slightly
eccentric nucleus.
any billions of cells from each maternal blood sample
ust be analysed. This is impractical and an enrichment
(ocedure, to improve this ratio, is necessary.
This can be achieved using fluorescence-activated
ill sorting (FACS), also known as flow sorting. Cells are
ielled with antigen-specific monoclonal antibodies
nAbs) which have a fluorescent marker attached. When
cell is detected, because it bears markers which fulfil
reset conditions, it is collected. It is unlikely that a pure
opulation of fetal cells from maternal blood can ever be
iiieved, but once they have been enriched, some form
Igenetic analysis can be performed.
DNA amplification using polymerase chain reaction
*CR) has been used to show that male DNA can be
mnd in the blood of pregnant women in early
regnancy both reliably and with great accuracy (Liou
'al. 1993). Unfortunately, PCR depends on the fetus
taring DNA unique from the mother and rarely, in
iis setting, could it be diagnostic for fetal genetic
Inormalities. Furthermore, its exquisite sensitivity
akes it prone to false-positive errors.
An alternative strategy is fluorescence in situ
ibridisation (FISH). This involves hybridising (binding)
lecific probes to complementary DNA sequences on
iromosomes. The binding sites can be visualised
irectly by attaching fluorescent markers (fluoro-
iromes) to the probe. Multiple probes can be employed
multaneously by using different coloured fluoro-
Iromes. For instance, using FISH with a probe for
&3»i and, -
acirome, three intranuclear signals would be observed.
There are a number of different types of fetal cell which
jght be isolated from maternal blood: namely,
aphoblast cells, lymphocytes, neutrophils and fetal
ythroblasts. Each has its drawbacks but, for many
asons, the last cell type appears to have the
latest potential.
FETAL ERYTHROBLASTS IN MATERNAL BLOOD
Eiythrobfasfs are the nucleated precursor of mature,
non-nucleated erythrocytes.
In 1990, Diana Bianchi and her colleagues in Boston
produced an enriched mixture of fetal erythroblasts from
the blood of pregnant women in early pregnancy using
< EACS<*nd, tftffislng PCR, correctly 'assigned the fetafsex
in 84% of cases. The enrichment of fetal erythroblasts
was based on several suppositions:
1 : In early pregnancy erythroblasts are the most numerous
: nucleated fetal blood cell. Therefore, in any minor
: fetomaternal haemorrhage they luould represent the
\ greatest proportion of nucleated cells crossing the
j placenta.
2 : They are large and easily differentiated from other cells
i (Figure 2).
3 : In the healthy adult, including pregnant women,
\ erythroblasts of adult origin are not expected in the
: peripheral circulation. So, if they are found, they should
i be offetal origin.
4 i Parks and Herzenberg (1982) demonstrated chronic
: leakage of fetal cells across the placenta. Thus, fetal
; erythroblasts should be escaping constantly into
\ maternal blood.
5 I It is unlikely that fetal erythroblasts persist for more than
I a few days in maternal blood and, consequently,
: persistence from one pregnancy to the next is extremely
: unlikely and will not confuse analyses.
6 : Fetal erythrocytes express relatively few blood group
; antigens, such as rhesus, and erythroblasts fewer still.
I Furthermore, only one-third of susceptible women
\ actually mount an immune response to rhesus-positive
i cells. Consequently, even in the cases where the blood
\ group is incompatible, fetal erythroid cell destruction
i may not be as rapid as in adult-to-adult incompatible
; transfusions, possibly allowing substantial accumulation
| ofcrythroblasts in maternal blood.
7 ' Finally, there is growing evidence that, because of
I abnormal placentation, more fetal cells escape into the
\ maternal circulation in aneuploid pregnancies such as
i Down's syndrome (Gdnshirt-Ahlert et al. 1993).
Using FACS based on a number of different cell
surface markers, several groups have reliably sorted fetal
W#f^maTBT8'o31 'aTid'ilKa^no^el'dfTetaT
trisomy have been made (Price et al. 1991). These results
demonstrated that common aneuploidies could be
detected from a blood test alone which potentially opens
the door to mass screening. However, any screening
technique must be robust, reliable and inexpensive and,
although FACS is the gold standard of cell enrichment, it
is prohibitively expensive and time consuming. Other
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groups have therefore been investigating alternative, less
expensive strategies which could be applicable on a
large scale.
Immunomagnetics involves specific monoclonal
antibodies, bound to microscopic magnetic particles,
which bind to target cells (Figure 3). Following
incubation the cell / bead suspension is placed adjacent
to a magnet and the beads, with attached cells, are
drawn to the magnet. This approach is both rapid and
inexpensive, and the incubations could be performed
automatically. Using such an approach diagnoses of fetal
trisomy have been made in early pregnancy (Ganshirt-
Ahlert et al. 1993). We have also applied this latter
approach prospectively in a series of 15 pregnant women
in the first and early second trimesters and have
successfully determined fetal sex with 86.7% accuracy
(P< 0.004). Figure 4 shows cells enriched from maternal
blood subjected to FISH using £tn X-chromosame probe
(labelled with fluorescein isothiocyanate, FITC, which is
seen as the green areas in Figure 4) and a Y-chromosome
probe (labelled with Texas red). These are male (XY)
cells in the blood of pregnant women in early pregnancy.
We have also confirmed a case of Down's syndrome
from cells in the blood of a woman at 12 weeks'
gestation, diagnosed a week previously by chorionic
villus sampling (Gaudoin et al., in preparation). Figure 5
shows cells from this case subjected to FISH using a
probe for chromosome 21 labelled with FITC. In each of
these nuclei three discrete intranuclear signals can be
seen clearly, demonstrating the trisomic nature of
the cells.
Regardless of the enrichment technique, maternal
cells will always outnumber fetal cells and it is vital
that some form of cell marker is used to identify the
cells positively. To date, only a Cambridge group has
Figure 4 Male (XY) fetal cells isolated from maternal blood. The X-
chromosome probe is labelled with fluorescein isothiooynate (FITC), while the
Y-chromosome probe is labelled with Texas red.
Figure 5 Trisomy 21 cells Isolated from the blood of a woman at 12




Figure 3 The principle of Immunomagnetics. Specific monoclonal
antibodies bind to specific cells and the beads pull the cells out of
suspension when placed adjacent to a magnet.
reported a successful attempt to do this prior to FISH
analysis (Zheng et al. 1993). They subjected the cells to
immunostaining using a mAb to the y-chain of fetal
haemoglobin, recorded the position of positive cells,
subjected the cells to FISH analysis and reviewed the
previously y-globin-positive cells. In five of six pregnan¬
cies, between two and 11 positive cells were identified
and in all of these gender was predicted accurately.
This is a crucial step. It would mean that only fetal
cells need to be analysed whilst contaminating cells
could be disregarded. Furthermore, we have successfully
repeated the Cambridge group's work in model systems
and research continues in this area of maternal blood.
Figure 6 shows three cells. Two are negative, but the
cytoplasm of the third is labelled with an mAb to fetal
haemoglobin and visualised with tetramethylrhodamine
isothiocyanate (TRITC, red areas). The slide was then
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Figure 6 Immunostaining with a monoclonal antibody to fetal haemoglobin
(HbF) and subsequent fluorescence in situ hybridisation analysis (FISH). The
cytoplasms of the two cells adjacent to each other are negative for HbF, but
the cytoplasm of the other is positive. All cells subsequently show two copies
of chromosome 11.
subjected to FISH analysis using a probe for
chromosome 11 and it can be seen that each of these cells
has two copies of chromosome 11. If this or similar
techniques can be devised to leave the cell cytoplasm
intact and the nucleus simultaneously accessible for
FISH analysis, then karyotype assignment will be made
with greater confidence (particularly in the 50% of cases
involving a female fetus). Moreover, prior positive
identification should allow computer-driven scanners to
locate positive cells so obviating the arduous task of
manual searching which, in turn, would allow large
numbers of samples to be processed.
CONCLUSIONS
Although erythroblasts are the most promising fetal
cell type, there is a need to determine the proportion of
pregnancies in which sufficient numbers can be found
and the optimal gestation for sampling. As so few
cells are being isolated, improvement in enrichment
procedures to maximise the absolute numbers recovered
is imperative. Furthermore, as the majority of cells
remain maternal, it is desirable to identify the fetal cells
positively.
The advantages of analysing fetal cells from maternal
blood are manifold but, as with many new techniques,
fetal cell retrieval may initially only be used as a
complementary test, being combined with current
screening methods such as maternal serum biochemical
markers and ultrasonography. This could have the
following wide implications for antenatal diagnosis:
If the finite detection rate of Down's syndrome is
maintained, then the number of invasive procedures
could be reduced; or
If the rate of invasive procedures was maintained, the
absolute detection rate could be improved dramatically.
In time, however, it may be possible to make and act
upon the blood sample alone, raising the possibility of a
truly non-invasive, and yet definitive, diagnosis. Using
multicolour FISH with a panel of chromosome probes, it
is hoped that all the common trisomies will be detected.
Ultimately, as techniques develop, it may be possible
to diagnose any genetic disorder where the gene has
been cloned and a probe will be available from a simple
maternal blood test.
Given the current relatively inexpensive and auto¬
matable enrichment procedures, the continuing rapid
development of molecular biological techniques and
modern computer-based slide-search capability, the day
of truly non-invasive, definitive antenatal diagnosis is
fast approaching.
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in the Journals: Prenatal Screening
and Diagnosis
A review of some selected papers that have recently appeared in various journals,
by Marco Gaudoin and Fiona Mackenzie
Marco Gaudoin, MRCOG, Specialist Registrar, and Fiona Mackenzie, MRCOG, Senior Registrar and
Fetal Medicine Sub-speciality Trainee, The Queen Mother's Hospital, Yorkhill, Glasgow G3 8SJ, UK.
It has been less than 30 yearssince definitive antenataldiagnostic tests have become
routine clinical practice. Over this
time different techniques have been
introduced with attempts to reduce
the gestational age at which
diagnoses are made (to allow easier
and less-traumatic termination if
wished) and less invasive methods
adopted to minimise the risk
to pregnancies from the tests
involved. Furthermore, the
relatively recent introduction of
maternal serum screening has
meant that more cases of Down's
svndrome, particularly in younger
women, are now being detected
prenatally.
The mainstays of antenatal
diagnosis remain amniocentesis
and chorionic villus sampling
(CVS), but ultrasound scanning for
structural anomalies has become
increasingly important.
We review a paper which
attempts to address the issues of
safety and early diagnosis, two
papers concerning the implications
of non-invasive diagnosis of
common fetal anomalies by ultra¬
sound and a paper looking at the
possibility of improving second-
trimester serum screening for
Down's syndrome.
Analysis of limb reduction
defects in babies exposed to
chorionic villus sampling.
Firth H. V., Boyd P. A.,
Chamberlain P. F., MacKenzie I. Z.,
Morriss-Kay G. M. & Huson S. M.
Lancet 1994, 343,1069-1071.
If a chromosomal anomaly is
detected in the mid-second tri¬
mester, prostaglandin termination
of pregnancy is necessary which
effectively involves the woman
going through labour. If the
abnormality is detected in the first
trimester then suction termination
of pregnancy can be offered which
is physically and psychologically
less traumatic for the couple.
CVS was developed in the late
1960s and early 1970s to allow fetal
tissue to be sampled reliably and
cultured rapidly in the first
trimester. However, it was only in
Table 1
Categories of limb reduction defects






the "mid-1980s that it became a
common diagnostic tool.
CVS is particularly useful for
women at greater risk of having
a child with a chromosomal
abnormality (e.g. older women and
women who have previously
delivered an affected child). Unfor¬
tunately, it carries with it the well-
recognised risk of an increased
abortion rate of approximately 2^1%.
Oromandibular-limb hypo-
genesis (micrognathia and micro¬
glossia) and terminal transverse
limb reduction defects have a
background rate of 1.8 per 100,000
live births and Table 1 categorises
limb reduction defects (LRDs)
according to their severity. Follow¬
ing a paper by Firth et al. in 1991 of
five cases from 289 CVSs, a number
of groups also reported a possible
aetiological link.
Absent limb or defect through humerus/femur
Defect through radius/tibia
Defect through carpus/tarsus or metacarpus/metatarsus
Defect through digits
Defect through terminal phalanx/nail
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Figure 1 Mean gestational age at CVS according to level of limb reduction defect (Firth et at. [1994;
Lancet 343, 1069-1071).
Subsequent correspondence was
conflicting and reports were largely
anecdotal. From our own figures in
the West of Scotland, there were
78,866 births and 47 reported LRDs,
although none was associated with
CVS. Furthermore, in the World
Health Organization CVS registry
there were 48 cases in 80,051 births
following CVS, an incidence not
different from accepted background
rates.
However, the authors pooled
data from all published reports and




Although the gestational age at
which LRDs associated with CVS
occurred was broad, there was a
definite trend to more severe cases
(category 1) with earlier CVS
(Figure 1). This trend was not
absolute as a category 1 defect was
associated with CVS as late as 65
days' and a category 5 lesion at 50
days' gestation. Therefore, although
there were no definite rules
governing gestational age, it would
appear that earlier CVS was
associated with greater likelihood of
a more severe lesion.
The pathogenesis of LRDs
and OLH syndrome is open
to conjecture and comes largely
from animal studies. Temporary
clamping of uterine blood vessels in
pregnant rats leads to dilatation of
vessels in the extremities of the
fetus. These vessels eventually
rupture, leading to further hypoxia,
necrosis and eventual resorption of
the appendage, producing LRDs in
the rat offspring.
In women undergoing CVS,
there is a trend to increasing feto-
maternal haemorrhage (manifest as
higher maternal serum a-fetoprotein
[AFP] levels) in cases which go on to
abort spontaneously, implying that
there is fetal blood vessel disruption.
It is plausible that in cases of LRDs
or OLH syndrome the vessel
disruption, although insufficient to
cause abortion, is severe enough to
produce distal anoxia and eventual
appendage resorption. This hypo¬
thesis would explain why the
hierarchy of limb damage correlates
inversely with gestational age as it
corresponds with the embryological
sequence of limb formation.
From their available data it
remains unclear if the absolute inci¬
dence of the syndrome is increased
by CVS but, given that the
pathogenic mechanism appears to be
interference with fetal vascularity,
this is possible. What is clear, how¬
ever, is that the earlier CVS is per¬
formed, the more severe the degree
of LRD and, because of this, many
units, including our own, avoid CVS
prior to 10 weeks' gestation.
Clinical significance of
choroid plexus cysts. Gupta
J. K., Cave M„ Lilford R. J„ Farrell
T. A., Irving H. C., Mason G. & Hau
C. M. Lancet 1995, 346, 724-729.
Choroid plexus (CP) cysts are
echo-free areas within the choroid
plexus located in the posterior
horn of the lateral cerebral
ventricles. They can vary in size,
may be bilateral and can be seen
easily by ultrasound in the
standard biparietal diameter view
(Figure 2).
Although not themselves
harmful, the management of
apparently isolated CP cysts is one
of the more controversial areas in
obstetric ultrasound as they man
be associated with major chromo¬
somal abnormalities. However, to
diagnose potential chromosomal
abnormalities requires an invasive
procedure which obviously carries
a risk of miscarriage. The dilemma
therefore arises in counselling
prospective parents if no other
abnormality is detected on detailed
ultrasound.
Prospective studies to date have
been too small to measure the risk
of isolated CP cysts on perinatal
outcome and this study, although
retrospective, aimed to address the
issue and perhaps offer guideline-
to practising obstetricians.
The authors analysed perinata.
outcome from 595 cases of known.
CP cvsts in the Yorkshire and
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Figure 2 Bilateral choroid plexus cysts in a karyotypically normal fetus (courtesy of Dr F. Mackenzie).
Dundee regions over a three-year
period and amalgamated these data
with 1361 cases from prospective
studies reported in the literature —
a total of 1956 cases.
The reported prevalence of CP
cysts ranged from 0.18% to 3.6%
and overall was 0.88%. The
variation was probably a reflection
of the sensitivity of ultrasonic
detection in different centres rather
than any true difference in
underlying incidence. CP cysts
usually resolved by 22-26 weeks'
gestation, even in the presence of
chromosomal abnormality.
Of the 1956 cases there were 69
chromosomally abnormal fetuses.
Overall the risk of chromosomal
abnormality in the general popula¬
tion is approximately 0.6% (1 in
170). From their analysis, the risk
of a chromosomal abnormality was
1 in 150 (12/1787) for an isolated CP
cyst (95% confidence interval 1 in
85, 1 in 261). However, this rose
dramatically to 1 in 3 (57/169) if
there was a concomitant sono-
graphically detectable anatomical
abnormality (95% confidence
interval 1 in 2.4, 1 in 3.7). Seventy-
six per cent were trisomy 18 (which
has characteristic ultrasound
features), 17% were trisomy 21 and
the remaining 7% were either
triploidy or Kleinfelter's syndrome.
Most previous reports had
never considered the effect of
maternal age and the risk of
chromosomal abnormality if a CP
cyst was identified. In the authors'
own series of 595 cases, they found
a statistically significant increased
risk of chromosomal abnormality if
the mother was older than 35 years,
but the numbers involved are
relatively small.
There was no evidence that the
size of the cysts, their location
(unilateral or bilateral) or whether
or not they resolved spontaneously
were predictive of abnormal
karyotype.
Should a woman whose unborn
baby has an isolated CP cyst be
informed of the presence of the cyst
and the potential implications of the
finding?
Isolated CP cysts may be an
anatomical variant rather than an
abnormality but the authors quite
rightly pointed out that there is a
subtle interplay between medical
beneficence, autonomy and the
possibility of future medico-legal
action if an abnormality is not
divulged to the patient and
investigated further if wished.
The authors therefore outlined a
course of management should a CP
cyst be identified (Figure 3). The
discovery of a CP cyst should
prompt a detailed fetal anomaly
scan in the first instance but further
investigation requires an invasive
procedure and risks of such a
procedure must be balanced
against that of finding a chromo¬
somal abnormality. The authors
recommended that only if the
mother is over 35 years old, or if
she falls into a high-risk group
because of the results of maternal
serum biochemical screening, or if
any other anatomical abnormality
is detected at ultrasound, should
she be offered an invasive antenatal
diagnostic test to determine the
fetal karyotype.
Although these recommenda¬
tions have yet to be evaluated
prospectively, from current know¬
ledge these data should assist
obstetricians when counselling
prospective parents as there
appears to be little increased risk of
chromosomal abnormality in cases
of isolated CP cysts when there are
no other risk factors for fetal
abnormality.
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Fetal Karyotyping Routine antenatal
follow-up
Figure 3 Suggested management of choroid plexus cysts detected by ultrasound scan (from Gupta et
at. [1995] Lancet 346, 724-729).
The implementation of first-
trimester scanning at 10-13
weeks' gestation and the
measurement of fetal nuchal
translucency thickness in
two maternity units. Pandya
P. P., Goldberg FT, Walton B.,
Riddle A., Shelley S., Snijders R. J.
M. & Nicolaides K. H. Ultrasound
Obstet Gynecol, 1995, 5, 20-25.
The term incidence of the
clinically most important aneu-
ploidy, Down's syndrome, is
approximately 1 in 800 deliveries.
Although the risk rises with
advancing maternal age, the
majority of Down's syndrome births
occur to women less than the
traditional age threshold of 35 years
and an invasive test (which carries
a risk to the pregnancy) is still
required to achieve a definitive
diagnosis.
An increase in fetal nuchal
translucency during the first
trimester is associated with an
increased risk of fetal chromosomal
abnormalities. The actual patho¬
physiology remains undetermined
but it is particularly associated with
Down's syndrome (Figure 4). The
potential to screen for this 'marker'
in the first trimester by ultrasound
in a non-invasive manner is
therefore extremely appealing.
This paper, which involved a
prospective study based at two
district general hospitals and a
coordinating tertiary referral centre,
examined the feasibility of
screening all pregnancies based on
fetal nuchal translucency thickness.
From August 1993 first-
trimester ultrasound was offered to
all women to determine fetal
viability, gestational dating and
measurement of nuchal trans¬
lucency thickness. Prior to August
1993 scans were only performed at
18-20 weeks' gestation and 70% of
women took advantage of this
earlier assessment.
Scans were performed by
trained ultrasonographers but,
importantly, implementation of the
programme did not require an
increase in staff or the purchase of
extra (expensive) machines.
Ultrasound scans were per¬
formed between 10 and 13 weeks'
gestation on 1763 fetuses (1673
singleton and 45 twin pregnancies)
in which the maximum thickness of
the subcutaneous translucency
between the skin and the soft tissue
overlying the cervical spine was
measured.
It was found that nuchal
translucency thickness increased
with advancing gestation and
overall 3.6% (63) of the fetuses
demonstrated a nuchal trans¬
lucency thickness of 2.5 mm or
more. All but one of these women
were offered CVS, of whom 49
accepted. The exception was a
woman carrying monochorionic,
monoamniotic twins where one of
the twins had a nuchal
translucency thickness of 6.0 mm
whilst the other was 2.0 mm; this
pregnancy ended spontaneously at
20 weeks' gestation with evidence
of twin-twin transfusion. Of the 49
who underwent CVS, 45 showed a
normal karyotype whilst four were
abnormal: three cases of Down's
syndrome and 1 case of Turner's
syndrome (45,XO). The other 13
cases which did not have CVS
performed went on to deliver
phenotypically normal infants.




(usually by amniocentesis) for
other reasons, 50 of them either
because of advanced maternal age
or because of increased risk based
on maternal serum biochemical
screening. Of these, there was one
case of trisomy 21 in a 42-vear-old
woman where nuchal translucencv
thickness had been 2.2 mm.
If we consider onlv Down -
syndrome, of 1763 fetuses ther-.
were four cases. Three of the--,
might have been detected b'
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3TTftUfl jENERRL HOSPITAL SSI)—650 #3 . . 81M14563increased nuchal translucency
thickness (sensitivity, 75%). Simi¬
larly, of the 63 positive scans, three
• ere true positives (positive pre¬
dictive value, 4.8%; false positive
rate, 3.4%). Likewise, the specificity
.-.'as 96.6% (1699/1759) with a false
negative rate of 25% (1/4).
The numbers involved in this
study are relatively small, there
being four Down's fetuses. The data,
however, compare very favourably
with detection rates from maternal
serum a-fetoprotein and human
chorionic gonadotrophin assays
which also require invasive testing
to confirm the suspicion of fetal
aneuploidy. Furthermore, biochem¬
ical assays for Down's syndrome are
not as reliable for twin pregnancies
compared with singleton preg¬
nancies.
The authors found that the total
rate of fetal karyotyping rose from
4.3% the previous year to 5.1%
during the study period. Although
this rise was not statistically
significant, it is somewhat inevit¬
able, as younger women who
would not otherwise have under¬
gone fetal karyotyping were being
offered CVS because of the
ultrasound findings.
Measurement of distances on an
ultrasound screen is dependent on
the quality of the image and the
plane at which the image is taken.
It is, therefore, a subjective assess¬
ment and concerns have been
expressed about the reproducibility
of such a technique with regard to
both inter-observer and intra-
observer variation.
Furthermore, there also appears
to be a higher pregnancy loss rate
associated with this phenomenon,
possibly because of pre-mortem
development of hydrops. There¬
fore, although the test may identify
pregnancies which were in any case
destined to abort, it might falsely
Figure 4 Nuchal oedema in a Down's syndrome fetus detected at 11 weeks' gestation by
transvaginal ultrasound scan (courtesy of Dr F. Mackenzie).
improve its predictive value as a
diagnostic test.
There is other evidence that as
nuchal translucency thickness
increases, the chance of aneuploidy
also rises. Furthermore, there might
be a greater chance of anatomical
abnormality as well which has
prompted suggestions that such
women should be offered second-
trimester detailed anomaly ultra¬
sound.
These last points illustrate one
of the difficulties of mass screening
for relatively rare conditions from
what is essentially a 'well' pop¬
ulation. A large, prospective,
multicentre study in a low-risk
population would be required to
build up a database of results which
could then be analysed to address
these issues.
In this way it may be possible
to combine nuchal translucency.
thickness and first-trimester bio¬
chemical assays (possibly also
taking into account maternal age)
to improve the sensitivity and
predictive values of testing com¬
pared with either test being used
singly. This would require
considerable reorganisation of
antenatal care as women would
need to attend their general
practitioners at an earlier stage and
be referred promptly for booking so
that first-trimester screening could
be performed.
The authors reported that many
older women 'were reassured by the
decreased risk for trisomies assoc¬
iated with nuchal translucency < 2.5
mm and decided against invasive
testing'. However, until larger
datasets have been evaluated, we
must exercise caution in adopting
such enthusiasm prematurely or, in
the long term, we run the risk of
jeopardising the implementation of
what is an extremely promising
development in the field.
Dimeric Inhibin A as a marker for
Down's syndrome in early preg¬
nancy. Aitken D. A., Wallace E. U.,
Crossley J. A., Swanston I. A., van
Pareren Y., van Maarle M., Groome
N. P., Macri J. N. & Connor J. M.
N Engl J Med, 1996, 334, 1231-1236.
Women over the age of 35
constitute approximately 5% of the
pregnant population, but only one-
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5% false positive rate
Figure 5 Schematic representation based on serum screening of the risk of having a baby with
Down's syndrome.
third of cases of Down's syndrome
are born to women in this group. If
we consider that, on age alone,
around 120 amniocenteses are
performed to detect one case of
Down's syndrome, this equates to a
false positive rate of approximately
5% as well. Clearly, maternal age
aloqe is a less than adequate
indicator of trisomy risk.
Although the exact mechanisms
remain unclear, maternal serum
a-fetoprotein (aFP) is reduced in
Down's syndrome compared with
unaffected pregnancies, whilst
human chorionic gonadotrophin
(hCG) is increased. Provided the
distributions of a single variable
are known for both unaffected and
affected pregnancies, the median
and multiples of the median
(MoMs) can be calculated. How¬
ever, because the serum levels of
individual markers overlap con¬
siderably between the two
populations, using a single para¬
meter gives only a very poor
predictive risk. More complex
mathematical analysis is required
as the number of variables
increases but this allows the
development of algorithms ('decis¬
ion trees').
aFP, hCG and other markers
have been incorporated into a
variety of algorithms to predict .the
chance (risk) of a pregnancy being
affected (Figure 5). In this example,
if 5% of unaffected pregnancies
carried a risk of Down's syndrome
greater than a particular threshold
(say, 1 in 220) and were offered
amniocentesis, perhaps 60% of
affected pregnancies might be
detected. The limitations to the
complexity of these algorithms
is the inevitable trade-off in
sensitivity, specificity and pre¬
dictive values of the test (i.e.
as the specificity increases, the
sensitivity mav decrease) and hence
an acceptable balance must
be struck.
An amniocentesis rate of 5% is
usually considered to be such an
acceptable level because of the
traditional maternal age factor.
Inhibin is a heterodimer of an
a- and a p-subunit. The (3-subunit
may be either a (3A- or a (3B-
subunit (inhibin A and inhibin B,
respectively).
Maternal serum inhibin is raised
in Down's syndrome pregnancies
compared with unaffected preg¬
nancies and studies have suggested
that inhibin A might be used as a
first- and second-trimester marker.
The authors of this paper set out
to determine if this was the case and
specifically evaluated the possibility
of incorporating maternal age, aFP,
intact hCG or free (JhCG (F(3hCG)
and inhibin A to see if thev might
detect more cases of Down's
svndrome than currently available
algorithms.
Thev analysed stored serum
collected between 1987 and 1994
and obtained from 528 pregnant
women at 7-18 weeks' gestation in
the West of Scotland. Of these, 58
were Down's syndrome preg¬
nancies (eight at 7-12 weeks'
gestation and fifty at 13-18
weeks' gestation), 32 were trisomy
18 samples and 438 were control
samples. If an ultrasound scan
suggested greater than one week's
difference compared with men¬
strual dates, the ultrasound was
used to date the pregnancy.
Serum dimeric inhibin A levels
were measured using a two-site
enzyme-linked immunosorbent
assay (ELISA) utilising first a
monoclonal antibody directed
against the (3A-subunit of inhibin
and then a further monoclonal
antibody directed against the a-
subunit of inhibin.
Median and multiples of the
median values are already well
established for intact hCG and aFP
in the West of Scotland population.
For inhibin A, the median values
and multiples of the median were
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calculated from the serum of the
control and the study groups.
The authors estimated the
detection rates and 95% confidence
intervals for Down's syndrome at a
fixed 5% false positive rate for
combinations of the individual
variables (Table 2).
Although inhibin A levels are
reduced in trisomy 18 pregnancies,
they were not statistically different
from the control group.
Inhibin levels in Down's
syndrome pregnancies are no
different from unaffected preg¬
nancies in the first trimester and the
authors of this study could find no
difference in inhibin A levels
between first-trimester groups
either. It was only after 13 weeks'
gestation that inhibin A levels in
affected pregnancies were signifi¬
cantly greater than controls. If two
multiples of the median were used
as a cut-off, using inhibin A levels
alone (i.e. without age or other
markers), 32 of the 50 cases of
Down's syndrome might have been
detected, although the confidence
interval would have been wide.
Currently in the West of
Scotland, risk scoring is based on
aFP, intact hCG and maternal age.
Table 2 demonstrates that the
addition of inhibin A might
improve detection rates by as much
as 20% whilst maintaining a 5%
amniocentesis rate.
The incorporation of inhibin A
will require large prospective
studies to determine if this new
marker is as promising as these
initial retrospective data suggest. If
so, although a test suggesting an
'increased risk' would still require
further investigation by amnio¬
centesis, it will be a substantial
step forward in prenatal serum
screening.
Table 2
Detection rates and 95% confidence intervals (95% CI) for Down's syndrome at a
| fixed 5% false positive rate.
Variable Detection rate 95% CI
aFP+Age 33 19-48
Intact hCG+Age 41 26-47
FphCG+Age 47 32-63
Inhibin A+Age 48 32-63
aFP+intact hCG+Age 54 38-69
aFP+FfShCG+Age 53 37-68
aFP+inhibin A+Age 57 41-72
Intact hCG+inhibin A+Age 57 41-72
FPhCG+inhibin A+Age 68 52-81
Intact hCG+FphCG+Age 40 25-56
aFP+intact hCG+inhibin A+Age72 57-84
aFP+FphCG+inhibin A+Age 75 60-87
aFP+intact hCG+FphCG+Age 52 36-67
Conclusions
1 Early CVS may be associated
with an increased risk of OLH
and LRDs and should be avoided
prior to 10 weeks' gestation.
2 There is little increased risk of
chromosomal abnormality in
cases of isolated choroid plexus
cysts. However, there is much
greater risk if the CP cyst is
associated with an anatomical
abnormality, if the mother is
greater than 35 years old or
maternal serum screening places
the woman at increased risk of
carrying a trisomic fetus.
3 Screening first-trimester fetuses
for increased nuchal
translucency associated with
Down's syndrome has enormous
potential, particularly if it could
be combined with first-trimester
biochemical screening.
4 The introduction of inhibin A
into maternal serum screening
algorithms has the potential to
improve the second-trimester
detection of Down's syndrome by
20% whilst maintaining the
current rate of invasive prenatal
investigations.
Erratum
The use of lavender oil in pregnancy
In the March 1997 issue of The Diplomate we published an article on comple¬
mentary medicine and childbearing in which a phrase was added in error to the
second paragraph on aromatherapy and the use of essential oils.
The author has asked us to point out that lavender oil is classified as an emmen-
agogue and therefore should be avoided during pregnancy until the last few
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